<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11435222</article-id><article-id pub-id-type="pmcid-ver">PMC11435222.1</article-id><article-id pub-id-type="pmcaid">11435222</article-id><article-id pub-id-type="pmcaiid">11435222</article-id><article-id pub-id-type="pmid">39339232</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics16091196</article-id><article-id pub-id-type="publisher-id">pharmaceutics-16-01196</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9578-3372</contrib-id><name name-style="western"><surname>Calheiros-Lobo</surname><given-names initials="M">Mafalda</given-names></name><xref rid="af1-pharmaceutics-16-01196" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4455-4286</contrib-id><name name-style="western"><surname>Silva</surname><given-names initials="JPN">Jo&#227;o P. N.</given-names></name><xref rid="af1-pharmaceutics-16-01196" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8804-6104</contrib-id><name name-style="western"><surname>Pinto</surname><given-names initials="B">B&#225;rbara</given-names></name><xref rid="af1-pharmaceutics-16-01196" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8938-1297</contrib-id><name name-style="western"><surname>Monteiro</surname><given-names initials="L">Lu&#237;s</given-names></name><xref rid="af1-pharmaceutics-16-01196" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-16-01196" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0694-7321</contrib-id><name name-style="western"><surname>Silva</surname><given-names initials="PMA">Patr&#237;cia M. A.</given-names></name><xref rid="af1-pharmaceutics-16-01196" ref-type="aff">1</xref><xref rid="af3-pharmaceutics-16-01196" ref-type="aff">3</xref><xref rid="af4-pharmaceutics-16-01196" ref-type="aff">4</xref><xref rid="c1-pharmaceutics-16-01196" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4006-5779</contrib-id><name name-style="western"><surname>Bousbaa</surname><given-names initials="H">Hassan</given-names></name><xref rid="af1-pharmaceutics-16-01196" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-16-01196" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>D&#252;zg&#252;ne&#351;</surname><given-names initials="N">Nejat</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-16-01196"><label>1</label>UNIPRO&#8212;Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Polit&#233;cnico e Universit&#225;rio (CESPU), Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal; <email>mafalda.duarte@iucs.cespu.pt</email> (M.C.-L.); <email>joaosilva_06@hotmail.com</email> (J.P.N.S.); <email>barbara.fernandes.15@gmail.com</email> (B.P.); <email>luis.monteiro@iucs.cespu.pt</email> (L.M.)</aff><aff id="af2-pharmaceutics-16-01196"><label>2</label>Medicine and Oral Surgery Department, University Institute of Health Sciences&#8212;CESPU (IUCS-CESPU), 4585-116 Gandra, Portugal</aff><aff id="af3-pharmaceutics-16-01196"><label>3</label>Associate Laboratory i4HB, Institute for Health and Bioeconomy, University Institute of Health Sciences&#8212;CESPU, 4585-116 Gandra, Portugal</aff><aff id="af4-pharmaceutics-16-01196"><label>4</label>UCIBIO&#8212;Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal</aff><author-notes><corresp id="c1-pharmaceutics-16-01196"><label>*</label>Correspondence: <email>patricia.silva@cespu.pt</email> (P.M.A.S.); <email>hassan.bousbaa@iucs.cespu.pt</email> (H.B.); Tel.: +351-224157189 (P.M.A.S.); +351-224157186 (H.B.)</corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2024</year></pub-date><volume>16</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">471650</issue-id><elocation-id>1196</elocation-id><history><date date-type="received"><day>01</day><month>8</month><year>2024</year></date><date date-type="rev-recd"><day>06</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>10</day><month>9</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>09</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-29 16:25:13.610"><day>29</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-16-01196.pdf"/><abstract><p>Head and neck cancer (HNC), the sixth most common cancer worldwide, is increasing in incidence, with oral squamous cell carcinoma (OSCC) as the predominant subtype. OSCC mainly affects middle-aged to elderly males, often occurring on the posterior lateral border of the tongue, leading to significant disfigurement and functional impairments, such as swallowing and speech difficulties. Despite advancements in understanding OSCC&#8217;s genetic and epigenetic variations, survival rates for advanced stages remain low, highlighting the need for new treatment options. Primary treatment includes surgery, often combined with radiotherapy (RT) and chemotherapy (CT). Cetuximab-based chemotherapy, targeting the overexpressed epidermal growth factor receptor (EGFR) in 80&#8211;90% of HNCs, is commonly used but correlates with poor prognosis. Additionally, monopolar spindle 1 (MPS1), a spindle assembly checkpoint (SAC) component, is a significant target due to its role in genomic fidelity during mitosis and its overexpression in several cancers. This review explores EGFR and MPS1 as therapeutic targets in HNC, analyzing their molecular mechanisms and the effects of their inhibition on cancer cells. It also highlights the promise of combinatorial approaches, such as microtubule-targeting agents (MTAs) and antimitotic agents, in improving HNC therapies, patient outcomes, and survival rates.</p></abstract><kwd-group><kwd>EGFR</kwd><kwd>MPS1</kwd><kwd>targeted therapy</kwd><kwd>preclinical assays</kwd><kwd>clinical trials</kwd><kwd>head and neck cancer</kwd></kwd-group><funding-group><award-group><funding-source>CESPU&#8212;Cooperativa de Ensino Superior Polit&#233;cnico e Univer- sit&#225;rio Crl</funding-source><award-id>AntiMitoSphere_APSFCT_IINFACTS_2021</award-id><award-id>Flav4Tumor-GI2-CESPU- 2022</award-id><award-id>SGA4Cancer-GI2-CESPU-2022</award-id><award-id>upPTXovcar-GI2-CESPU-2022</award-id><award-id>BeatCancer-GI2-CESPU-2023</award-id></award-group><award-group><funding-source>CESPU</funding-source><award-id>BD/CBAS/CESPU/01/2021</award-id><award-id>BD/CBAS/CESPU/01/2020</award-id></award-group><award-group><funding-source>Funda&#231;&#227;o para a Ci&#234;ncia e a Tecnologia (FCT)</funding-source><award-id>2022.09451.BD</award-id></award-group><funding-statement>This work was funded by CESPU&#8212;Cooperativa de Ensino Superior Polit&#233;cnico e Univer- sit&#225;rio Crl (Grants Ref. AntiMitoSphere_APSFCT_IINFACTS_2021; Ref. Flav4Tumor-GI2-CESPU- 2022; Ref. SGA4Cancer-GI2-CESPU-2022, Ref. upPTXovcar-GI2-CESPU-2022; and Ref. BeatCancer-GI2-CESPU-2023) to H.B. and P.M.A.S. J.P.N.S. gratefully acknowledges CESPU (BD/CBAS/CESPU/01/2021) for financial support. B.P. gratefully acknowledges CESPU (BD/CBAS/CESPU/01/2020) and Funda&#231;&#227;o para a Ci&#234;ncia e a Tecnologia (FCT) (2022.09451.BD) for financial support.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-16-01196"><title>1. Introduction</title><p>Head and neck cancer (HNC) is the sixth most common cancer subsite globally, with more than 890,000 new cases and 450,000 deaths reported in 2022 [<xref rid="B1-pharmaceutics-16-01196" ref-type="bibr">1</xref>]. The incidence of HNC is on the rise, and it is estimated to increase around 30% annually by 2030 [<xref rid="B2-pharmaceutics-16-01196" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-16-01196" ref-type="bibr">3</xref>]. Oral squamous cell carcinoma (OSCC) is the most widespread histological subtype of HNC, representing approximately 90% of all cases, affecting more males than females, with middle-aged to elderly men being the most susceptible [<xref rid="B3-pharmaceutics-16-01196" ref-type="bibr">3</xref>]. The posterior lateral border of the tongue exhibits the highest incidence of OSCC, approximately 50% of all cases, followed by occurrences on the floor of the mouth, the soft palate, the gingiva, the buccal mucosa, and the hard palate [<xref rid="B4-pharmaceutics-16-01196" ref-type="bibr">4</xref>]. This cancer leads to disfigurement and functional impairments, including difficulties with swallowing, speech, and taste, which significantly impact the quality of life for patients [<xref rid="B5-pharmaceutics-16-01196" ref-type="bibr">5</xref>]. OSCC is a heterogeneous neoplasm with an arrangement of genetic and epigenetic variations linked with different risk factors [<xref rid="B6-pharmaceutics-16-01196" ref-type="bibr">6</xref>]. These traits provide cancer cells with several advantages in division and survival, such as growth factor-independent spread, resistance to apoptosis, and an increased capability to surpass extracellular matrix barriers and invade adjacent or distant tissues, contributing to aggressiveness and unsuccessful treatment [<xref rid="B7-pharmaceutics-16-01196" ref-type="bibr">7</xref>]. Clinically, it is characterized by red and white or solely red lesions with a slightly uneven surface and distinct borders. Ulceration is a common symptom of OSCC, presenting with an irregular floor and margins and a hard texture upon palpation [<xref rid="B8-pharmaceutics-16-01196" ref-type="bibr">8</xref>]. </p><p>The treatment approach for OSCC often involves a combination of modalities such as surgery, radiotherapy (RT), and chemotherapy (CT). The specific treatment plan depends on factors such as the location and stage of the disease, as well as the patient&#8217;s overall health and preferences. For early and advanced stages of OSCC, surgery remains the primary treatment, which may be combined with RT and CT for patients with a high risk of recurrence or with pathological adverse features such as positive or close margins, perineural invasion, vascular invasion, and lymphatic invasion [<xref rid="B9-pharmaceutics-16-01196" ref-type="bibr">9</xref>]. For pharynx and larynx cancers, primary chemoradiation is often the preferred approach, particularly for HPV-positive tumors [<xref rid="B10-pharmaceutics-16-01196" ref-type="bibr">10</xref>]. OSCC primarily metastasizes to ipsilateral lymph nodes in the neck through lymphatic drainage but can also invade contralateral or bilateral lymph nodes. Typical metastatic sites for OSCC include the lungs, bones, and liver [<xref rid="B11-pharmaceutics-16-01196" ref-type="bibr">11</xref>].The overall survival for patients with advanced stages of HNSCC is quite low and new treatment options need to be investigated [<xref rid="B12-pharmaceutics-16-01196" ref-type="bibr">12</xref>]. </p><p>Cetuximab-based chemotherapy is one of the most widely used treatments for HNSCC, a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase (RTK) within the HER/ErbB family, which includes HER2&#8211;4 [<xref rid="B13-pharmaceutics-16-01196" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-16-01196" ref-type="bibr">14</xref>]. In head and neck cancers, EGFR is overexpressed in 80&#8211;90% of cases and is linked to poor prognosis and less favorable treatment outcomes [<xref rid="B10-pharmaceutics-16-01196" ref-type="bibr">10</xref>]. The signaling network involving EGFR is complex and involves several individual components, as well as overlap with other pathways [<xref rid="B15-pharmaceutics-16-01196" ref-type="bibr">15</xref>]. The activation of RTK signaling pathways in human cancers is attributed to various events, including ligand or receptor overexpression, aberrant ligand binding, and gene rearrangements. These events ultimately result in enhanced tumor cell migration, survival, and proliferation [<xref rid="B16-pharmaceutics-16-01196" ref-type="bibr">16</xref>]. Although early results were promising and led to the clinical use of Cetuximab, one of the first approved targeted therapies for solid tumors, both intrinsic and acquired resistance frequently develop, negatively impacting treatment outcomes [<xref rid="B17-pharmaceutics-16-01196" ref-type="bibr">17</xref>].</p><p>To prevent the development of abnormal cells, quality control mechanisms, called checkpoints, are established at various phases of the cell cycle, both at interphase and mitosis [<xref rid="B18-pharmaceutics-16-01196" ref-type="bibr">18</xref>]. The spindle assembly checkpoint (SAC) keeps the cell arrested in mitosis until all chromosomes form stable bipolar attachments to mitotic spindle microtubules and become aligned at the equatorial midzone [<xref rid="B19-pharmaceutics-16-01196" ref-type="bibr">19</xref>]. Any defect in this path causes premature exit from mitosis, without proper chromosome attachment and biorientation, leading to mis-segregation and, consequently, to the formation of aneuploid cells [<xref rid="B20-pharmaceutics-16-01196" ref-type="bibr">20</xref>]. SAC components have garnered significant interest as promising microtubule-independent targets, leading to the development of inhibitors against many of these components, with encouraging results in preclinical studies that have advanced to clinical trials for cancer therapy [<xref rid="B21-pharmaceutics-16-01196" ref-type="bibr">21</xref>].</p><p>Monopolar spindle 1 (MPS1), also referred to as threonine tyrosine kinase (TTK), is an essential component of the SAC pathway [<xref rid="B22-pharmaceutics-16-01196" ref-type="bibr">22</xref>]. MPS1 is overexpressed in different cancer types, including breast cancer, hepatocellular carcinoma, pancreatic cancer, gastric cancer, and endometrial cancer, and is correlated with poor patient prognosis [<xref rid="B23-pharmaceutics-16-01196" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-16-01196" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-16-01196" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-16-01196" ref-type="bibr">26</xref>]. In addition, in breast cancer cell lines, the reduction in MPS1 expression led to decreased cell viability, making it a promising cancer therapeutic target [<xref rid="B27-pharmaceutics-16-01196" ref-type="bibr">27</xref>]. </p><p>As mentioned above, EGFR is overexpressed in a significant majority of HNSCC cases and is associated with aggressive tumor behavior and resistance to conventional therapies. Similarly, MPS1 is overexpressed and its overexpression correlates with poor prognosis in several cancers. Therefore, simultaneously targeting the EGFR pathway and the MPS1-mediated SAC pathway appears to be a logical approach to overcoming HNSCC resistance to conventional treatments.</p><p>In this review, we explored the significance of EGFR and MPS1 as therapeutic targets in head and neck cancer. Our analysis covered their roles in both preclinical and clinical stages. We explored their molecular mechanisms, the impact of their inhibition on cancer cells, and the current status of therapies targeting these proteins, both alone and in combination. By accessing data from preclinical studies and clinical trials, we provided insights into the potential benefits and challenges of targeting EGFR and MPS1 in the treatment of HNC. This comprehensive overview underscores the promise of these targets in developing more effective and specific therapies for HNC patients. </p></sec><sec id="sec2-pharmaceutics-16-01196"><title>2. Targeting EGFR for Head and Neck Cancer Treatment</title><p>EGFR is a 170 kDa transmembrane glycoprotein composed of a single polypeptide chain of 1186 amino acids that belongs to the RTK family [<xref rid="B28-pharmaceutics-16-01196" ref-type="bibr">28</xref>]. The structure of EGFR can be divided into three domains: an extracellular ligand-binding domain, a transmembrane domain, and an intracellular domain. The extracellular domain of EGFR consists of 621 amino acids and is responsible for binding to ligands such as epidermal growth factor. The transmembrane domain of EGFR contains 23 hydrophobic amino acids that anchor the protein in the plasma membrane. The intracellular domain of EGFR contains 542 amino acids and is composed of a tyrosine kinase domain. This domain is responsible for initiating intracellular signaling cascades upon ligand binding. EGFR has several phosphorylation sites at Y845, Y974, Y992, Y1045, Y1068, Y1086, Y1101, Y1148, and Y1173 [<xref rid="B29-pharmaceutics-16-01196" ref-type="bibr">29</xref>]. Some of these sites serve as docking sites for intracellular signaling proteins [<xref rid="B30-pharmaceutics-16-01196" ref-type="bibr">30</xref>]. In addition, Y845 and Y1101 are two oncogenic signal-activated transphosphorylation sites that are phosphorylated by other tyrosine kinases, leading to the activation of downstream signaling pathways that promote cell growth and proliferation (<xref rid="pharmaceutics-16-01196-f001" ref-type="fig">Figure 1</xref>a) [<xref rid="B31-pharmaceutics-16-01196" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-16-01196" ref-type="bibr">32</xref>]. </p><p>A protein binding to specific phosphotyrosine residues in EGFR initiates intracellular signaling through the following pathways: RAS/RAF/mitogen-activated protein kinase pathway, phosphatidylinositol 3-kinase (PI3K)/Akt pathway, phospholipase C&#947; pathway, signal transducers and activators of transcription pathway, Src kinase pathway, endocytic pathway, stress pathway, and autophagy pathway (<xref rid="pharmaceutics-16-01196-f001" ref-type="fig">Figure 1</xref>a) [<xref rid="B33-pharmaceutics-16-01196" ref-type="bibr">33</xref>].</p><p>The primary function of EGFR is to regulate cellular processes such as growth, proliferation, differentiation, and survival in various cell types, including epithelial, glial, and neuronal cells [<xref rid="B34-pharmaceutics-16-01196" ref-type="bibr">34</xref>]. In epithelial cells, the EGFR plays a vital role in regulating cell growth, differentiation, and migration [<xref rid="B35-pharmaceutics-16-01196" ref-type="bibr">35</xref>]. Its expression is particularly prominent in the epidermal basal layer and the outer root sheath of hair cells. Here, it plays an important role in promoting keratinocyte cell migration and differentiation, as well as follicular cell development [<xref rid="B36-pharmaceutics-16-01196" ref-type="bibr">36</xref>]. In neurons, EGFR signaling pathways are involved in the regulation of migration and neurodegeneration. Mutations in EGFR can cause glioma-like tumors, highlighting its importance in regulating cellular processes that impact cancer development [<xref rid="B37-pharmaceutics-16-01196" ref-type="bibr">37</xref>]. The expression and function of EGFR are regulated by receptor downregulation or dephosphorylation. However, abnormal expression of EGFR is observed in human epithelial cancers, including HNSCCs [<xref rid="B38-pharmaceutics-16-01196" ref-type="bibr">38</xref>]. Overexpression of EGFR is associated with poor cancer prognosis, likely due to its role as a signal for cell proliferation [<xref rid="B39-pharmaceutics-16-01196" ref-type="bibr">39</xref>]. </p><p>Currently, two main strategies are employed to target EGFR with distinct mechanisms [<xref rid="B40-pharmaceutics-16-01196" ref-type="bibr">40</xref>]. These include inhibiting the tyrosine kinase domain activity (intracellular) with small molecules and blocking extracellular ligand binding by using monoclonal antibodies (mAbs). mAbs that target EGFR selectively recognize the EGFR protein and bind to its extracellular domain competing with the receptor binding of ligands and blocking ligand-induced activation of EGFR tyrosine kinase activity, resulting in the internalization and degradation of the antibody&#8211;receptor complex [<xref rid="B41-pharmaceutics-16-01196" ref-type="bibr">41</xref>]. This leads to tumor cell death through direct inhibition of EGFR signaling. Additionally, these antibodies mediate tumor cell elimination via an indirect mechanism known as antibody-dependent cell-mediated cytotoxicity (ADCC), which involves the activation of natural killer (NK) cells [<xref rid="B42-pharmaceutics-16-01196" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-16-01196" ref-type="bibr">43</xref>]. EGFR tyrosine kinase inhibitors (TKIs) compete in a reversible manner with ATP and bind to the intracellular domain of EGFR tyrosine kinase. This binding inhibits the autophosphorylation of EGFR and downstream signaling pathways. In addition to blocking EGFR activity, these inhibitors can also inhibit other growth factor receptor tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), an important regulator of angiogenesis, which is critical for tumor growth and progression. By inhibiting VEGFR, EGFR TKIs can hinder the formation of new blood vessels and limit nutrient and oxygen supply to tumor cells [<xref rid="B44-pharmaceutics-16-01196" ref-type="bibr">44</xref>]. </p><p>Until the recent FDA approval of immunotherapies, Cetuximab, a human&#8211;murine chimeric anti-EGFR immunoglobulin G-1 antibody approved in 2006, has been the only targeted drug approved for locally advanced HNC (LA-HNC) (HPV-positive and -negative subtypes) in combination with radiotherapy (RT) and as a monotherapy for recurrent or metastatic (R/M) cancer after failure of platinum-based therapies [<xref rid="B45-pharmaceutics-16-01196" ref-type="bibr">45</xref>]. However, Cetuximab and other therapies designed to target EGFR have limited efficacy mostly due to cancer cells acquiring resistance through alterations in EGFR or downstream EGFR signaling pathways such as PI3K/AKT [<xref rid="B46-pharmaceutics-16-01196" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceutics-16-01196" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-16-01196" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceutics-16-01196" ref-type="bibr">49</xref>]. For instance, as a monotherapy, only 13% of patients showed responses, which suggests some form of intrinsic resistance, while several patients with positive tumor response acquired resistance to Cetuximab, leading to recurrences [<xref rid="B50-pharmaceutics-16-01196" ref-type="bibr">50</xref>].</p><p>Even though of all EGFR-targeting drugs, only Cetuximab has been approved by the FDA for HNC treatment, the use of Nimotuzumab in HNC has been approved in several countries [<xref rid="B51-pharmaceutics-16-01196" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceutics-16-01196" ref-type="bibr">52</xref>]. However, other EGFR-targeting inhibitors, including Gefitinib, Erlotinib, Lapatinib, Afatinib, Panitumumab, Zalutumumab, Poziotinib, Duligotuzumab, Patritumab, and Dacomitinib, have been investigated in clinical trials for HNC therapy (<xref rid="pharmaceutics-16-01196-t001" ref-type="table">Table 1</xref>). Indeed, these studies frequently encompass patients with advanced or recurrent HNSCC who exhibit suboptimal responses to conventional therapeutic modalities or possess restricted therapeutic alternatives. </p><p>For instance, Gefitinib, a reversible EGFR TKI, was investigated in a phase III trial for the treatment of R/M HNSCC. Unfortunately, the study did not show any significant improvement in overall survival (OS) compared to Methotrexate, and as a result, Gefitinib is unlikely to be used clinically for HNSCC [<xref rid="B53-pharmaceutics-16-01196" ref-type="bibr">53</xref>]. However, it is important to note that Gefitinib is still FDA-approved for the treatment of locally advanced or metastatic NSCLC with EGFR mutations. It has been shown to significantly improve PFS and overall response rate (ORR) in these patients compared to standard chemotherapy [<xref rid="B54-pharmaceutics-16-01196" ref-type="bibr">54</xref>]. Therefore, Gefitinib remains an important treatment option for NSCLC patients with EGFR mutations in the tyrosine kinase domain (TMD), specifically, those with exon 19 deletions or a substitution in codon 858 of a leucine for an arginine in exon 21 [<xref rid="B50-pharmaceutics-16-01196" ref-type="bibr">50</xref>,<xref rid="B53-pharmaceutics-16-01196" ref-type="bibr">53</xref>]. </p><p>A systematic review found that exon 19 deletions and the L858R substitution comprise approximately 25% (22% and 2.5%, respectively) of all EGFR mutations in HNSCC compared to approximately 50% in NSCLC [<xref rid="B55-pharmaceutics-16-01196" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceutics-16-01196" ref-type="bibr">56</xref>]. However, mutations in the TMD are observed in 0 to 8% of HNSCC patients, depending on ethnicity and region/country. Moreover, mutations in exon 20 seem to be more frequent [<xref rid="B57-pharmaceutics-16-01196" ref-type="bibr">57</xref>]. In addition, two studies showed that EGFR mutation status was not predictive of Gefitinib response in patients with HNC. However, the number of patients assessed was limited in both studies (2 out of 15 and 3 out of 19 patients presenting EGFR mutations) [<xref rid="B58-pharmaceutics-16-01196" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceutics-16-01196" ref-type="bibr">59</xref>]. Nonetheless, in one of the studies, patients with somatic EGFR mutations showed better time to progression and survival than patients without these mutations, even if not statistically significant [<xref rid="B59-pharmaceutics-16-01196" ref-type="bibr">59</xref>]. However, another report assessing somatic mutations in EGFR in patients who were responsive to Gefitinib or Erlotinib treatment showed that none of the eight patients analyzed had any EGFR mutation [<xref rid="B60-pharmaceutics-16-01196" ref-type="bibr">60</xref>].</p><p>Furthermore, contrary to NSCLC, in HNSCC, Gefitinib resistance is usually not acquired through EGFR mutations [<xref rid="B61-pharmaceutics-16-01196" ref-type="bibr">61</xref>]. Instead, HNSCC cells develop resistance by alterations downstream of EGFR overcoming EGFR signaling dependence [<xref rid="B62-pharmaceutics-16-01196" ref-type="bibr">62</xref>]. Moreover, EGFR TMD mutations in NSCLC are observed in adenocarcinomas and never-smokers at a higher frequency while in HNSCC these mutations can occur in squamous cell carcinomas and smokers [<xref rid="B63-pharmaceutics-16-01196" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceutics-16-01196" ref-type="bibr">64</xref>]. Thus, other tumor characteristics might influence the predictive factors for Gefitinib treatment response. However, in recurrent HNSCC, Gefitinib showed equivalent efficacy to Methotrexate both alone and in combination with Fluorouracil and it seemed to improve the quality of life in these patients [<xref rid="B65-pharmaceutics-16-01196" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceutics-16-01196" ref-type="bibr">66</xref>,<xref rid="B67-pharmaceutics-16-01196" ref-type="bibr">67</xref>]. Thus, it is possible that Gefitinib treatment might be more interesting for recurrent HNSCC than for patients with mutated EGFR. Nonetheless, studies focusing on HNSCC patients with exon 19 deletions and L858R substitution treated with Gefitinib should be conducted to clarify once and for all their predictive potential in HNSCC.</p><p>Erlotinib is also a reversible EGFR-binding TKI that showed good tolerability and some antitumor activity in phase II studies both as monotherapy and in combination with Cisplatin in patients with R/M HNSCC. However, randomized phase II trials did not show any significant improvement in recurrence rate or PFS in patients with R/M HNSCC, and phase II trials in patients with EGFR variant III mutations also showed no significant difference between Erlotinib-treated and control patients [<xref rid="B68-pharmaceutics-16-01196" ref-type="bibr">68</xref>,<xref rid="B69-pharmaceutics-16-01196" ref-type="bibr">69</xref>,<xref rid="B70-pharmaceutics-16-01196" ref-type="bibr">70</xref>]. As of now, no successful phase III studies of Erlotinib have been completed in the treatment of HNSCC. </p><p>Lapatinib is a reversible dual TKI that targets EGFR and HER2 and inhibits tumor progression. The drug has received FDA approval for the treatment of metastatic breast cancer in combination with Capecitabine [<xref rid="B71-pharmaceutics-16-01196" ref-type="bibr">71</xref>]. Phase II clinical trials have demonstrated Lapatinib&#8217;s potential as a therapeutic agent in previously untreated patients with HNSCC. Results showed an ORR of 17% compared to 0% for placebo [<xref rid="B72-pharmaceutics-16-01196" ref-type="bibr">72</xref>]. Another phase II trial conducted in patients with locally advanced HNSCC demonstrated that Lapatinib with RT was well tolerated and resulted in increased complete response rates of 53% compared to 36% with placebo six months post-treatment [<xref rid="B73-pharmaceutics-16-01196" ref-type="bibr">73</xref>]. However, a subsequent phase III study revealed that adjuvant Lapatinib therapy in combination with long-term concurrent chemoradiotherapy did not improve outcomes in patients with surgically treated high-risk HNSCC. Moreover, the treatment was associated with additional toxicity. Therefore, further research is needed to evaluate the safety and efficacy of Lapatinib in patients with HNSCC [<xref rid="B74-pharmaceutics-16-01196" ref-type="bibr">74</xref>]. </p><p>As a potent and irreversible pan-HER inhibitor, Afatinib binds to and inhibits the activities of EGFR, HER2, and HER4 [<xref rid="B75-pharmaceutics-16-01196" ref-type="bibr">75</xref>]. A phase II clinical trial conducted in patients with R/M HNSCC who failed prior platinum-based chemotherapy showed that Afatinib was comparable to Cetuximab in terms of tumor size reduction, ORR, and disease control rates [<xref rid="B76-pharmaceutics-16-01196" ref-type="bibr">76</xref>]. Moreover, Afatinib as maintenance therapy after platinum-based chemotherapy was associated with improvements in PFS and had a manageable safety profile. The PFS achieved with Afatinib was 2.6 months compared to 1.7 months for the Methotrexate group [<xref rid="B77-pharmaceutics-16-01196" ref-type="bibr">77</xref>]. Further, phase III studies have demonstrated that Afatinib therapy in patients with R/M HNSCC who are 65 years of age or older did not have worse safety profiles compared to Methotrexate therapy alone. These positive results suggest that Afatinib may have the potential to be approved for clinical use in HNSCC [<xref rid="B78-pharmaceutics-16-01196" ref-type="bibr">78</xref>]. </p><p>Dacomitinib is a small molecule that inhibits EGFR, HER2, and HER4 by irreversibly binding to them [<xref rid="B79-pharmaceutics-16-01196" ref-type="bibr">79</xref>]. The efficacy of Dacomitinib as a first-line treatment for R/M HNSCC has been investigated in only one phase II clinical trial. The study reported a median PFS of 2.8 months and OS of 9.3 months [<xref rid="B80-pharmaceutics-16-01196" ref-type="bibr">80</xref>]. However, these findings are insufficient to draw definitive conclusions about the efficacy of Dacomitinib in treating HNSCC. Nonetheless, further randomized and controlled studies are needed to assess the safety and efficacy of EGFR TKIs as a treatment option for HNSCC. </p><p>Even though the targeting of EGFR with Cetuximab in HNC has proven to be quite successful mostly when in combination with taxanes, a class of microtubule-targeting agents (MTAs), 5-Fluorouracil, and Cisplatin or radiotherapy, resistance and tumor recurrence can occur [<xref rid="B81-pharmaceutics-16-01196" ref-type="bibr">81</xref>,<xref rid="B82-pharmaceutics-16-01196" ref-type="bibr">82</xref>]. This need to overcome resistance and enhance therapeutic efficacy has led to extensive research on antimitotic drugs. Thus, other combinatorial approaches with EGFR should probably be explored.</p><table-wrap position="anchor" id="pharmaceutics-16-01196-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-16-01196-t001_Table 1</object-id><label>Table 1</label><caption><p>Clinical trials targeting EGFR alone or in combination for HNSCC treatment (from 2002 to 2024).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Intervention</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NCT/References</th></tr></thead><tbody><tr><td rowspan="65" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
Cetuximab, EGFR Monoclonal Antibody
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dysplastic lesions of the upper<break/>aerodigestive tract</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab-treated patients showed a higher reduction in grade of dysplasia, with 4 of 12 patients showing no dysplasia after treatment and none of the 5 patients in the observation groups achieving complete resolution. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00894413">NCT00894413</ext-link><break/>[<xref rid="B83-pharmaceutics-16-01196" ref-type="bibr">83</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab improved the suppressive phenotypes of Fc&#947;R-bearing myeloid cells, leading to better clinical outcomes.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01218048">NCT01218048</ext-link><break/>[<xref rid="B84-pharmaceutics-16-01196" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M SGC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stable disease for &#8805;6 months was observed in half of the treated R/M SGC patients. In particular, all patients with adenoid cystic carcinoma achieved stable disease for &#8805;6 months. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B85-pharmaceutics-16-01196" ref-type="bibr">85</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Twelve weeks of cetuximab maintenance improved outcomes in the first year but this improvement was not observed after 2 years.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B86-pharmaceutics-16-01196" ref-type="bibr">86</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No therapeutic benefit was observed with increased dose of Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B87-pharmaceutics-16-01196" ref-type="bibr">87</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tolerable with activity comparable to Cetuximab and platinum combination.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-pharmaceutics-16-01196" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Comparative study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab alone showed similar outcomes to Cetuximab with platinum after platinum failure.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B88-pharmaceutics-16-01196" ref-type="bibr">88</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RM-1929 (Cetuximab&#8211;IR700 dye conjugate)<break/>photoimmunotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/IIa</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It was deemed safe and showed meaningful activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02422979">NCT02422979</ext-link><break/>[<xref rid="B89-pharmaceutics-16-01196" ref-type="bibr">89</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OPSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab combined with<break/>Palbociclib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The primary endpoint of ORR &#8805; 20% was not met.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02101034">NCT02101034</ext-link><break/>[<xref rid="B90-pharmaceutics-16-01196" ref-type="bibr">90</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab and Palbociclib<break/>vs.<break/>Cetuximab alone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The addition of Palbociclib to Cetuximab showed no significant improvement in the median OS. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02499120">NCT02499120</ext-link><break/>[<xref rid="B91-pharmaceutics-16-01196" ref-type="bibr">91</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab in combination with<break/>Palbociclib and Avelumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The combinatorial approach was deemed safe.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03498378">NCT03498378</ext-link><break/>[<xref rid="B92-pharmaceutics-16-01196" ref-type="bibr">92</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination of Cetuximab and<break/>Ribociclib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The MTD was achieved (600 mg daily Ribociclib in combination with a standard dose of Cetuximab for 3 weeks on and 1 week off). Additionally, the combination was deemed safe with clinical activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02429089">NCT02429089</ext-link><break/>[<xref rid="B93-pharmaceutics-16-01196" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab plus<break/>Vinorelbine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The combination was safe and feasible and showed anticancer activity. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B94-pharmaceutics-16-01196" ref-type="bibr">94</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recurrent HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Palliative weekly Paclitaxel plus<break/>Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The combinatorial approach was deemed effective leading to a RR of 55% and a median response duration of 5.0 months. Furthermore, the PFS observed was 4.0 months and the OS was 10 months.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B95-pharmaceutics-16-01196" ref-type="bibr">95</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weekly Cetuximab with<break/>Paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The combinatorial approach was deemed safe and showed antitumoral activity leading to a DCR of 74%, a PFS of 3.9 months, and an OS of 7.6 months.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B96-pharmaceutics-16-01196" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab plus<break/>Paclitaxel<break/>vs.<break/>Paclitaxel alone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Addition of Cetuximab to Paclitaxel after EXTREME leads to moderate benefit and seems to be associated with better PFS and OS.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-pharmaceutics-16-01196" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab and<break/>weekly Paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safe and showed clinical activity. An ORR of 54%, 10 (22%) complete responses, a DCR of 80%, a PFS of 4.2 months, and an OS of 8.1 months were observed.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B98-pharmaceutics-16-01196" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biweekly Cetuximab plus Paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In previously treated patients (platinum-based and PD-1 immunotherapy) the combination was tolerable and showed promising anticancer activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">jRCTs051200040<break/>[<xref rid="B99-pharmaceutics-16-01196" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab plus Paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The combination showed a RR of 37.7%, PFS of 4.5 months, and an OS of 8.9 months, confirming the efficacy and tolerability of the regimen.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-pharmaceutics-16-01196" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weekly Cetuximab and Paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The regimen shows clinical activity and is tolerable.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B101-pharmaceutics-16-01196" ref-type="bibr">101</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab combined with<break/>Paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">As first-line treatment, it showed an ORR of 43% and a DCR of 79%, while as second-line and later therapies, the ORR achieved was 20% and the DCR was 90%. The PFS and OS were 5.3 and 12.5 months, respectively. Furthermore, it seemed to be more useful after treatment with immune checkpoint inhibitors.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B102-pharmaceutics-16-01196" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biweekly Cetuximab and<break/>Docetaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The treatment was safe and efficient leading to an OS of 8.3 months, PFS of 4.0 months, DCR of 41.9%, and ORR of 12.9%.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B103-pharmaceutics-16-01196" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage III/IV<break/>HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weekly Cetuximab plus<break/>Nab-paclitaxel and IMRT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A recommended phase II dose was achieved (60 mg/m<sup>2</sup> of weekly nab-paclitaxel with a standard weekly dose of Cetuximab plus IMRT).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00736619">NCT00736619</ext-link><break/>[<xref rid="B104-pharmaceutics-16-01196" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA NPC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with Cetuximab,<break/>Carboplatin, and<break/>Paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The treatment option was deemed feasible and effective leading to a 3-year recurrence-free survival, locoregional failure-free survival, distant recurrence-free survival, and OS of 75.9%, 79.3%, 84.3%, and 96.3%, respectively.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B105-pharmaceutics-16-01196" ref-type="bibr">105</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with Carboplatin, Paclitaxel, and Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The therapeutic approach was tolerable and effective.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B106-pharmaceutics-16-01196" ref-type="bibr">106</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with Cetuximab,<break/>Carboplatin, and<break/>Nab-paclitaxel followed by standard chemoradiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Showed clinical activity and was deemed safe.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01412229">NCT01412229</ext-link><break/>[<xref rid="B107-pharmaceutics-16-01196" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC Cisplatin and<break/>Docetaxel with or without Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The addition of Cetuximab led to higher toxicity and the primary endpoint was not met. Nonetheless, further investigation is warranted.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00623558">NCT00623558</ext-link><break/>[<xref rid="B108-pharmaceutics-16-01196" ref-type="bibr">108</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab<break/>Cisplatin<break/>Docetaxel<break/>vs.<break/>Docetaxel<break/>Cisplatin<break/>5-FU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Effective and tolerable regimen.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B109-pharmaceutics-16-01196" ref-type="bibr">109</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M NPC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab plus<break/>Carboplatin and<break/>Paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safe and potentially effective since it led to an ORR of 58.3% and a PFS of 4.1 months.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B110-pharmaceutics-16-01196" ref-type="bibr">110</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab combined with<break/>Cisplatin and<break/>Docetaxel followed by maintenance with Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It was tolerable and the median PFS (6.9 months) was similar to other studies investigating the same combination. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B111-pharmaceutics-16-01196" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab plus<break/>Cisplatin with or without<break/>Paclitaxel followed by maintenance Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Addition of Paclitaxel to Cetuximab did not significantly improve PFS or OS.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B112-pharmaceutics-16-01196" ref-type="bibr">112</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination of Cetuximab,<break/>Docetaxel, and<break/>Cisplatin followed by maintenance Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Promising activity as a first-line treatment.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01289522">NCT01289522</ext-link><break/>[<xref rid="B113-pharmaceutics-16-01196" ref-type="bibr">113</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Palliative treatment with weekly Cetuximab,<break/>Docetaxel, and<break/>Cisplatin or Carboplatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The regimen showed promising efficacy and favorable response rates, PFS, and OS when compared to other combinatorial treatments.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01437449">NCT01437449</ext-link><break/>[<xref rid="B114-pharmaceutics-16-01196" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination of Cetuximab,<break/>Paclitaxel, and Carboplatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acceptable toxicity with promising activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B115-pharmaceutics-16-01196" ref-type="bibr">115</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab combined with<break/>Carboplatin and<break/>Nab-paclitaxel<break/>followed by maintenance<break/>Nab-paclitaxel and Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Showed better ORR and OS than historical EXTREME but no improvement in PFS.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02270814">NCT02270814</ext-link><break/>[<xref rid="B116-pharmaceutics-16-01196" ref-type="bibr">116</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weekly Cetuximab, Paclitaxel, and Carboplatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The regimen was deemed safe and showed favorable PFS and OS when compared to the EXTREME regimen. It can be an option for cisplatin-unfit patients. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B117-pharmaceutics-16-01196" ref-type="bibr">117</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab,<break/>Paclitaxel, and Carboplatin<break/>vs.<break/>Cetuximab,<break/>5-FU, and Cisplatin or Carboplatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab with Paclitaxel and Carboplatin showed similar efficacy with lower toxicity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-pharmaceutics-16-01196" ref-type="bibr">118</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab plus<break/>Cisplatin and<break/>Docetaxel followed by maintenance Cetuximab<break/>vs.<break/>EXTREME regimen (Cetuximab plus<break/>Platinum,<break/>5-FU followed by maintenance Cetuximab)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The regimen with Cetuximab plus Cisplatin and Docetaxel showed a favorable safety profile compared to the EXTREME regimen, but no significant improvement in OS was observed.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02268695">NCT02268695</ext-link><break/>[<xref rid="B119-pharmaceutics-16-01196" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TPF IC followed by<break/>Cetuximab plus<break/>IMRT<break/>Carbon ion boost</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment was tolerable and showed promising results.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01245985">NCT01245985</ext-link><break/>[<xref rid="B120-pharmaceutics-16-01196" ref-type="bibr">120</xref>,<xref rid="B121-pharmaceutics-16-01196" ref-type="bibr">121</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with TPF followed by Cetuximab plus Radiotherapy vs.<break/>Carboplatin, Fluorouracil, and Radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No benefits for PFS, OS, and locoregional control were observed for the IC with TPF followed by Cetuximab plus radiotherapy regimen.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01233843">NCT01233843</ext-link><break/>[<xref rid="B122-pharmaceutics-16-01196" ref-type="bibr">122</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Postoperative<break/>HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab plus<break/>Radiotherapy and Docetaxel or<break/>Cisplatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The regimens were feasible and tolerable. The docetaxel combination improved DFS and OS when compared with historical controls.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00084318">NCT00084318</ext-link><break/>[<xref rid="B123-pharmaceutics-16-01196" ref-type="bibr">123</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Resectable OSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with Cetuximab,<break/>Cisplatin, and<break/>Paclitaxel followed by weekly Cetuximab plus<break/>IMRT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The 2-year PFS and OS rates were 80% and 94%, respectively, and the radiation dose reduction led to improved swallowing and nutritional status.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01084083">NCT01084083</ext-link><break/>[<xref rid="B124-pharmaceutics-16-01196" ref-type="bibr">124</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage III/IV HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with Cetuximab,<break/>Paclitaxel, and<break/>Carboplatin followed by Cetuximab plus Carboplatin, Paclitaxel, and<break/>Radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The treatment approach was safe and showed promising survival.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00089297">NCT00089297</ext-link><break/>[<xref rid="B125-pharmaceutics-16-01196" ref-type="bibr">125</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC Cetuximab,<break/>Nab-paclitaxel,<break/>Cisplatin, and<break/>5-FU followed by Cisplatin plus<break/>Radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High CRR was observed in the primary tumor site.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00736944">NCT00736944</ext-link><break/>[<xref rid="B126-pharmaceutics-16-01196" ref-type="bibr">126</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage III/IV<break/>larynx/hypopharynx SCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with Docetaxel, Cisplatin, and 5-FU followed by Radiotherapy plus Cisplatin or Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No treatment approach investigated was superior.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00169247">NCT00169247</ext-link><break/>[<xref rid="B127-pharmaceutics-16-01196" ref-type="bibr">127</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with Cetuximab,<break/>Cisplatin,<break/>Paclitaxel, and<break/>Everolimus followed by TFHX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The addition of everolimus to IC showed no benefit. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01133678">NCT01133678</ext-link><break/>[<xref rid="B128-pharmaceutics-16-01196" ref-type="bibr">128</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab,<break/>Docetaxel, and<break/>Cisplatin plus Radiation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It was impossible to conclude if it was better than TPF with radiation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B129-pharmaceutics-16-01196" ref-type="bibr">129</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nab-paclitaxel followed by Cetuximab plus radiotherapy vs<break/>Nab-paclitaxel with<break/>Cisplatin followed by Cisplatin plus<break/>Radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Due to limited sample size, it was not possible to assess if any regimen was superior. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02573493">NCT02573493</ext-link><break/>[<xref rid="B130-pharmaceutics-16-01196" ref-type="bibr">130</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage III/IV OPSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with Cetuximab,<break/>Docetaxel,<break/>Cisplatin, and<break/>5-FU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The combination dose could not be recommended. However, there were signs of clinical activity and it should be investigated further.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00665392">NCT00665392</ext-link><break/>[<xref rid="B131-pharmaceutics-16-01196" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with<break/>Docetaxel,<break/>Cisplatin, and<break/>5-FU followed by Cetuximab plus<break/>Radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The regimen was feasible and showed promising results.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT0050463<break/>[<xref rid="B132-pharmaceutics-16-01196" ref-type="bibr">132</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage III/IV HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TPF plus Cetuximab followed by weekly Cetuximab and Cisplatin or Carboplatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The regimen led to high toxicity and the study was terminated early.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B133-pharmaceutics-16-01196" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with<break/>Nab-paclitaxel,<break/>Cisplatin, and<break/>5-FU with or without Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective comparative<break/>study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The addition of Cetuximab to the regimen showed no improvement.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00736944">NCT00736944</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01566435">NCT01566435</ext-link><break/>[<xref rid="B134-pharmaceutics-16-01196" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC TPF followed by Cetuximab plus Radiotherapy<break/>vs.<break/>Cisplatin plus<break/>Radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Both tested regimens have similar efficacies and toxicities.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00999700">NCT00999700</ext-link><break/>[<xref rid="B135-pharmaceutics-16-01196" ref-type="bibr">135</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC TPF followed by Cisplatin and Radiotherapy or Cetuximab plus<break/>Radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II/III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients who received IC with TPF showed higher OS, CR, and PFS than the no-IC arm.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01086826">NCT01086826</ext-link><break/>[<xref rid="B136-pharmaceutics-16-01196" ref-type="bibr">136</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unresectable HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with Cetuximab,<break/>Taxotere,<break/>Cisplatin, and<break/>5-FU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High ORR and CR but with high toxicity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B137-pharmaceutics-16-01196" ref-type="bibr">137</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC Cetuximab followed by weekly Cetuximab,<break/>Paclitaxel,<break/>Carboplatin, and<break/>Radiation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Led to a 3-year median OS of 4.4 years identical to other trials with paclitaxel-based chemoradiation without Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B138-pharmaceutics-16-01196" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with weekly Cetuximab,<break/>Carboplatin, and<break/>Paclitaxel followed by<break/>Cisplatin plus<break/>Radiation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab combined with Carboplatin and Paclitaxel as IC was deemed feasible with good efficacy. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B139-pharmaceutics-16-01196" ref-type="bibr">139</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination of Cetuximab,<break/>Nab-paclitaxel,<break/>Cisplatin, and<break/>Radiation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Showed a 2-year PFS similar to historical controls.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-pharmaceutics-16-01196" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OCSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab plus TPF followed by<break/>Cisplatin<break/>and<break/>Radiation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shown to be safe and effective.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B141-pharmaceutics-16-01196" ref-type="bibr">141</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Postoperative III&#8211;IVb HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weekly Cetuximab,<break/>Docetaxel, and<break/>Radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deemed feasible and safe and led to 1- and 2-year DFS rates of 91 and 55%, respectively.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B142-pharmaceutics-16-01196" ref-type="bibr">142</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with Cetuximab,<break/>Cisplatin, and<break/>Docetaxel followed by<break/>concurrent Radiotherapy with Cisplatin and Cetuximab followed by<break/>maintenance Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Led to great long-term survival with 3-year PFS and OS rates of 70% and 74%.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B143-pharmaceutics-16-01196" ref-type="bibr">143</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Laryngeal cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with Docetaxel, Cisplatin, and<break/>5-FU followed by Carboplatin or Cetuximab plus Radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cetuximab is a reasonable alternative, but no significant improvement was observed.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B144-pharmaceutics-16-01196" ref-type="bibr">144</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with Cisplatin, Docetaxel, and Capecitabine followed by Cetuximab and Radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Discontinued early due to high toxicity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B145-pharmaceutics-16-01196" ref-type="bibr">145</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with Docetaxel, Cisplatin,<break/>5-FU, and<break/>Cetuximab followed by Cetuximab and Radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deemed safe with promising efficacy.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B146-pharmaceutics-16-01196" ref-type="bibr">146</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with Cetuximab,<break/>Paclitaxel, and<break/>Carboplatin followed by Cetuximab,<break/>5-FU,<break/>Hydroxyurea, and<break/>Radiotherapy or Cisplatin,<break/>Cetuximab, and<break/>Radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tolerable and led to long-term control of LA HNSCC.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B147-pharmaceutics-16-01196" ref-type="bibr">147</xref>]</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
Erlotinib,<break/>EGFR<break/>TK Inhibitor
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral premalignant lesions</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erlotinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Did not improve CFS.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00402779">NCT00402779</ext-link><break/>[<xref rid="B148-pharmaceutics-16-01196" ref-type="bibr">148</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HNC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erlotinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Window-of-opportunity study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The results suggest that early in-treatment PET/CT can predict patients&#8217; response to erlotinib. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00601913">NCT00601913</ext-link><break/>[<xref rid="B149-pharmaceutics-16-01196" ref-type="bibr">149</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erlotinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erlotinib was deemed safe and led to prolonged disease stabilization.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-pharmaceutics-16-01196" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erlotinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pilot study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Well tolerated. Nine patients showed tumor reduction at the time of surgery.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B150-pharmaceutics-16-01196" ref-type="bibr">150</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erlotinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Long-term erlotinib, although safe, showed low tolerability. Nonetheless, a potential improvement in survival when compared to historical controls was observed.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B151-pharmaceutics-16-01196" ref-type="bibr">151</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erlotinib plus<break/>Docetaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High toxicity observed. However, the dose for phase II trials was determined (Docetaxel 35 mg/m<sup>2</sup> and Erlotinib 50 mg).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00049283">NCT00049283</ext-link><break/>[<xref rid="B152-pharmaceutics-16-01196" ref-type="bibr">152</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HNC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erlotinib combined with <break/>Docetaxel and IMRT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The regimen was deemed safe and should be investigated further in selected patients. May be useful for patients who cannot receive cisplatin treatment. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00720304">NCT00720304</ext-link><break/>[<xref rid="B153-pharmaceutics-16-01196" ref-type="bibr">153</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erlotinib plus Cisplatin and<break/>Docetaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The combination led to an ORR of 62%, a median PFS of 6.1 months, and an OS of 11.0 months which compares favorably with historical controls of treatment with Cisplatin and Docetaxel. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00076310">NCT00076310</ext-link><break/>[<xref rid="B154-pharmaceutics-16-01196" ref-type="bibr">154</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with<break/>Paclitaxel,<break/>Carboplatin,<break/>5-FU, and<break/>Bevacizumab followed by<break/>Radiotherapy, Erlotinib, Paclitaxel, and Bevacizumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High efficacy with manageable toxicity. The estimated PFS and OS rates were 71% and 82%, respectively.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B155-pharmaceutics-16-01196" ref-type="bibr">155</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
Lapatinib,
<break/>
EGFR and HER2
<break/>
TK Inhibitor
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lapatinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Short-term administration of Lapatinib showed clinical activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00371566">NCT00371566</ext-link><break/>[<xref rid="B72-pharmaceutics-16-01196" ref-type="bibr">72</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Malignant tumors of the salivary glands</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lapatinib ditosylate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lapatinib administration was shown to be tolerable, leading, in 36% of patients, to a 6-month tumor stabilization; however, the effects observed were mainly cytostatic.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00095563">NCT00095563</ext-link><break/>[<xref rid="B156-pharmaceutics-16-01196" ref-type="bibr">156</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lapatinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Well tolerated but showed no clinical activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B157-pharmaceutics-16-01196" ref-type="bibr">157</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with Lapatinib, Carboplatin, and Paclitaxel followed by Transoral surgery and neck dissection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The therapeutic approach was feasible and led to DSS, PFS, and OS rates of 100%, 97%, and 97%, respectively, with a median follow-up of 4.9 years.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01612351">NCT01612351</ext-link><break/>[<xref rid="B158-pharmaceutics-16-01196" ref-type="bibr">158</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
Dacomitinib, EGFR, HER2, and HER4
<break/>
TK Inhibitor
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dacomitinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Administration of Dacomitinib with a gastrostomy feeding tube led to reduced AUC and Cmax compared to oral dosing of intact immediate-release tablets.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01484847">NCT01484847</ext-link><break/>[<xref rid="B159-pharmaceutics-16-01196" ref-type="bibr">159</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dacomitinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Manageable toxicity with clinical activity. Primary endpoint was met.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B80-pharmaceutics-16-01196" ref-type="bibr">80</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dacomitinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The treatment was tolerable, showing clinical efficacy in platinum-refractory R/M HNSCC patients. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01449201">NCT01449201</ext-link><break/>[<xref rid="B160-pharmaceutics-16-01196" ref-type="bibr">160</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
Poziotinib,
<break/>
EGFR, HER2, and HER4
<break/>
TK Inhibitor
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poziotinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poziotinib led to an ORR of 22.4%, median PFS of 4.0 months, and median OS of 7.6 months.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02216916">NCT02216916</ext-link><break/>[<xref rid="B161-pharmaceutics-16-01196" ref-type="bibr">161</xref>]</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
Panitumumab, EGFR Monoclonal Antibody
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Panitumumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Showed moderate clinical activity with a considerable disease-control rate. It was deemed safe.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02643056">NCT02643056</ext-link><break/>[<xref rid="B162-pharmaceutics-16-01196" ref-type="bibr">162</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Panitumumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Showed limited activity, leading to ORR of 4%, DCR of 39%, PFS of 1.4 months, and OS of 5.1 months.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00446446">NCT00446446</ext-link><break/>[<xref rid="B163-pharmaceutics-16-01196" ref-type="bibr">163</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Panitumumab plus Paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Showed clinical activity with a good safety profile.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01264328">NCT01264328</ext-link><break/>[<xref rid="B164-pharmaceutics-16-01196" ref-type="bibr">164</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC with Panitumumab and<break/>Paclitaxel followed by Panitumumab plus<break/>Radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Worse toxicity than anticipated but showed clinical activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B165-pharmaceutics-16-01196" ref-type="bibr">165</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Panitumumab plus Paclitaxel, Carboplatin, and<break/>IMRT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safe with good activity, with 95% of patients remaining disease-free at median follow-up of 21 months.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B166-pharmaceutics-16-01196" ref-type="bibr">166</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Panitumumab, Docetaxel, and<break/>Cisplatin<break/>vs.<break/>Docetaxel plus Cisplatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Addition of Panitumumab to Docetaxel plus Cisplatin increased the PFS (6.9 vs 5.5 months) and ORR (44% vs 37%). However, a worse OS was observed (12.9 vs 13.8 months).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00454779">NCT00454779</ext-link><break/>[<xref rid="B167-pharmaceutics-16-01196" ref-type="bibr">167</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
Nimotuzumab, EGFR Monoclonal Antibody
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Resistant LA NPC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nimotuzumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Showed clinical activity with mild toxicity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04508816">NCT04508816</ext-link><break/>[<xref rid="B168-pharmaceutics-16-01196" ref-type="bibr">168</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
Duligotuzumab
<break/>
EGFR and HER3 Monoclonal Antibody
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duligotuzumab<break/>vs.<break/>Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duligotuzumab did not improve the outcomes when compared with Cetuximab.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01577173">NCT01577173</ext-link><break/>[<xref rid="B169-pharmaceutics-16-01196" ref-type="bibr">169</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duligotuzumab plus Cisplatin and 5-FU<break/>or<break/>Carboplatin and<break/>Paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Both combinations showed good activity but with increased toxicity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01911598">NCT01911598</ext-link><break/>[<xref rid="B170-pharmaceutics-16-01196" ref-type="bibr">170</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
A166,
<break/>
HER2
<break/>
Antibody Drug Conjugate
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid tumors (including SGC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A166</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In phase I, the recommended concentration was obtained. Manageable toxicity and promising clinical activity were observed. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03602079">NCT03602079</ext-link><break/>[<xref rid="B171-pharmaceutics-16-01196" ref-type="bibr">171</xref>]</td></tr><tr><td rowspan="11" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
Gefitinib,
<break/>
EGFR
<break/>
TK Inhibitor
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid tumors (including HNSCC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gefitinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Showed activity and a manageable safety profile.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B172-pharmaceutics-16-01196" ref-type="bibr">172</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cutaneous HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gefitinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Showed clinical activity and was deemed safe.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B173-pharmaceutics-16-01196" ref-type="bibr">173</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M NPC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gefitinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weak response rate but well tolerated.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B174-pharmaceutics-16-01196" ref-type="bibr">174</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SGC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gefitinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No significant clinical activity was observed.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00509002">NCT00509002</ext-link><break/>[<xref rid="B175-pharmaceutics-16-01196" ref-type="bibr">175</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gefitinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Was well tolerated. An ORR of 10.6%, a DCR of 53%, a PFS of 3.4 months, and an OS of 8.1 months were observed.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B176-pharmaceutics-16-01196" ref-type="bibr">176</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gefitinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gefitinib monotherapy showed clinical activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B177-pharmaceutics-16-01196" ref-type="bibr">177</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gefitinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gefitinib showed less activity at 250 mg than at 500 mg.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B178-pharmaceutics-16-01196" ref-type="bibr">178</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced solid tumors<break/>(including HNC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gefitinib plus Docetaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A recommended dose for phase II trials was achieved (gefitinib 2250 mg on days 1 and 2, followed by docetaxel 75 mg/m<sup>2</sup> on day 3).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B179-pharmaceutics-16-01196" ref-type="bibr">179</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gefitinib plus<break/>Docetaxel<break/>vs.<break/>Docetaxel alone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The combination showed good tolerability but no outcome improvements.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00088907">NCT00088907</ext-link><break/>[<xref rid="B180-pharmaceutics-16-01196" ref-type="bibr">180</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gefitinib plus Paclitaxel and Radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Addition of Gefitinib to Paclitaxel with radiotherapy does not seem to improve response rates.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B181-pharmaceutics-16-01196" ref-type="bibr">181</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carboplatin or Paclitaxel IC followed by<break/>5-FU,<break/>Hydroxyurea, Radiotherapy, and Gefitinib followed by continued Gefitinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The treatment approach was feasible and showed promising activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B182-pharmaceutics-16-01196" ref-type="bibr">182</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
Zalutumumab, EGFR Monoclonal Antibody
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zalutumumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preliminary data indicated promising tumor response and the MTD was achieved.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B183-pharmaceutics-16-01196" ref-type="bibr">183</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Platinum-refractory HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zalutumumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zalutumumab led to an ORR of 5.7%, a DCR of 39.8%, an OS of 5.3 months, and a PFS of 2.1 months.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00542308">NCT00542308</ext-link><break/>[<xref rid="B184-pharmaceutics-16-01196" ref-type="bibr">184</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zalutumumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In patients who failed platinum-based chemotherapy, it improved the PFS, but no improvement was observed in OS.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00382031">NCT00382031</ext-link><break/>[<xref rid="B185-pharmaceutics-16-01196" ref-type="bibr">185</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
CDX-3379,
<break/>
HER3
<break/>
Monoclonal Antibody
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CDX-3379</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Window-of-<break/>opportunity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The regimen was tolerable and led to tumor regression.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02473731">NCT02473731</ext-link><break/>[<xref rid="B186-pharmaceutics-16-01196" ref-type="bibr">186</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
Barecetamab,
<break/>
HER3 Monoclonal Antibody
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Barecetamab<break/>vs.<break/>Barecetamab plus Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ia/Ib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The recommended dose for phase II trials was achieved. Both treatment approaches were deemed safe and led to meaningful anticancer activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03552406">NCT03552406</ext-link><break/>[<xref rid="B187-pharmaceutics-16-01196" ref-type="bibr">187</xref>]</td></tr><tr><td rowspan="10" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
Afatinib,
<break/>
EGFR, HER2, and HER4
<break/>
TK Inhibitor
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib induced a high rate of metabolic response. Patients who responded to treatment had a higher expression of pERK1/2 and lower expressions of pHER4 and pRB1.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01415674">NCT01415674</ext-link><break/>[<xref rid="B188-pharmaceutics-16-01196" ref-type="bibr">188</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib led to a high rate of FDG-PET partial metabolic response and partial response. Furthermore, it was deemed safe to be administered before surgery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01538381">NCT01538381</ext-link><break/>[<xref rid="B189-pharmaceutics-16-01196" ref-type="bibr">189</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DFS showed no improvement after treatment with afatinib<break/>after CRT while increasing the number of adverse events.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01345669">NCT01345669</ext-link><break/>[<xref rid="B190-pharmaceutics-16-01196" ref-type="bibr">190</xref>,<xref rid="B191-pharmaceutics-16-01196" ref-type="bibr">191</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib vs. Methotrexate as second-line treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib was deemed safe and improved PFS.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01345682">NCT01345682</ext-link><break/>[<xref rid="B77-pharmaceutics-16-01196" ref-type="bibr">77</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib as a second-line treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Effective by oral and tube administration with manageable toxicity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01345682">NCT01345682</ext-link><break/>[<xref rid="B192-pharmaceutics-16-01196" ref-type="bibr">192</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib vs. Methotrexate as a second-line treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib was deemed safe and improved PFS.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01856478">NCT01856478</ext-link><break/>[<xref rid="B193-pharmaceutics-16-01196" ref-type="bibr">193</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib as second line treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Effective by oral and tube administration with manageable toxicity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01345682">NCT01345682</ext-link><break/>[<xref rid="B192-pharmaceutics-16-01196" ref-type="bibr">192</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R/M HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib<break/>vs.<break/>Cetuximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib showed similar efficacy to Cetuximab but with higher toxicity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B76-pharmaceutics-16-01196" ref-type="bibr">76</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib plus Ribavirin and weekly Carboplatin and<break/>Paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The combinatorial approach was safe and well tolerated.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B194-pharmaceutics-16-01196" ref-type="bibr">194</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA HNSCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Afatinib,<break/>Carboplatin, and Paclitaxel as IC followed by Cisplatin and Radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The MTD was achieved.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01732640">NCT01732640</ext-link><break/>[<xref rid="B195-pharmaceutics-16-01196" ref-type="bibr">195</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: 5-FU: 5-fluorouracil; AUC: area under the concentration&#8211;time curve; CFS: cancer-free survival; C<sub>max</sub>: maximum observed concentration; CR: complete response; CRR: complete response rate; CRT: chemoradiation; DCR: disease-control rate; DFS: disease-free survival; DSS: disease-specific survival; EGFR: epidermal growth factor receptor; FDG-PET: 18-Fluoro-deoxyglucose positron emission tomography; HER3: human epidermal growth factor receptor 3; HNC: head and neck cancer; HNSCC: head and neck squamous cell carcinoma; IC: induction chemotherapy; IMRT: intensity-modulated radiation therapy; LA HNC: locoregionally advanced head and neck cancer; LA HNSCC: locoregionally advanced head and neck squamous cell carcinoma; LA NPC: locoregionally advanced nasopharyngeal carcinoma; MTD: maximum tolerated dose; Nab-paclitaxel: nanoparticle albumin-bound paclitaxel; NPC: nasopharyngeal carcinoma; OCSCC: oral cavity squamous cell carcinoma; OPSCC: oropharyngeal squamous cell carcinoma; ORR: objective response rate; OS: overall survival; OSCC: oral squamous cell carcinoma; PD-1: programmed cell death 1; PET/CT: positron emission tomography/computed tomography; PFS: progression-free survival; R/M HNSCC: recurrent or metastatic head and neck squamous cell carcinoma; R/M NPC: recurrent or metastatic nasopharyngeal carcinoma; R/M SGC: recurrent or metastatic salivary gland carcinoma; RR: response rate; SGC: salivary gland cancer; TFHX: paclitaxel, fluorouracil, hydroxyurea, and radiotherapy; TK: tyrosine kinase; TPF: docetaxel, cisplatin, and 5-FU.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3-pharmaceutics-16-01196"><title>3. Overview of Classic Microtubule-Targeting Agents (MTAs) versus Second-Generation of Antimitotics (SGAs)</title><p>The deregulation of cellular metabolism and the alterations in the cell cycle of tumor cells has triggered vast research on therapies focusing on antimitotic drugs, mostly MTAs, which can be categorized into two groups based on their distinct mechanisms of action: microtubule destabilizers, such as the vinca alkaloids, which impede the polymerization of microtubules, and microtubule stabilizers, such as taxanes, which enhance microtubule polymerization [<xref rid="B196-pharmaceutics-16-01196" ref-type="bibr">196</xref>]. Both classes exert their effects by disrupting the proper formation of the mitotic spindle, leading to the activation of the SAC, subsequent arrest of the cell cycle at the mitotic phase, and typically followed by cell death [<xref rid="B197-pharmaceutics-16-01196" ref-type="bibr">197</xref>]. However, prolonged mitotic arrest caused by MTAs can trigger the exit of cells from mitosis without undergoing cytokinesis, resulting in the generation of tetraploid cells. This process, known as mitotic slippage, arises from the gradual and continuous degradation of cyclin B1, even in the presence of an active SAC [<xref rid="B198-pharmaceutics-16-01196" ref-type="bibr">198</xref>]. Cells that have undergone mitotic slippage have three possible outcomes: entering a senescent state, undergoing post-mitotic death, or continuing to divide. Therefore, mitotic slippage, in conjunction with factors such as efflux pumps, mutations in tubulin genes, and compromised apoptotic signaling, significantly contribute to the therapeutic inefficacy of MTAs [<xref rid="B199-pharmaceutics-16-01196" ref-type="bibr">199</xref>]. Moreover, treatment with MTAs frequently gives rise to neurological and myeloid toxicity [<xref rid="B200-pharmaceutics-16-01196" ref-type="bibr">200</xref>]. Because of all these limitations, the need arose to develop drugs targeting mitotic proteins, especially kinases and motor proteins. Thus, second-generation antimitotics (SGAs) emerged with inhibitors of MPS1, polo-like kinase 1 (PLK1), Aurora kinases, KSP, and centromeric protein E (CENP-E) [<xref rid="B201-pharmaceutics-16-01196" ref-type="bibr">201</xref>]. From the perspective of SAC response, the small molecule inhibitors known as SGAs can be classified into two distinct groups [<xref rid="B201-pharmaceutics-16-01196" ref-type="bibr">201</xref>]. The first group comprises mitotic blockers, which target essential proteins such as CENP-E, KSP, and PLK1. These inhibitors trigger the activation of the SAC, leading to a prolonged delay in mitosis with the ultimate expectation of inducing cell death. Conversely, the second group, known as mitotic drivers, includes inhibitors targeting MPS1 and Aurora B kinase. These compounds override the SAC, causing premature exit from mitosis, accompanied by extensive chromosome mis-segregation. Consequently, this results in the emergence of chromosome aberrations that render daughter cells non-viable. Given this phenotype, the combination of MPS1 inhibition with MTA co-treatment has been explored in different cancer types (<xref rid="pharmaceutics-16-01196-t002" ref-type="table">Table 2</xref>).</p></sec><sec id="sec4-pharmaceutics-16-01196"><title>4. Targeting Monopolar Spindle 1 (MPS1) in Cancer</title><p>MPS1 is a dual-specific protein kinase composed of 857 residues that phosphorylates serine and threonine residues [<xref rid="B203-pharmaceutics-16-01196" ref-type="bibr">203</xref>]. It is located on chromosome 6q13-q21 and functions as a crucial regulator of the SAC, playing a pivotal role in controlling cell cycle progression and preserving genomic stability (<xref rid="pharmaceutics-16-01196-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B204-pharmaceutics-16-01196" ref-type="bibr">204</xref>]. In addition, it is involved in the regulation of cytochrome c release, response to DNA damage, and centrosome duplication [<xref rid="B205-pharmaceutics-16-01196" ref-type="bibr">205</xref>]. MPS1 is a vital regulator of chromosome alignment during metaphase, ensuring that aneuploidy is prevented. SAC is responsible for monitoring chromosome segregation and halting cell division upon detecting any anomalies. MPS1 is recruited to unattached kinetochores where it is suggested it binds to the NDC80 complex, part of the KMN network [<xref rid="B206-pharmaceutics-16-01196" ref-type="bibr">206</xref>]. There, MPS1 phosphorylates kinetochore scaffold 1, another component of the KMN network that is essential for the recruitment of SAC proteins such as budding uninhibited by benzimidazoles (BUB) 3, which is bound to BUB1. MPS1 also phosphorylates BUB1, promoting the recruitment of the mitotic arrest deficient (MAD) 1:C&#8211;MAD2 complex [<xref rid="B206-pharmaceutics-16-01196" ref-type="bibr">206</xref>,<xref rid="B207-pharmaceutics-16-01196" ref-type="bibr">207</xref>]. The activity of MPS1 is essential for the formation of the mitotic checkpoint complex (MCC) and activation of the SAC [<xref rid="B208-pharmaceutics-16-01196" ref-type="bibr">208</xref>]. MCC inhibits the anaphase-promoting complex/Cyclosome (APC/C), thus preventing premature initiation of anaphase. The interaction between MPS1 and APC is critical for cell cycle regulation. Specifically, when APC/C binds to its positive regulator, cell-division cycle protein 20 (CDC20), SAC activity is inhibited. Conversely, SAC can interfere with APC/C-CDC20 binding through MAD2, a negative regulator of APC/C. MPS1 is involved in this process through the phosphorylation of Mad1, which promotes the interaction of MAD2 with CDC20 [<xref rid="B206-pharmaceutics-16-01196" ref-type="bibr">206</xref>]. In this negative feedback loop, if chromosome misalignment occurs, activated SAC can result in APC/C inactivation, leading to MPS1 stabilization and enhanced checkpoint activity. As chromosomes become aligned on the equatorial plate, SAC activity gradually reduces, and APC/C is activated, ultimately resulting in the degradation of MPS1. This process reduces checkpoint activity and initiates the next cell cycle [<xref rid="B209-pharmaceutics-16-01196" ref-type="bibr">209</xref>,<xref rid="B210-pharmaceutics-16-01196" ref-type="bibr">210</xref>]. Another level of MPS1 activity regulation comes from protein phosphatase 1 (PP1). PP1 is a serine/threonine phosphatase involved in essential processes such as the cell cycle, apoptosis, etc. [<xref rid="B211-pharmaceutics-16-01196" ref-type="bibr">211</xref>]. This protein directly prevents MPS1 T-loop autophosphorylation, leading to the inactivation of this kinase at metaphase kinetochores and in the cytoplasm. This inactivation is crucial for the rapid silencing of SAC and timely progression through mitosis [<xref rid="B212-pharmaceutics-16-01196" ref-type="bibr">212</xref>]. </p><p>In addition to SAC overdriving, inhibition of MPS1 leads to chromosome mis-segregation and consequently to cell death. Nonetheless, in aneuploid cancer cells, it was shown that SAC inactivation is not necessary for MPS1 inhibition to cause cell death since MPS1 is also involved in the regulation of cytochrome c release [<xref rid="B213-pharmaceutics-16-01196" ref-type="bibr">213</xref>]. Therefore, the relevancy of MPS1 for tumor cell viability has led to the development of compounds for this therapeutic target over the last few years. </p><p>Currently, there are six MPS1 inhibitors approved and in use for clinical trials; these are S81694, BOS172722, BAY 1217389, BAY 1161909, CFI-402257, and BAL0891 [<xref rid="B18-pharmaceutics-16-01196" ref-type="bibr">18</xref>,<xref rid="B34-pharmaceutics-16-01196" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-16-01196" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-16-01196" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-16-01196" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-16-01196" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceutics-16-01196" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-16-01196" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-16-01196" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-16-01196" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-16-01196" ref-type="bibr">43</xref>] (<xref rid="pharmaceutics-16-01196-t001" ref-type="table">Table 1</xref>). </p><p>In human colorectal carcinoma cell lines, BOS172722 led to growth inhibition while early mitotic exit and induction of aneuploidy were observed in triple-negative breast cancer cells (TNBCs). Synergistic effects in combination with paclitaxel were also observed both in vitro and in vivo [<xref rid="B214-pharmaceutics-16-01196" ref-type="bibr">214</xref>]. An ongoing phase 1/1b clinical trial is assessing the safety and maximum tolerated dose of BOS172722 in combination with Paclitaxel in advanced nonhematologic malignancies (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03328494">NCT03328494</ext-link>) [<xref rid="B215-pharmaceutics-16-01196" ref-type="bibr">215</xref>].</p><p>S81694 leads to mitotic overriding, chromosomal alignment errors, induction of apoptosis, and consequently cell death, and showed antitumor effects both in vitro and in vivo [<xref rid="B216-pharmaceutics-16-01196" ref-type="bibr">216</xref>]. A phase I clinical trial with patients with advanced metastatic solid tumors showed that administration of S81694 was safe, with an 8.1-week median progression-free survival (PFS). Nonetheless, the recommended phase II dose was not defined since combination with paclitaxel in breast cancer patients was prioritized due to promising preclinical results [<xref rid="B216-pharmaceutics-16-01196" ref-type="bibr">216</xref>]. However, the study was terminated due to disappointing clinical activity.</p><p>BAY 1161909 in an osteosarcoma cell line (U-2 OS) induced aneuploidy, while in a cisplatin-resistant ovarian tumor xenograft model (A2780cis), moderate efficacy was observed with a good safety profile and improved inhibition of tumor growth when compared with cisplatin. BAY 1217389 showed similar results in the same murine model [<xref rid="B217-pharmaceutics-16-01196" ref-type="bibr">217</xref>]. In addition, both inhibitors reported moderate efficacy as monotherapy in several tumor murine models mainly because of tolerability issues [<xref rid="B218-pharmaceutics-16-01196" ref-type="bibr">218</xref>]. Nonetheless, in TNBC xenografts, antitumor synergistic effects were observed for these inhibitors when in combination with paclitaxel [<xref rid="B218-pharmaceutics-16-01196" ref-type="bibr">218</xref>]. In accordance, tumor growth delay was observed with the combination of BAY 1217389 and paclitaxel while the combination of paclitaxel and BAY 1161909 led to full tumor remission. In non-small cell lung cancer (NSCLC) xenograft models, BAY 1217389 and paclitaxel showed better results than paclitaxel alone. Moreover, paclitaxel in combination with BAY 1161909 showed good tolerability and reduced tumor growth and size [<xref rid="B217-pharmaceutics-16-01196" ref-type="bibr">217</xref>]. Based on the encouraging outcomes observed in preclinical in vivo studies, demonstrating a synergistic effect between MPS1 inhibitors and taxanes, several small molecules have undergone clinical trials in combination with paclitaxel. In a clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02138812">NCT02138812</ext-link>) evaluating the efficacy of BAY1161909 in the treatment of advanced solid malignancies, the combination of BAY1161909 and paclitaxel at doses of 75 mg/m<sup>2</sup> and 90 mg/m<sup>2</sup> yielded five (14%) and four (14%) partial responses (PRs), respectively [<xref rid="B28-pharmaceutics-16-01196" ref-type="bibr">28</xref>]. Despite these promising results, Bayer suspended the clinical trial and replaced BAY 1161909 with BAY 1217389 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02366949">NCT02366949</ext-link>). The results of this phase I clinical trial for patients with advanced malignancies showed that the combination of paclitaxel and BAY 1217389 led to high toxicity, with bone marrow toxicity as a significant adverse reaction. Nonetheless, a maximum tolerated dose was achieved for the combination [<xref rid="B202-pharmaceutics-16-01196" ref-type="bibr">202</xref>].</p><p>CFI-402257 is a potent inhibitor of MPS1 that leads to errors in chromosome segregation, DNA damage, and consequently cell death [<xref rid="B219-pharmaceutics-16-01196" ref-type="bibr">219</xref>]. In lung cancer, both in vitro and in vivo, this inhibitor showed promising antitumor effects by enhancing apoptosis and polyploidy [<xref rid="B220-pharmaceutics-16-01196" ref-type="bibr">220</xref>]. The administration of CFI-402257 in hepatocellular carcinoma increased apoptosis and aneuploidy and suppressed tumor growth while leading to the activation of a DNA pathway involved in senescence-associated secretory phenotype. In addition, in a murine model, combining an anti-PD-1 drug with CFI-402257 increased survival [<xref rid="B221-pharmaceutics-16-01196" ref-type="bibr">221</xref>]. Furthermore, the addition of CFI-402257 to breast cancer cell lines resistant to the inhibition of CDK4/6 demonstrated improved anticancer effects. Thus, it is suggested that CFI-402257 administration could be beneficial to ER<sup>+</sup> breast cancer patients resistant to CDK4/6-targeting therapies [<xref rid="B220-pharmaceutics-16-01196" ref-type="bibr">220</xref>]. In malignant mesothelioma cell lines, CFI-402257 led to increased aneuploidy and cell death while it led to tumor growth delay in vivo. Additionally, when combined with cisplatin and pemetrexed, it showed increased anticancer effects [<xref rid="B222-pharmaceutics-16-01196" ref-type="bibr">222</xref>]. Nonetheless, it is important to note that determining the long-term tolerance and toxicity associated with the use of MPS1 inhibitors requires further investigation [<xref rid="B28-pharmaceutics-16-01196" ref-type="bibr">28</xref>,<xref rid="B52-pharmaceutics-16-01196" ref-type="bibr">52</xref>]. All the completed or ongoing clinical trials investigating MPS1 inhibitors have been performed on patients with advanced malignancies (solid tumors) or breast cancer, with no reference to treatments in patients with oral or head and neck cancer.</p></sec><sec id="sec5-pharmaceutics-16-01196"><title>5. Clinical Relevance of MPS1 and EGFR Co-Targeting for Head and Neck Cancer</title><p>Co-targeting MPS1 and EGFR could be a promising therapeutic strategy for the treatment of head and neck cancer, particularly OSCC. On one hand, MPS1 is a key component of the spindle assembly checkpoint, ensuring proper chromosome segregation during mitosis, and its overexpression is correlated with poor prognosis in several cancers. On the other hand, EGFR, a receptor tyrosine kinase, is overexpressed in a significant majority of head and neck cancers and is associated with aggressive tumor behavior and resistance to conventional therapies. Combining inhibitors of MPS1 with EGFR-targeted therapies such as Cetuximab could synergistically enhance treatment efficacy. By simultaneously disrupting mitotic control and EGFR signaling, this approach may effectively halt tumor progression, reduce resistance to treatment, and improve overall survival rates. Preclinical studies have shown that dual inhibition can lead to increased apoptosis and decreased proliferation of cancer cells compared to targeting either pathway alone. Furthermore, this combinatorial strategy aligns with precision medicine goals, offering tailored treatment plans based on the molecular profile of the tumor.</p><p>Thus, to explore a possible co-targeted therapy of both EGFR and MPS1 for the treatment of HNSCC, we used the UALCAN database to obtain data mainly concerning MPS1 expression and head and neck cancer. UALCAN is a comprehensive computational platform that employs advanced bioinformatics techniques and data analytics to facilitate integrative analysis and visualization of cancer genomics data. It serves as a valuable resource for researchers and clinicians, offering access to a vast array of publicly available cancer transcriptomics and clinical data [<xref rid="B223-pharmaceutics-16-01196" ref-type="bibr">223</xref>]. UALCAN uses The Cancer Genome Atlas (TCGA) database to display transcriptomic results, which are presented in transcripts per million. For proteomic information, the Clinical Proteomic Tumor Analysis Consortium (CPTAC) database is used and shown in Z-values. Z-values represent standard deviations from the median across HNSCC samples. Pearson correlation analysis is performed by UALCAN for correlation analysis. For transcriptomic data, the results were provided by UALCAN as transcripts per million, while for proteomic information, the results were expressed as Z-values, which represent standard deviations from the median across HNSCC samples. For correlation analysis, UALCAN used Pearson correlation analysis and provided the Pearson correlation coefficient values. For survival plots, Kaplan&#8211;Meyer curves were generated to express HNSCC patient survival according to MPS1 expression and clinicopathological features. Data are shown as the mean &#177; standard deviation (SD). Statistical significance represented as <italic toggle="yes">p</italic> values were provided by UALCAN. Z-values represent standard deviations from the median across HNSCC samples. Log2 Spectral count ratio values from CPTAC were first normalized within each sample profile and then normalized across samples.</p><p>The analysis performed with the UALCAN web resource showed that both MPS1 mRNA and protein expression levels are upregulated in HNSCC primary tumors, with a median value of transcripts per million approximately 2.5 times higher for tumor samples (<xref rid="pharmaceutics-16-01196-f003" ref-type="fig">Figure 3</xref>a,b). In HNSCC samples with lymphovascular invasion, the MPS1 gene expression was shown to be upregulated when compared to normal samples, and samples with high expression of MPS1 were associated with worse prognosis [<xref rid="B224-pharmaceutics-16-01196" ref-type="bibr">224</xref>], highlighting the potential of MPS1 targeting for head and neck cancer. Moreover, overexpression of MPS1 has been associated with shorter periods of recurrence and survival time and is correlated with poor prognosis in several types of cancers [<xref rid="B205-pharmaceutics-16-01196" ref-type="bibr">205</xref>,<xref rid="B225-pharmaceutics-16-01196" ref-type="bibr">225</xref>]. </p><p>Most HPV-positive HNSCC tumors originate from the oropharynx where there is a correlation between HPV status and patient survival since HPV-positive tumors are usually more responsive to treatment and associated with favorable survival [<xref rid="B226-pharmaceutics-16-01196" ref-type="bibr">226</xref>,<xref rid="B227-pharmaceutics-16-01196" ref-type="bibr">227</xref>]. The UALCAN analysis of MPS1 transcriptional expression by HPV status showed a statistically significant increase in MPS1 expression levels in both HPV-positive and negative samples when compared to normal samples. In addition, a significant difference was observed when comparing both HPV statuses, suggesting that HPV-positive HNSCC has a higher expression of MPS1 (<xref rid="pharmaceutics-16-01196-f003" ref-type="fig">Figure 3</xref>c). </p><p>According to UALCAN data, increased levels of MPS1 are linked with the presence of altered mTOR, RTK, and nuclear factor erythroid 2 related factor 2 (NRF2) pathways (<xref rid="pharmaceutics-16-01196-f004" ref-type="fig">Figure 4</xref>).</p><p>The NRF2 pathway is involved in the regulation of oxidative stress response and was recently shown to be frequently mutated in HPV-negative HNSCC but rarely so in HPV-positive HNSCC [<xref rid="B228-pharmaceutics-16-01196" ref-type="bibr">228</xref>]. In addition, high levels of NRF2 are associated with poor prognosis and thus since this pathway acts as a defensive mechanism, its alteration could explain in part why HPV-negative HNSCC is more unresponsive to treatment [<xref rid="B229-pharmaceutics-16-01196" ref-type="bibr">229</xref>]. NRF2 is a transcription factor involved in the expression of antioxidant proteins and chaperones, among others. Its function is negatively regulated by KEAP1, a BTB-Kelch protein that is part of the E3 ubiquitin kinase complex, which is inactivated during oxidative stress [<xref rid="B228-pharmaceutics-16-01196" ref-type="bibr">228</xref>,<xref rid="B230-pharmaceutics-16-01196" ref-type="bibr">230</xref>]. In estrogen-induced breast cancer, NRF2 was shown to prevent oxidative DNA damage by upregulating 8-Oxoguanine DNA glycosylase, a DNA repair protein [<xref rid="B231-pharmaceutics-16-01196" ref-type="bibr">231</xref>]. MPS1 also plays a role in the repair of oxidative DNA lesions by phosphorylating MDM2, which leads to the loosening of the chromatin, allowing DNA cleavage by DNA repair proteins [<xref rid="B232-pharmaceutics-16-01196" ref-type="bibr">232</xref>]. In cancer cells, reactive oxygen species are associated with the promotion of tumorigenesis and chemoresistance and can increase tumor angiogenesis [<xref rid="B233-pharmaceutics-16-01196" ref-type="bibr">233</xref>]. In this sense, co-inhibition of MPS1 and NRF2 could lead to increased cell death through oxidative stress and thus the exploration of this combination could be of interest mainly for the treatment of HPV-negative HNSCC.</p><p>In several types of cancers, MPS1 was shown to be associated with the AKT/mTOR pathway [<xref rid="B24-pharmaceutics-16-01196" ref-type="bibr">24</xref>,<xref rid="B234-pharmaceutics-16-01196" ref-type="bibr">234</xref>,<xref rid="B235-pharmaceutics-16-01196" ref-type="bibr">235</xref>,<xref rid="B236-pharmaceutics-16-01196" ref-type="bibr">236</xref>,<xref rid="B237-pharmaceutics-16-01196" ref-type="bibr">237</xref>,<xref rid="B238-pharmaceutics-16-01196" ref-type="bibr">238</xref>]. This pathway is involved in tumor cell proliferation and survival and is reported to be overexpressed in 90% of HNSCC tumors [<xref rid="B239-pharmaceutics-16-01196" ref-type="bibr">239</xref>]. Moreover, it has been shown that increased MPS1 protein expression leads to an increase in phosphorylated AKT proteins [<xref rid="B234-pharmaceutics-16-01196" ref-type="bibr">234</xref>,<xref rid="B235-pharmaceutics-16-01196" ref-type="bibr">235</xref>]. However, it is not clear if MPS1 directly phosphorylates AKT or if other proteins are involved in this phosphorylation. Nonetheless, in both esophageal squamous cell carcinoma (ESCC) and hepatocellular carcinoma cells, MPS1 activates the AKT/mTOR pathway, promoting cell proliferation and migration [<xref rid="B24-pharmaceutics-16-01196" ref-type="bibr">24</xref>,<xref rid="B238-pharmaceutics-16-01196" ref-type="bibr">238</xref>]. Furthermore, in ESCC, this activation was shown to be regulated by Annexin A2 [<xref rid="B238-pharmaceutics-16-01196" ref-type="bibr">238</xref>], while in ovarian cancer and renal cancer, it was shown that MPS1 inhibits apoptosis through this pathway [<xref rid="B235-pharmaceutics-16-01196" ref-type="bibr">235</xref>]. Additionally, EGFR, an RTK, was shown to activate the PI3K/AKT/mTOR pathway, and it is overexpressed in HNSCC, as corroborated by the UALCAN analysis (<xref rid="pharmaceutics-16-01196-f005" ref-type="fig">Figure 5</xref>) [<xref rid="B240-pharmaceutics-16-01196" ref-type="bibr">240</xref>].</p><p>Nonetheless, alterations in this pathway can lead to resistance to EGFR inhibition [<xref rid="B241-pharmaceutics-16-01196" ref-type="bibr">241</xref>]. Recently, in lung cancer cells, inhibition of Aurora B, a kinase involved in chromosomal segregation and cytokinesis, was shown to prevent and overcome EGFR inhibition resistance by increasing apoptosis mediated by BIM and PUMA, BH3 domain-containing proteins that are involved in the activation of proapoptotic proteins [<xref rid="B242-pharmaceutics-16-01196" ref-type="bibr">242</xref>]. Aurora B also plays a role in the recruitment of MPS1 to unattached kinetochores by phosphorylating Hec1, a NDC80 complex protein [<xref rid="B243-pharmaceutics-16-01196" ref-type="bibr">243</xref>]. This complex is involved in the attachment of microtubules to chromosomes [<xref rid="B244-pharmaceutics-16-01196" ref-type="bibr">244</xref>]. In addition, it was also reported that MPS1 is essential for activating regulators of Aurora B activity and consequently for promoting Aurora B recruitment to centromeres [<xref rid="B245-pharmaceutics-16-01196" ref-type="bibr">245</xref>,<xref rid="B246-pharmaceutics-16-01196" ref-type="bibr">246</xref>]. Thus, since MPS1 has a role in both the AKT/mTOR pathway and in the activation of Aurora B activity, we believe that a combinatorial approach targeting EGFR and MPS1 could lead to an enhanced antiproliferative effect and increased cell death, and also prevent or overcome resistance to EGFR inhibition therapy in HNSCC. </p></sec><sec sec-type="conclusions" id="sec6-pharmaceutics-16-01196"><title>6. Conclusions and Future Perspectives </title><p>Currently, no studies have explored the combination of MPS1 and EGFR-targeting in any cancer type, nor have there been studies into the use of EGFR with other second-generation antimitotic agents in HNSCC. Thus, this constitutes a novel approach to be evaluated in both in vitro and in vivo models that could potentially enhance EGFR-targeting drug efficacy and/or overcome cancer resistance to anti-EGFR drugs.</p><p>Additionally, the potential benefits of co-inhibiting MPS1 and NRF2, particularly for HPV-negative HNSCC, warrant further investigation. Co-inhibiting MPS1 and NRF2 could induce oxidative stress and enhance cell death in cancer cells. Investigating this combination could provide insights into new therapeutic approaches for treating HPV-negative HNSCC, a subtype often associated with worse outcomes compared to HPV-positive HNSCC.</p><p>Research should also focus on the interplay between MPS1, the AKT/mTOR pathway, and Aurora B kinase activity. The AKT/mTOR pathway is a critical regulator of cell proliferation, survival, and metabolism, and is overexpressed in a significant majority of HNSCC tumors. MPS1 has been shown to interact with this pathway, promoting cell proliferation and migration. Additionally, Aurora B kinase is involved in chromosomal segregation and cytokinesis, and its inhibition has been demonstrated to overcome resistance to EGFR inhibition in various cancers. By targeting both MPS1 and EGFR, along with modulating the AKT/mTOR and Aurora B pathways, we could potentially develop a multi-faceted approach to overcome resistance mechanisms in HNSCC. For example, combining MPS1 and Aurora B inhibitors with EGFR-targeted therapies could disrupt multiple critical points in the cell cycle and signaling pathways, leading to enhanced apoptosis and reduced proliferation of cancer cells. </p><p>By addressing these research gaps, we can move closer to developing more effective, targeted treatments for HNC, ultimately improving patient outcomes and survival rates. Integrating co-targeting strategies and exploring the interplay between key signaling pathways will provide a holistic approach to HNC treatment. Continued research and clinical trials will be essential to translate these findings into viable therapeutic options, paving the way for personalized and precision medicine in cancer treatment.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, H.B., L.M., P.M.A.S., J.P.N.S. and M.C.-L.; data collection, M.C.-L., J.P.N.S., B.P. and P.M.A.S.; resources, H.B. and P.M.A.S.; writing&#8212;original draft preparation, M.C.-L.; writing&#8212;review and editing, J.P.N.S., B.P., L.M., P.M.A.S. and H.B.; supervision, H.B., L.M. and P.M.A.S.; funding acquisition and management, H.B. and P.M.A.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data can be shared upon request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-16-01196"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title><source>CA Cancer J. Clin.</source><year>2024</year><volume>74</volume><fpage>229</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id></element-citation></ref><ref id="B2-pharmaceutics-16-01196"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McIlvanna</surname><given-names>E.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gurzawska-Comis</surname><given-names>K.</given-names></name></person-group><article-title>The Impact of the COVID-19 Pandemic on Oral and Oropharyngeal Cancer</article-title><source>Curr. Oral Health Rep.</source><year>2023</year><volume>10</volume><fpage>154</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1007/s40496-023-00349-w</pub-id></element-citation></ref><ref id="B3-pharmaceutics-16-01196"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name></person-group><article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title><source>CA Cancer J. Clin.</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="B4-pharmaceutics-16-01196"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kikuchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Asato</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hamaguchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tamaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mizuta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hori</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kojima</surname><given-names>T.</given-names></name><name name-style="western"><surname>Honda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tsujimura</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Characteristics of Oral Squamous Cell Carcinoma Focusing on Cases Unaffected by Smoking and Drinking: A Multicenter Retrospective Study</article-title><source>Head Neck</source><year>2023</year><volume>45</volume><fpage>1812</fpage><lpage>1822</lpage><pub-id pub-id-type="doi">10.1002/hed.27398</pub-id><pub-id pub-id-type="pmid">37161880</pub-id></element-citation></ref><ref id="B5-pharmaceutics-16-01196"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meier</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Schuderer</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Zeman</surname><given-names>F.</given-names></name><name name-style="western"><surname>Klingelh&#246;ffer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hullmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Spanier</surname><given-names>G.</given-names></name><name name-style="western"><surname>Reichert</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Ettl</surname><given-names>T.</given-names></name></person-group><article-title>Health-Related Quality of Life: A Retrospective Study on Local vs. Microvascular Reconstruction in Patients with Oral Cancer</article-title><source>BMC Oral Health</source><year>2019</year><volume>19</volume><elocation-id>62</elocation-id><pub-id pub-id-type="doi">10.1186/s12903-019-0760-2</pub-id><pub-id pub-id-type="pmid">31029131</pub-id><pub-id pub-id-type="pmcid">PMC6487048</pub-id></element-citation></ref><ref id="B6-pharmaceutics-16-01196"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leemans</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Snijders</surname><given-names>P.J.F.</given-names></name><name name-style="western"><surname>Brakenhoff</surname><given-names>R.H.</given-names></name></person-group><article-title>The Molecular Landscape of Head and Neck Cancer</article-title><source>Nat. Rev. Cancer</source><year>2018</year><volume>18</volume><fpage>269</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1038/nrc.2018.11</pub-id><pub-id pub-id-type="pmid">29497144</pub-id></element-citation></ref><ref id="B7-pharmaceutics-16-01196"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanahan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>Hallmarks of Cancer: The Next Generation</article-title><source>Cell</source><year>2011</year><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="B8-pharmaceutics-16-01196"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sarrion</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>Y.</given-names></name></person-group><article-title>Oral Cancer: Clinical Features</article-title><source>Oral Oncol.</source><year>2010</year><volume>46</volume><fpage>414</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2010.03.009</pub-id><pub-id pub-id-type="pmid">20400366</pub-id></element-citation></ref><ref id="B9-pharmaceutics-16-01196"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohamad</surname><given-names>I.</given-names></name><name name-style="western"><surname>Glaun</surname><given-names>M.D.E.</given-names></name><name name-style="western"><surname>Prabhash</surname><given-names>K.</given-names></name><name name-style="western"><surname>Busheri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Noronha</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hosni</surname><given-names>A.</given-names></name></person-group><article-title>Current Treatment Strategies and Risk Stratification for Oral Carcinoma</article-title><source>Am. Soc. Clin. Oncol. Educ. Book</source><year>2023</year><volume>43</volume><fpage>e389810</fpage><pub-id pub-id-type="doi">10.1200/EDBK_389810</pub-id><pub-id pub-id-type="pmid">37200591</pub-id></element-citation></ref><ref id="B10-pharmaceutics-16-01196"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Burtness</surname><given-names>B.</given-names></name><name name-style="western"><surname>Leemans</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Lui</surname><given-names>V.W.Y.</given-names></name><name name-style="western"><surname>Bauman</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Grandis</surname><given-names>J.R.</given-names></name></person-group><article-title>Head and Neck Squamous Cell Carcinoma</article-title><source>Nat. Rev. Dis. Primers</source><year>2020</year><volume>6</volume><fpage>92</fpage><pub-id pub-id-type="doi">10.1038/s41572-020-00224-3</pub-id><pub-id pub-id-type="pmid">33243986</pub-id><pub-id pub-id-type="pmcid">PMC7944998</pub-id></element-citation></ref><ref id="B11-pharmaceutics-16-01196"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jerjes</surname><given-names>W.</given-names></name><name name-style="western"><surname>Upile</surname><given-names>T.</given-names></name><name name-style="western"><surname>Petrie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Riskalla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hamdoon</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Vourvachis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karavidas</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sandison</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>G.J.</given-names></name><etal/></person-group><article-title>Clinicopathological Parameters, Recurrence, Locoregional and Distant Metastasis in 115 T1-T2 Oral Squamous Cell Carcinoma Patients</article-title><source>Head Neck Oncol.</source><year>2010</year><volume>2</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/1758-3284-2-9</pub-id><pub-id pub-id-type="pmid">20406474</pub-id><pub-id pub-id-type="pmcid">PMC2882907</pub-id></element-citation></ref><ref id="B12-pharmaceutics-16-01196"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name></person-group><article-title>PES1 Is a Biomarker of Head and Neck Squamous Cell Carcinoma and Is Associated with the Tumor Microenvironment</article-title><source>Cancer Med.</source><year>2023</year><volume>12</volume><fpage>12622</fpage><lpage>12638</lpage><pub-id pub-id-type="doi">10.1002/cam4.5948</pub-id><pub-id pub-id-type="pmid">37076985</pub-id><pub-id pub-id-type="pmcid">PMC10278488</pub-id></element-citation></ref><ref id="B13-pharmaceutics-16-01196"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Clinical Utility of PDX Cohorts to Reveal Biomarkers of Intrinsic Resistance and Clonal Architecture Changes Underlying Acquired Resistance to Cetuximab in HNSCC</article-title><source>Signal Transduct. Target. Ther.</source><year>2022</year><volume>7</volume><fpage>73</fpage><pub-id pub-id-type="doi">10.1038/s41392-022-00908-0</pub-id><pub-id pub-id-type="pmid">35260570</pub-id><pub-id pub-id-type="pmcid">PMC8904860</pub-id></element-citation></ref><ref id="B14-pharmaceutics-16-01196"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Rayes</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>LoRusso</surname><given-names>P.M.</given-names></name></person-group><article-title>Targeting the Epidermal Growth Factor Receptor</article-title><source>Br. J. Cancer</source><year>2004</year><volume>91</volume><fpage>418</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6601921</pub-id><pub-id pub-id-type="pmid">15238978</pub-id><pub-id pub-id-type="pmcid">PMC2409851</pub-id></element-citation></ref><ref id="B15-pharmaceutics-16-01196"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solomon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Young</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Rischin</surname><given-names>D.</given-names></name></person-group><article-title>Head and Neck Squamous Cell Carcinoma: Genomics and Emerging Biomarkers for Immunomodulatory Cancer Treatments</article-title><source>Semin. Cancer Biol.</source><year>2018</year><volume>52</volume><fpage>228</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2018.01.008</pub-id><pub-id pub-id-type="pmid">29355614</pub-id></element-citation></ref><ref id="B16-pharmaceutics-16-01196"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pai</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Westra</surname><given-names>W.H.</given-names></name></person-group><article-title>Molecular Pathology of Head and Neck Cancer: Implications for Diagnosis, Prognosis, and Treatment</article-title><source>Annu. Rev. Pathol. Mech. Dis.</source><year>2009</year><volume>4</volume><fpage>49</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1146/annurev.pathol.4.110807.092158</pub-id><pub-id pub-id-type="pmid">18729723</pub-id><pub-id pub-id-type="pmcid">PMC3703474</pub-id></element-citation></ref><ref id="B17-pharmaceutics-16-01196"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaryouh</surname><given-names>H.</given-names></name><name name-style="western"><surname>De Pauw</surname><given-names>I.</given-names></name><name name-style="western"><surname>Baysal</surname><given-names>H.</given-names></name><name name-style="western"><surname>Peeters</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vermorken</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Lardon</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>A.</given-names></name></person-group><article-title>Recent Insights in the PI3K/Akt Pathway as a Promising Therapeutic Target in Combination with EGFR-targeting Agents to Treat Head and Neck Squamous Cell Carcinoma</article-title><source>Med. Res. Rev.</source><year>2022</year><volume>42</volume><fpage>112</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1002/med.21806</pub-id><pub-id pub-id-type="pmid">33928670</pub-id></element-citation></ref><ref id="B18-pharmaceutics-16-01196"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnum</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>O&#8217;Connell</surname><given-names>M.J.</given-names></name></person-group><article-title>Cell Cycle Regulation by Checkpoints</article-title><source>Methods Mol. Biol.</source><year>2014</year><volume>1170</volume><fpage>29</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">24906307</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-0888-2_2</pub-id><pub-id pub-id-type="pmcid">PMC4990352</pub-id></element-citation></ref><ref id="B19-pharmaceutics-16-01196"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lara-Gonzalez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Westhorpe</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>S.S.</given-names></name></person-group><article-title>The Spindle Assembly Checkpoint</article-title><source>Curr. Biol.</source><year>2012</year><volume>22</volume><fpage>R966</fpage><lpage>R980</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2012.10.006</pub-id><pub-id pub-id-type="pmid">23174302</pub-id></element-citation></ref><ref id="B20-pharmaceutics-16-01196"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qiang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>Upregulation of TTK Expression Is Associated with Poor Prognosis and Immune Infiltration in Endometrial Cancer Patients</article-title><source>Cancer Cell Int.</source><year>2024</year><volume>24</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.1186/s12935-023-03192-2</pub-id><pub-id pub-id-type="pmid">38195567</pub-id><pub-id pub-id-type="pmcid">PMC10775523</pub-id></element-citation></ref><ref id="B21-pharmaceutics-16-01196"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Novais</surname><given-names>P.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>P.M.A.</given-names></name><name name-style="western"><surname>Amorim</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bousbaa</surname><given-names>H.</given-names></name></person-group><article-title>Second-Generation Antimitotics in Cancer Clinical Trials</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>1011</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13071011</pub-id><pub-id pub-id-type="pmid">34371703</pub-id><pub-id pub-id-type="pmcid">PMC8309102</pub-id></element-citation></ref><ref id="B22-pharmaceutics-16-01196"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pugh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pancholi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Purat</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Agudo-Alvarez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Benito-Arenas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bastida</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bolanos-Garcia</surname><given-names>V.M.</given-names></name></person-group><article-title>Computational Biology Dynamics of Mps1 Kinase Molecular Interactions with Isoflavones Reveals a Chemical Scaffold with Potential to Develop New Therapeutics for the Treatment of Cancer</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>14228</elocation-id><pub-id pub-id-type="doi">10.3390/ijms232214228</pub-id><pub-id pub-id-type="pmid">36430712</pub-id><pub-id pub-id-type="pmcid">PMC9692432</pub-id></element-citation></ref><ref id="B23-pharmaceutics-16-01196"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S.</given-names></name><etal/></person-group><article-title>TTK Is a Favorable Prognostic Biomarker for Triple-Negative Breast Cancer Survival</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>81815</fpage><lpage>81829</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.13245</pub-id><pub-id pub-id-type="pmid">27833085</pub-id><pub-id pub-id-type="pmcid">PMC5348432</pub-id></element-citation></ref><ref id="B24-pharmaceutics-16-01196"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name></person-group><article-title>TTK Activates Akt and Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>34309</fpage><lpage>34320</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.5295</pub-id><pub-id pub-id-type="pmid">26418879</pub-id><pub-id pub-id-type="pmcid">PMC4741454</pub-id></element-citation></ref><ref id="B25-pharmaceutics-16-01196"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stratford</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Major</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Graves</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Der</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>J.J.</given-names></name></person-group><article-title>Genetic and Pharmacological Inhibition of TTK Impairs Pancreatic Cancer Cell Line Growth by Inducing Lethal Chromosomal Instability</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0174863</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0174863</pub-id><pub-id pub-id-type="pmid">28380042</pub-id><pub-id pub-id-type="pmcid">PMC5381904</pub-id></element-citation></ref><ref id="B26-pharmaceutics-16-01196"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name></person-group><article-title>Prognostic Prediction Using a Stemness Index-Related Signature in a Cohort of Gastric Cancer</article-title><source>Front. Mol. Biosci.</source><year>2020</year><volume>7</volume><elocation-id>570702</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2020.570702</pub-id><pub-id pub-id-type="pmid">33134315</pub-id><pub-id pub-id-type="pmcid">PMC7504590</pub-id></element-citation></ref><ref id="B27-pharmaceutics-16-01196"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mason</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Kiarash</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brokx</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hodgson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Beletskaya</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>T.W.</given-names></name></person-group><article-title>Functional Characterization of CFI-402257, a Potent and Selective Mps1/TTK Kinase Inhibitor, for the Treatment of Cancer</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>3127</fpage><lpage>3132</lpage><pub-id pub-id-type="doi">10.1073/pnas.1700234114</pub-id><pub-id pub-id-type="pmid">28270606</pub-id><pub-id pub-id-type="pmcid">PMC5373378</pub-id></element-citation></ref><ref id="B28-pharmaceutics-16-01196"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kuroda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hirose</surname><given-names>M.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Handa</surname><given-names>T.</given-names></name></person-group><article-title>Inhibition of Autophosphorylation of Epidermal Growth Factor Receptor by Small Peptides in Vitro</article-title><source>Br. J. Pharmacol.</source><year>2006</year><volume>147</volume><fpage>402</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0706634</pub-id><pub-id pub-id-type="pmid">16402038</pub-id><pub-id pub-id-type="pmcid">PMC1616988</pub-id></element-citation></ref><ref id="B29-pharmaceutics-16-01196"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerritsen</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Faraguna</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Bonavia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Furnari</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>White</surname><given-names>F.M.</given-names></name></person-group><article-title>Predictive Data-Driven Modeling of C-Terminal Tyrosine Function in the EGFR Signaling Network</article-title><source>Life Sci. Alliance</source><year>2023</year><volume>6</volume><fpage>e202201466</fpage><pub-id pub-id-type="doi">10.26508/lsa.202201466</pub-id><pub-id pub-id-type="pmid">37169593</pub-id><pub-id pub-id-type="pmcid">PMC10176108</pub-id></element-citation></ref><ref id="B30-pharmaceutics-16-01196"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsuan</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Totty</surname><given-names>N.</given-names></name><name name-style="western"><surname>Waterfield</surname><given-names>M.D.</given-names></name></person-group><article-title>Identification of a Novel Autophosphorylation Site (P4) on the Epidermal Growth Factor Receptor</article-title><source>Biochem. J.</source><year>1989</year><volume>262</volume><fpage>659</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1042/bj2620659</pub-id><pub-id pub-id-type="pmid">2803273</pub-id><pub-id pub-id-type="pmcid">PMC1133318</pub-id></element-citation></ref><ref id="B31-pharmaceutics-16-01196"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name></person-group><article-title>Transphosphorylation of EGFR at Y845 Plays an Important Role in Its Autophosphorylation and Kinase Activity</article-title><source>Oncol. Rep.</source><year>2014</year><volume>31</volume><fpage>2393</fpage><lpage>2398</lpage><pub-id pub-id-type="doi">10.3892/or.2014.3102</pub-id><pub-id pub-id-type="pmid">24677053</pub-id></element-citation></ref><ref id="B32-pharmaceutics-16-01196"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biscardi</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Maa</surname><given-names>M.-C.</given-names></name><name name-style="western"><surname>Tice</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Leu</surname><given-names>T.-H.</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>S.J.</given-names></name></person-group><article-title>C-Src-Mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor Function</article-title><source>J. Biol. Chem.</source><year>1999</year><volume>274</volume><fpage>8335</fpage><lpage>8343</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.12.8335</pub-id><pub-id pub-id-type="pmid">10075741</pub-id></element-citation></ref><ref id="B33-pharmaceutics-16-01196"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scaltriti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baselga</surname><given-names>J.</given-names></name></person-group><article-title>The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy</article-title><source>Clin. Cancer Res.</source><year>2006</year><volume>12</volume><fpage>5268</fpage><lpage>5272</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-1554</pub-id><pub-id pub-id-type="pmid">17000658</pub-id></element-citation></ref><ref id="B34-pharmaceutics-16-01196"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weng</surname><given-names>M.-S.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>W.-Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Chien</surname><given-names>M.-H.</given-names></name></person-group><article-title>The Interplay of Reactive Oxygen Species and the Epidermal Growth Factor Receptor in Tumor Progression and Drug Resistance</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2018</year><volume>37</volume><fpage>61</fpage><pub-id pub-id-type="doi">10.1186/s13046-018-0728-0</pub-id><pub-id pub-id-type="pmid">29548337</pub-id><pub-id pub-id-type="pmcid">PMC5857086</pub-id></element-citation></ref><ref id="B35-pharmaceutics-16-01196"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wee</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name></person-group><article-title>Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways</article-title><source>Cancers</source><year>2017</year><volume>9</volume><elocation-id>52</elocation-id><pub-id pub-id-type="doi">10.3390/cancers9050052</pub-id><pub-id pub-id-type="pmid">28513565</pub-id><pub-id pub-id-type="pmcid">PMC5447962</pub-id></element-citation></ref><ref id="B36-pharmaceutics-16-01196"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Si</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name></person-group><article-title>Epidermal Growth Factor Promotes Proliferation and Migration of Follicular Outer Root Sheath Cells via Wnt/&#946;-Catenin Signaling</article-title><source>Cell. Physiol. Biochem.</source><year>2016</year><volume>39</volume><fpage>360</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1159/000445630</pub-id><pub-id pub-id-type="pmid">27352380</pub-id></element-citation></ref><ref id="B37-pharmaceutics-16-01196"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ayuso-Sacido</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moliterno</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Kratovac</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>O&#8217;Rourke</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Holland</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Garc&#237;a-Verdugo</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Boockvar</surname><given-names>J.A.</given-names></name></person-group><article-title>Activated EGFR Signaling Increases Proliferation, Survival, and Migration and Blocks Neuronal Differentiation in Post-Natal Neural Stem Cells</article-title><source>J. Neuro.</source><year>2010</year><volume>97</volume><fpage>323</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1007/s11060-009-0035-x</pub-id><pub-id pub-id-type="pmid">19855928</pub-id></element-citation></ref><ref id="B38-pharmaceutics-16-01196"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sigismund</surname><given-names>S.</given-names></name><name name-style="western"><surname>Avanzato</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lanzetti</surname><given-names>L.</given-names></name></person-group><article-title>Emerging Functions of the EGFR in Cancer</article-title><source>Mol. Oncol.</source><year>2018</year><volume>12</volume><fpage>3</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12155</pub-id><pub-id pub-id-type="pmid">29124875</pub-id><pub-id pub-id-type="pmcid">PMC5748484</pub-id></element-citation></ref><ref id="B39-pharmaceutics-16-01196"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sibilia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kroismayr</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lichtenberger</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Natarajan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hecking</surname><given-names>M.</given-names></name><name name-style="western"><surname>Holcmann</surname><given-names>M.</given-names></name></person-group><article-title>The Epidermal Growth Factor Receptor: From Development to Tumorigenesis</article-title><source>Differentiation</source><year>2007</year><volume>75</volume><fpage>770</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1111/j.1432-0436.2007.00238.x</pub-id><pub-id pub-id-type="pmid">17999740</pub-id></element-citation></ref><ref id="B40-pharmaceutics-16-01196"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobersberger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sumesgutner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zajc</surname><given-names>C.U.</given-names></name><name name-style="western"><surname>Salzer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Laurent</surname><given-names>E.</given-names></name><name name-style="western"><surname>Emminger</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sylvander</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lehner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Teufl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seigner</surname><given-names>J.</given-names></name><etal/></person-group><article-title>An Engineering Strategy to Target Activated EGFR with CAR T Cells</article-title><source>Cell Rep. Methods</source><year>2024</year><volume>4</volume><fpage>100728</fpage><pub-id pub-id-type="doi">10.1016/j.crmeth.2024.100728</pub-id><pub-id pub-id-type="pmid">38492569</pub-id><pub-id pub-id-type="pmcid">PMC11045874</pub-id></element-citation></ref><ref id="B41-pharmaceutics-16-01196"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a-Foncillas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sunakawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Aderka</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wainberg</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ronga</surname><given-names>P.</given-names></name><name name-style="western"><surname>Witzler</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stintzing</surname><given-names>S.</given-names></name></person-group><article-title>Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors</article-title><source>Front. Oncol.</source><year>2019</year><volume>9</volume><elocation-id>849</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2019.00849</pub-id><pub-id pub-id-type="pmid">31616627</pub-id><pub-id pub-id-type="pmcid">PMC6763619</pub-id></element-citation></ref><ref id="B42-pharmaceutics-16-01196"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lurje</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lenz</surname><given-names>H.-J.</given-names></name></person-group><article-title>EGFR Signaling and Drug Discovery</article-title><source>Oncology</source><year>2009</year><volume>77</volume><fpage>400</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1159/000279388</pub-id><pub-id pub-id-type="pmid">20130423</pub-id></element-citation></ref><ref id="B43-pharmaceutics-16-01196"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markovic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>C.H.</given-names></name></person-group><article-title>Current Role of EGF Receptor Monoclonal Antibodies and Tyrosine Kinase Inhibitors in the Management of Head and Neck Squamous Cell Carcinoma</article-title><source>Expert Rev. Anticancer Ther.</source><year>2012</year><volume>12</volume><fpage>1149</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1586/era.12.91</pub-id><pub-id pub-id-type="pmid">23098115</pub-id><pub-id pub-id-type="pmcid">PMC3715045</pub-id></element-citation></ref><ref id="B44-pharmaceutics-16-01196"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klinghammer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gauler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dietz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gr&#252;nwald</surname><given-names>V.</given-names></name><name name-style="western"><surname>St&#246;hlmacher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Knipping</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guntinas-Lichius</surname><given-names>O.</given-names></name><name name-style="western"><surname>Frickhofen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lindeman</surname><given-names>H.W.</given-names></name><etal/></person-group><article-title>Cetuximab, Fluorouracil and Cisplatin with or without Docetaxel for Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (CeFCiD): An Open-Label Phase II Randomised Trial (AIO/IAG-KHT Trial 1108)</article-title><source>Eur. J. Cancer</source><year>2019</year><volume>122</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2019.08.018</pub-id><pub-id pub-id-type="pmid">31618704</pub-id></element-citation></ref><ref id="B45-pharmaceutics-16-01196"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermorken</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Trigo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hitt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Koralewski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Diaz-Rubio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rolland</surname><given-names>F.</given-names></name><name name-style="western"><surname>Knecht</surname><given-names>R.</given-names></name><name name-style="western"><surname>Amellal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schueler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baselga</surname><given-names>J.</given-names></name></person-group><article-title>Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab as a Single Agent in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy</article-title><source>J. Clin. Oncol.</source><year>2007</year><volume>25</volume><fpage>2171</fpage><lpage>2177</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.06.7447</pub-id><pub-id pub-id-type="pmid">17538161</pub-id></element-citation></ref><ref id="B46-pharmaceutics-16-01196"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>J.P.N.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>B.</given-names></name><name name-style="western"><surname>Monteiro</surname><given-names>L.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>P.M.A.</given-names></name><name name-style="western"><surname>Bousbaa</surname><given-names>H.</given-names></name></person-group><article-title>Combination Therapy as a Promising Way to Fight Oral Cancer</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>1653</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15061653</pub-id><pub-id pub-id-type="pmid">37376101</pub-id><pub-id pub-id-type="pmcid">PMC10301495</pub-id></element-citation></ref><ref id="B47-pharmaceutics-16-01196"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moskovitz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>R.L.</given-names></name></person-group><article-title>Immunotherapy for Head and Neck Squamous Cell Carcinoma</article-title><source>Curr. Oncol. Rep.</source><year>2018</year><volume>20</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.1007/s11912-018-0654-5</pub-id><pub-id pub-id-type="pmid">29502288</pub-id><pub-id pub-id-type="pmcid">PMC5835060</pub-id></element-citation></ref><ref id="B48-pharmaceutics-16-01196"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamaoka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ohba</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ohmori</surname><given-names>T.</given-names></name></person-group><article-title>Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><elocation-id>2420</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18112420</pub-id><pub-id pub-id-type="pmid">29140271</pub-id><pub-id pub-id-type="pmcid">PMC5713388</pub-id></element-citation></ref><ref id="B49-pharmaceutics-16-01196"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuneo</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Nyati</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>T.S.</given-names></name></person-group><article-title>EGFR Targeted Therapies and Radiation: Optimizing Efficacy by Appropriate Drug Scheduling and Patient Selection</article-title><source>Pharmacol. Ther.</source><year>2015</year><volume>154</volume><fpage>67</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2015.07.002</pub-id><pub-id pub-id-type="pmid">26205191</pub-id><pub-id pub-id-type="pmcid">PMC4570853</pub-id></element-citation></ref><ref id="B50-pharmaceutics-16-01196"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byeon</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Ku</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name></person-group><article-title>Beyond EGFR Inhibition: Multilateral Combat Strategies to Stop the Progression of Head and Neck Cancer</article-title><source>Exp. Mol. Med.</source><year>2019</year><volume>51</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s12276-018-0202-2</pub-id><pub-id pub-id-type="pmcid">PMC6353966</pub-id><pub-id pub-id-type="pmid">30700700</pub-id></element-citation></ref><ref id="B51-pharmaceutics-16-01196"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramakrishnan</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Eswaraiah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Crombet</surname><given-names>T.</given-names></name><name name-style="western"><surname>Piedra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Saurez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Iyer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Arvind</surname><given-names>A.S.</given-names></name></person-group><article-title>Nimotuzumab, a Promising Therapeutic Monoclonal for Treatment of Tumors of Epithelial Origin</article-title><source>mAbs</source><year>2009</year><volume>1</volume><fpage>41</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.4161/mabs.1.1.7509</pub-id><pub-id pub-id-type="pmid">20046573</pub-id><pub-id pub-id-type="pmcid">PMC2715181</pub-id></element-citation></ref><ref id="B52-pharmaceutics-16-01196"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kil</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Mallen-St Clair</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Srivatsan</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Clair</surname><given-names>J.M.-S.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.B.</given-names></name><etal/></person-group><article-title>EGFR Pathway Targeting Drugs in Head and Neck Cancer in the Era of Immunotherapy</article-title><source>Biochim. Biophys. Acta Rev. Cancer</source><year>2023</year><volume>1878</volume><elocation-id>188827</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbcan.2022.188827</pub-id><pub-id pub-id-type="pmid">36309124</pub-id></element-citation></ref><ref id="B53-pharmaceutics-16-01196"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>J.S.W.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>E.E.W.</given-names></name><name name-style="western"><surname>Licitra</surname><given-names>L.</given-names></name><name name-style="western"><surname>Van Herpen</surname><given-names>C.M.L.</given-names></name><name name-style="western"><surname>Khorprasert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Soulieres</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vodvarka</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rischin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Garin</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>F.R.</given-names></name><etal/></person-group><article-title>Phase III Study of Gefitinib Compared with Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck</article-title><source>J. Clin. Oncol.</source><year>2009</year><volume>27</volume><fpage>1864</fpage><lpage>1871</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.17.0530</pub-id><pub-id pub-id-type="pmid">19289630</pub-id></element-citation></ref><ref id="B54-pharmaceutics-16-01196"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.-F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.-Q.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>C.-X.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>S.-S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.-J.</given-names></name></person-group><article-title>Critical Appraisal of the Role of Gefitinib in the Management of Locally Advanced or Metastatic Non-Small Cell Lung Cancer</article-title><source>Onco Targets Ther.</source><year>2014</year><volume>7</volume><fpage>841</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.2147/OTT.S34124</pub-id><pub-id pub-id-type="pmid">24920926</pub-id><pub-id pub-id-type="pmcid">PMC4045263</pub-id></element-citation></ref><ref id="B55-pharmaceutics-16-01196"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perisanidis</surname><given-names>C.</given-names></name></person-group><article-title>Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review</article-title><source>Vivo</source><year>2017</year><volume>31</volume><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.21873/invivo.11020</pub-id><pub-id pub-id-type="pmcid">PMC5354143</pub-id><pub-id pub-id-type="pmid">28064216</pub-id></element-citation></ref><ref id="B56-pharmaceutics-16-01196"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nair</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bonner</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Bredel</surname><given-names>M.</given-names></name></person-group><article-title>EGFR Mutations in Head and Neck Squamous Cell Carcinoma</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>3818</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23073818</pub-id><pub-id pub-id-type="pmid">35409179</pub-id><pub-id pub-id-type="pmcid">PMC8999014</pub-id></element-citation></ref><ref id="B57-pharmaceutics-16-01196"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalil</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jameson</surname><given-names>M.J.</given-names></name></person-group><article-title>The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro</article-title><source>Drugs R D</source><year>2017</year><volume>17</volume><fpage>545</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1007/s40268-017-0204-x</pub-id><pub-id pub-id-type="pmid">28828595</pub-id><pub-id pub-id-type="pmcid">PMC5694417</pub-id></element-citation></ref><ref id="B58-pharmaceutics-16-01196"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>E.-H.</given-names></name><name name-style="western"><surname>Goh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Soo</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Khoo</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>D.S.W.</given-names></name><name name-style="western"><surname>Ang</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>Q.S.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>P.H.</given-names></name><etal/></person-group><article-title>Gefitinib, Cisplatin, and Concurrent Radiotherapy for Locally Advanced Head and Neck Cancer: EGFR FISH, Protein Expression, and Mutational Status Are Not Predictive Biomarkers</article-title><source>Ann. Oncol.</source><year>2012</year><volume>23</volume><fpage>1010</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdr327</pub-id><pub-id pub-id-type="pmid">21768327</pub-id></element-citation></ref><ref id="B59-pharmaceutics-16-01196"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bobos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Angouridakis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nikolaou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Linardou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Razis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fountzilas</surname><given-names>G.</given-names></name></person-group><article-title>Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study</article-title><source>J. Oncol.</source><year>2010</year><volume>2010</volume><fpage>709678</fpage><pub-id pub-id-type="doi">10.1155/2010/709678</pub-id><pub-id pub-id-type="pmid">21274259</pub-id><pub-id pub-id-type="pmcid">PMC3022192</pub-id></element-citation></ref><ref id="B60-pharmaceutics-16-01196"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>E.E.W.</given-names></name><name name-style="western"><surname>Lingen</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Brannigan</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Haserlat</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Okimoto</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Sgroi</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Dahiya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Muir</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 Rather than EGFR</article-title><source>Clin. Cancer Res.</source><year>2005</year><volume>11</volume><fpage>8105</fpage><lpage>8108</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0926</pub-id><pub-id pub-id-type="pmid">16299242</pub-id></element-citation></ref><ref id="B61-pharmaceutics-16-01196"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Low</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kwang</surname><given-names>X.-L.</given-names></name><name name-style="western"><surname>Rohatgi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>F.-T.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S.Q.R.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>H.-S.</given-names></name><name name-style="western"><surname>Thangavelu</surname><given-names>M.T.</given-names></name><etal/></person-group><article-title>A Chemical Genetic Screen Identifies Aurora Kinases as a Therapeutic Target in EGFR T790M Negative, Gefitinib-Resistant Head and Neck Squamous Cell Carcinoma (HNSCC)</article-title><source>EBioMedicine</source><year>2021</year><volume>64</volume><elocation-id>103220</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103220</pub-id><pub-id pub-id-type="pmid">33529999</pub-id><pub-id pub-id-type="pmcid">PMC7851772</pub-id></element-citation></ref><ref id="B62-pharmaceutics-16-01196"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>T.-F.</given-names></name><name name-style="western"><surname>Grushko</surname><given-names>T.</given-names></name><name name-style="western"><surname>Olopade</surname><given-names>O.I.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Seiwert</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>E.E.W.</given-names></name></person-group><article-title>Molecular Phenotype Predicts Sensitivity of Squamous Cell Carcinoma of the Head and Neck to Epidermal Growth Factor Receptor Inhibition</article-title><source>Mol. Oncol.</source><year>2013</year><volume>7</volume><fpage>359</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2012.11.001</pub-id><pub-id pub-id-type="pmid">23200321</pub-id><pub-id pub-id-type="pmcid">PMC3661759</pub-id></element-citation></ref><ref id="B63-pharmaceutics-16-01196"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Soung</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Park</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Somatic Mutations of EGFR Gene in Squamous Cell Carcinoma of the Head and Neck</article-title><source>Clin. Cancer Res.</source><year>2005</year><volume>11</volume><fpage>2879</fpage><lpage>2882</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-2029</pub-id><pub-id pub-id-type="pmid">15837736</pub-id></element-citation></ref><ref id="B64-pharmaceutics-16-01196"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Na</surname><given-names>I.I.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Ryoo</surname><given-names>B.-Y.</given-names></name><etal/></person-group><article-title>EGFR Mutations and Human Papillomavirus in Squamous Cell Carcinoma of Tongue and Tonsil</article-title><source>Eur. J. Cancer</source><year>2007</year><volume>43</volume><fpage>520</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2006.09.025</pub-id><pub-id pub-id-type="pmid">17224267</pub-id></element-citation></ref><ref id="B65-pharmaceutics-16-01196"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irshad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Haider</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hashmi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>A.</given-names></name></person-group><article-title>Efficacy of Gefitinib and Methorexate in Patients with Advanced Stage and Recurrent Head and Neck Cancer</article-title><source>Cureus</source><year>2021</year><volume>13</volume><fpage>e15451</fpage><pub-id pub-id-type="doi">10.7759/cureus.15451</pub-id><pub-id pub-id-type="pmid">34262802</pub-id><pub-id pub-id-type="pmcid">PMC8260212</pub-id></element-citation></ref><ref id="B66-pharmaceutics-16-01196"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kushwaha</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Husain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Negi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jamal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ghatak</surname><given-names>A.</given-names></name></person-group><article-title>Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as Palliative Treatment in Recurrent Head and Neck Squamous Cell Carcinoma</article-title><source>Cancer Biol. Ther.</source><year>2015</year><volume>16</volume><fpage>346</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.4161/15384047.2014.961881</pub-id><pub-id pub-id-type="pmid">25756517</pub-id><pub-id pub-id-type="pmcid">PMC4623054</pub-id></element-citation></ref><ref id="B67-pharmaceutics-16-01196"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Efficacy and Safety of Gefitinib in Patients with Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials</article-title><source>J. Oncol.</source><year>2019</year><volume>2019</volume><fpage>6273438</fpage><pub-id pub-id-type="doi">10.1155/2019/6273438</pub-id><pub-id pub-id-type="pmid">31239839</pub-id><pub-id pub-id-type="pmcid">PMC6556337</pub-id></element-citation></ref><ref id="B68-pharmaceutics-16-01196"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martins</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Parvathaneni</surname><given-names>U.</given-names></name><name name-style="western"><surname>Bauman</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Raez</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Papagikos</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Yunus</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kurland</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Eaton</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial</article-title><source>J. Clin. Oncol.</source><year>2013</year><volume>31</volume><fpage>1415</fpage><lpage>1421</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.46.3299</pub-id><pub-id pub-id-type="pmid">23460709</pub-id></element-citation></ref><ref id="B69-pharmaceutics-16-01196"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siu</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Soulieres</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>E.X.</given-names></name><name name-style="western"><surname>Pond</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dancey</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study</article-title><source>J. Clin. Oncol.</source><year>2007</year><volume>25</volume><fpage>2178</fpage><lpage>2183</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.07.6547</pub-id><pub-id pub-id-type="pmid">17538162</pub-id></element-citation></ref><ref id="B70-pharmaceutics-16-01196"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soulieres</surname><given-names>D.</given-names></name><name name-style="western"><surname>Senzer</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Vokes</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Hidalgo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Agarvala</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Siu</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Agarwala</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Siu</surname><given-names>L.L.</given-names></name></person-group><article-title>Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck</article-title><source>J. Clin. Oncol.</source><year>2004</year><volume>22</volume><fpage>77</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.06.075</pub-id><pub-id pub-id-type="pmid">14701768</pub-id></element-citation></ref><ref id="B71-pharmaceutics-16-01196"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sridhara</surname><given-names>R.</given-names></name><name name-style="western"><surname>Justice</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pazdur</surname><given-names>R.</given-names></name></person-group><article-title>FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2</article-title><source>Oncologist</source><year>2008</year><volume>13</volume><fpage>1114</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2008-0816</pub-id><pub-id pub-id-type="pmid">18849320</pub-id></element-citation></ref><ref id="B72-pharmaceutics-16-01196"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campo</surname><given-names>J.M.D.</given-names></name><name name-style="western"><surname>Hitt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sebastian</surname><given-names>P.</given-names></name><name name-style="western"><surname>Carracedo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lokanatha</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bourhis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Temam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cupissol</surname><given-names>D.</given-names></name><name name-style="western"><surname>Raucourt</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Maroudias</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Effects of Lapatinib Monotherapy: Results of a Randomised Phase II Study in Therapy-Naive Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck</article-title><source>Br. J. Cancer</source><year>2011</year><volume>105</volume><fpage>618</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1038/bjc.2011.237</pub-id><pub-id pub-id-type="pmid">21829197</pub-id><pub-id pub-id-type="pmcid">PMC3188940</pub-id></element-citation></ref><ref id="B73-pharmaceutics-16-01196"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrington</surname><given-names>K.</given-names></name><name name-style="western"><surname>Berrier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Remenar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Housset</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mendoza</surname><given-names>F.H.D.</given-names></name><name name-style="western"><surname>Fayette</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mehanna</surname><given-names>H.</given-names></name><name name-style="western"><surname>El-Hariry</surname><given-names>I.</given-names></name><name name-style="western"><surname>Compton</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Randomised Phase II Study of Oral Lapatinib Combined with Chemoradiotherapy in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck: Rationale for Future Randomised Trials in Human Papilloma Virus-Negative Disease</article-title><source>Eur. J. Cancer</source><year>2013</year><volume>49</volume><fpage>1609</fpage><lpage>1618</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2012.11.023</pub-id><pub-id pub-id-type="pmid">23265705</pub-id></element-citation></ref><ref id="B74-pharmaceutics-16-01196"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrington</surname><given-names>K.</given-names></name><name name-style="western"><surname>Temam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mehanna</surname><given-names>H.</given-names></name><name name-style="western"><surname>D&#8217;Cruz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>M.</given-names></name><name name-style="western"><surname>D&#8217;Onofrio</surname><given-names>I.</given-names></name><name name-style="western"><surname>Manikhas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dietzsch</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study</article-title><source>J. Clin. Oncol.</source><year>2015</year><volume>33</volume><fpage>4202</fpage><lpage>4209</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.61.4370</pub-id><pub-id pub-id-type="pmid">26527790</pub-id></element-citation></ref><ref id="B75-pharmaceutics-16-01196"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yonesaka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kudo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takahama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Iwasa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kaneda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>I.</given-names></name><etal/></person-group><article-title>The Pan-HER Family Tyrosine Kinase Inhibitor Afatinib Overcomes HER3 Ligand Heregulin-Mediated Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>33602</fpage><lpage>33611</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.5286</pub-id><pub-id pub-id-type="pmid">26418897</pub-id><pub-id pub-id-type="pmcid">PMC4741788</pub-id></element-citation></ref><ref id="B76-pharmaceutics-16-01196"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seiwert</surname><given-names>T.Y.Y.</given-names></name><name name-style="western"><surname>Fayette</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cupissol</surname><given-names>D.</given-names></name><name name-style="western"><surname>del Campo</surname><given-names>J.M.M.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>P.M.M.</given-names></name><name name-style="western"><surname>Hitt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Degardin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Blackman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ehrnrooth</surname><given-names>E.</given-names></name><etal/></person-group><article-title>A Randomized, Phase II Study of Afatinib versus Cetuximab in Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck</article-title><source>Ann. Oncol.</source><year>2014</year><volume>25</volume><fpage>1813</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu216</pub-id><pub-id pub-id-type="pmid">24928832</pub-id><pub-id pub-id-type="pmcid">PMC4143093</pub-id></element-citation></ref><ref id="B77-pharmaceutics-16-01196"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machiels</surname><given-names>J.P.H.</given-names></name><name name-style="western"><surname>Haddad</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Fayette</surname><given-names>J.</given-names></name><name name-style="western"><surname>Licitra</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Tahara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vermorken</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Gauler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cupissol</surname><given-names>D.</given-names></name><name name-style="western"><surname>Grau</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Afatinib versus Methotrexate as Second-Line Treatment in Patients with Recurrent or Metastatic Squamous-Cell Carcinoma of the Head and Neck Progressing on or after Platinum-Based Therapy (LUX-Head &amp; Neck 1): An Open-Label, Randomised Phase 3 Trial</article-title><source>Lancet Oncol.</source><year>2015</year><volume>16</volume><fpage>583</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)70124-5</pub-id><pub-id pub-id-type="pmid">25892145</pub-id></element-citation></ref><ref id="B78-pharmaceutics-16-01196"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clement</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Gauler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Machiels</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Haddad</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Fayette</surname><given-names>J.</given-names></name><name name-style="western"><surname>Licitra</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Tahara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>E.E.W.</given-names></name><name name-style="western"><surname>Cupissol</surname><given-names>D.</given-names></name><name name-style="western"><surname>Grau</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Afatinib versus Methotrexate in Older Patients with Second-Line Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Subgroup Analysis of the LUX-Head &amp; Neck 1 Trial</article-title><source>Ann. Oncol.</source><year>2016</year><volume>27</volume><fpage>1585</fpage><lpage>1593</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdw151</pub-id><pub-id pub-id-type="pmid">27084954</pub-id><pub-id pub-id-type="pmcid">PMC4959921</pub-id></element-citation></ref><ref id="B79-pharmaceutics-16-01196"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzales</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Hook</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Althaus</surname><given-names>I.W.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Trachet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Delaney</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Amato</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Antitumor Activity and Pharmacokinetic Properties of PF-00299804, a Second-Generation Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor</article-title><source>Mol. Cancer Ther.</source><year>2008</year><volume>7</volume><fpage>1880</fpage><lpage>1889</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-07-2232</pub-id><pub-id pub-id-type="pmid">18606718</pub-id></element-citation></ref><ref id="B80-pharmaceutics-16-01196"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Razak</surname><given-names>A.R.A.</given-names></name><name name-style="western"><surname>Souli&#233;res</surname><given-names>D.</given-names></name><name name-style="western"><surname>Laurie</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Hotte</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Winquist</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tourneau</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Nguyen-Tan</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>E.X.</given-names></name><etal/></person-group><article-title>A Phase II Trial of Dacomitinib, an Oral Pan-Human EGF Receptor (HER) Inhibitor, as First-Line Treatment in Recurrent and/or Metastatic Squamous-Cell Carcinoma of the Head and Neck</article-title><source>Ann. Oncol.</source><year>2013</year><volume>24</volume><fpage>761</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1093/annonc/mds503</pub-id><pub-id pub-id-type="pmid">23108949</pub-id></element-citation></ref><ref id="B81-pharmaceutics-16-01196"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Argiris</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Tahara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schulten</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chomette</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ferreira Castro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Licitra</surname><given-names>L.</given-names></name></person-group><article-title>Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck</article-title><source>Front. Oncol.</source><year>2017</year><volume>7</volume><elocation-id>72</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2017.00072</pub-id><pub-id pub-id-type="pmid">28536670</pub-id><pub-id pub-id-type="pmcid">PMC5422557</pub-id></element-citation></ref><ref id="B82-pharmaceutics-16-01196"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muraro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fanetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lupato</surname><given-names>V.</given-names></name><name name-style="western"><surname>Giacomarra</surname><given-names>V.</given-names></name><name name-style="western"><surname>Steffan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gobitti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vaccher</surname><given-names>E.</given-names></name><name name-style="western"><surname>Franchin</surname><given-names>G.</given-names></name></person-group><article-title>Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma: Biological Mechanisms Involved in Efficacy, Toxicity and Resistance</article-title><source>Crit. Rev. Oncol. Hematol.</source><year>2021</year><volume>164</volume><fpage>103424</fpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2021.103424</pub-id><pub-id pub-id-type="pmid">34245856</pub-id></element-citation></ref><ref id="B83-pharmaceutics-16-01196"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Marur</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>H.-L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sciubba</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>R.L.</given-names></name><etal/></person-group><article-title>Cetuximab Activity in Dysplastic Lesions of the Upper Aerodigestive Tract</article-title><source>Oral Oncol.</source><year>2016</year><volume>53</volume><fpage>60</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2015.11.016</pub-id><pub-id pub-id-type="pmid">26686755</pub-id><pub-id pub-id-type="pmcid">PMC7751887</pub-id></element-citation></ref><ref id="B84-pharmaceutics-16-01196"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Ettyreddy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>R.L.</given-names></name></person-group><article-title>Cetuximab Ameliorates Suppressive Phenotypes of Myeloid Antigen Presenting Cells in Head and Neck Cancer Patients</article-title><source>J. Immunother. Cancer</source><year>2015</year><volume>3</volume><fpage>54</fpage><pub-id pub-id-type="doi">10.1186/s40425-015-0097-6</pub-id><pub-id pub-id-type="pmid">26579227</pub-id><pub-id pub-id-type="pmcid">PMC4647471</pub-id></element-citation></ref><ref id="B85-pharmaceutics-16-01196"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Locati</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Bossi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Perrone</surname><given-names>F.</given-names></name><name name-style="western"><surname>Potepan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Crippa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mariani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Casieri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Orsenigo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Losa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bergamini</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Cetuximab in Recurrent and/or Metastatic Salivary Gland Carcinomas: A Phase II Study</article-title><source>Oral Oncol.</source><year>2009</year><volume>45</volume><fpage>574</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2008.07.010</pub-id><pub-id pub-id-type="pmid">18804410</pub-id></element-citation></ref><ref id="B86-pharmaceutics-16-01196"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mes&#237;a</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rueda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vera</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lozano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Medina</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Aguiar</surname><given-names>D.</given-names></name><name name-style="western"><surname>&#193;rias</surname><given-names>F.</given-names></name><name name-style="western"><surname>Triana</surname><given-names>G.</given-names></name><name name-style="western"><surname>Carles</surname><given-names>J.</given-names></name><name name-style="western"><surname>L&#243;pez-L&#243;pez</surname><given-names>R.</given-names></name></person-group><article-title>Adjuvant Therapy with Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Oropharynx: Results from a Randomized, Phase II Prospective Trial</article-title><source>Ann. Oncol.</source><year>2013</year><volume>24</volume><fpage>448</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1093/annonc/mds291</pub-id><pub-id pub-id-type="pmid">23041591</pub-id></element-citation></ref><ref id="B87-pharmaceutics-16-01196"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fury</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lisa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Algazy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brockstein</surname><given-names>B.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mehra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rajan</surname><given-names>S.K.</given-names></name><etal/></person-group><article-title>A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 Mg/m<sup>2</sup> for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer</article-title><source>J. Natl. Compr. Cancer Netw.</source><year>2012</year><volume>10</volume><fpage>1391</fpage><lpage>1398</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2012.0144</pub-id><pub-id pub-id-type="pmcid">PMC5726232</pub-id><pub-id pub-id-type="pmid">23138167</pub-id></element-citation></ref><ref id="B88-pharmaceutics-16-01196"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermorken</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Herbst</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Leon</surname><given-names>X.</given-names></name><name name-style="western"><surname>Amellal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Baselga</surname><given-names>J.</given-names></name></person-group><article-title>Overview of the Efficacy of Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck in Patients Who Previously Failed Platinum-based Therapies</article-title><source>Cancer</source><year>2008</year><volume>112</volume><fpage>2710</fpage><lpage>2719</lpage><pub-id pub-id-type="doi">10.1002/cncr.23442</pub-id><pub-id pub-id-type="pmid">18481809</pub-id></element-citation></ref><ref id="B89-pharmaceutics-16-01196"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cognetti</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Curry</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Kochuparambil</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mott</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fidler</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Stenson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vasan</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Razaq</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Phase 1/2a, Open-Label, Multicenter Study of RM-1929 Photoimmunotherapy in Patients with Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma</article-title><source>Head Neck</source><year>2021</year><volume>43</volume><fpage>3875</fpage><lpage>3887</lpage><pub-id pub-id-type="doi">10.1002/hed.26885</pub-id><pub-id pub-id-type="pmid">34626024</pub-id><pub-id pub-id-type="pmcid">PMC9293150</pub-id></element-citation></ref><ref id="B90-pharmaceutics-16-01196"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oppelt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ley</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Worden</surname><given-names>F.</given-names></name><name name-style="western"><surname>Palka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maggiore</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Adkins</surname><given-names>D.</given-names></name></person-group><article-title>Palbociclib and Cetuximab in Cetuximab-Resistant Human Papillomavirus-Related Oropharynx Squamous-Cell Carcinoma: A Multicenter Phase 2 Trial</article-title><source>Oral Oncol.</source><year>2021</year><volume>114</volume><fpage>105164</fpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2020.105164</pub-id><pub-id pub-id-type="pmid">33465681</pub-id></element-citation></ref><ref id="B91-pharmaceutics-16-01196"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adkins</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>Sacco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oppelt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vanchenko</surname><given-names>V.</given-names></name><name name-style="western"><surname>Komashko</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>C.-J.</given-names></name><name name-style="western"><surname>Wise-Draper</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lopez-Picazo Gonzalez</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Palbociclib and Cetuximab Compared with Placebo and Cetuximab in Platinum-Resistant, Cetuximab-Na&#239;ve, Human Papillomavirus-Unrelated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Double-Blind, Randomized, Phase 2 Trial</article-title><source>Oral Oncol.</source><year>2021</year><volume>115</volume><fpage>105192</fpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2021.105192</pub-id><pub-id pub-id-type="pmid">33571736</pub-id></element-citation></ref><ref id="B92-pharmaceutics-16-01196"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dennis</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Sacco</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bykowski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pittman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Messer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>E.E.W.</given-names></name><name name-style="western"><surname>Gold</surname><given-names>K.A.</given-names></name></person-group><article-title>A Phase I Study of Avelumab, Palbociclib, and Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma</article-title><source>Oral Oncol.</source><year>2022</year><volume>135</volume><fpage>106219</fpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2022.106219</pub-id><pub-id pub-id-type="pmid">36279618</pub-id></element-citation></ref><ref id="B93-pharmaceutics-16-01196"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seront</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Papier</surname><given-names>M.</given-names></name><name name-style="western"><surname>van Maanen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lonchay</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rottey</surname><given-names>S.</given-names></name><name name-style="western"><surname>van Caloen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Machiels</surname><given-names>J.-P.</given-names></name></person-group><article-title>Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic P16-Negative Squamous Cell Carcinoma of the Head and Neck</article-title><source>Front. Oncol.</source><year>2019</year><volume>9</volume><elocation-id>155</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2019.00155</pub-id><pub-id pub-id-type="pmid">30941307</pub-id><pub-id pub-id-type="pmcid">PMC6433958</pub-id></element-citation></ref><ref id="B94-pharmaceutics-16-01196"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Massa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dess&#236;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gaspardini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Saba</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cherchi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>G.</given-names></name></person-group><article-title>Phase II Study of Vinorelbine/Cetuximab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Progressing after at Least Two Chemotherapy Regimens</article-title><source>Oral Oncol.</source><year>2010</year><volume>46</volume><fpage>818</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2010.08.013</pub-id><pub-id pub-id-type="pmid">20920877</pub-id></element-citation></ref><ref id="B95-pharmaceutics-16-01196"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sosa</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Grau</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Feliz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>V.</given-names></name><name name-style="western"><surname>Alcaraz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mu&#241;oz-Garc&#237;a</surname><given-names>C.</given-names></name><name name-style="western"><surname>Caballero</surname><given-names>M.</given-names></name></person-group><article-title>Outcome of Patients Treated with Palliative Weekly Paclitaxel plus Cetuximab in Recurrent Head and Neck Cancer after Failure of Platinum-Based Therapy</article-title><source>Eur. Arch. Oto-Rhino-Laryngol.</source><year>2014</year><volume>271</volume><fpage>373</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1007/s00405-013-2537-6</pub-id><pub-id pub-id-type="pmid">23644939</pub-id></element-citation></ref><ref id="B96-pharmaceutics-16-01196"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P&#233;ron</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ceruse</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lavergne</surname><given-names>E.</given-names></name><name name-style="western"><surname>Buiret</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>B.-N.</given-names></name><name name-style="western"><surname>Chabaud</surname><given-names>S.</given-names></name><name name-style="western"><surname>Favier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Girodet</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zrounba</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ramade</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Paclitaxel and Cetuximab Combination Efficiency after the Failure of a Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma</article-title><source>Anticancer. Drugs</source><year>2012</year><volume>23</volume><fpage>996</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1097/CAD.0b013e32835507e5</pub-id><pub-id pub-id-type="pmid">22643048</pub-id></element-citation></ref><ref id="B97-pharmaceutics-16-01196"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chevalier</surname><given-names>T.</given-names></name><name name-style="western"><surname>Daste</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saada-Bouzid</surname><given-names>E.</given-names></name><name name-style="western"><surname>Loundou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peyraud</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>T.</given-names></name><name name-style="western"><surname>Le Tourneau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Peyrade</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dupuis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alfonsi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Cetuximab Combined with Paclitaxel or Paclitaxel Alone for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Progressing after EXTREME</article-title><source>Cancer Med.</source><year>2021</year><volume>10</volume><fpage>3952</fpage><lpage>3963</lpage><pub-id pub-id-type="doi">10.1002/cam4.3953</pub-id><pub-id pub-id-type="pmid">34080776</pub-id><pub-id pub-id-type="pmcid">PMC8209557</pub-id></element-citation></ref><ref id="B98-pharmaceutics-16-01196"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hitt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Irigoyen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cortes-Funes</surname><given-names>H.</given-names></name><name name-style="western"><surname>Grau</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Garc&#237;a-S&#225;enz</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Cruz-Hernandez</surname><given-names>J.J.</given-names></name></person-group><article-title>Phase II Study of the Combination of Cetuximab and Weekly Paclitaxel in the First-Line Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck</article-title><source>Ann. Oncol.</source><year>2012</year><volume>23</volume><fpage>1016</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdr367</pub-id><pub-id pub-id-type="pmid">21865152</pub-id></element-citation></ref><ref id="B99-pharmaceutics-16-01196"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kiyota</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boku</surname><given-names>S.</given-names></name><name name-style="western"><surname>Imamura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Satake</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Onoe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Asada</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A Phase II Trial of Paclitaxel plus Biweekly Cetuximab for Patients with Recurrent or Metastatic Head and Neck Cancer Previously Treated with Both Platinum-Based Chemotherapy and Anti-PD-1 Antibody</article-title><source>ESMO Open</source><year>2024</year><volume>9</volume><fpage>103476</fpage><pub-id pub-id-type="doi">10.1016/j.esmoop.2024.103476</pub-id><pub-id pub-id-type="pmid">38833968</pub-id><pub-id pub-id-type="pmcid">PMC11179070</pub-id></element-citation></ref><ref id="B100-pharmaceutics-16-01196"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubi&#243;-Casadevall</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cirauqui Cirauqui</surname><given-names>B.</given-names></name><name name-style="western"><surname>Martinez Trufero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Plana Serrahima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a Casta&#241;o</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carral Maseda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iglesias Docampo</surname><given-names>L.</given-names></name><name name-style="western"><surname>P&#233;rez Segura</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ceballos Lenza</surname><given-names>I.</given-names></name><name name-style="western"><surname>Guti&#233;rrez Calder&#243;n</surname><given-names>V.</given-names></name><etal/></person-group><article-title>TTCC-2019-02: Real-World Evidence of First-Line Cetuximab plus Paclitaxel in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</article-title><source>Front. Oncol.</source><year>2023</year><volume>13</volume><elocation-id>1226939</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2023.1226939</pub-id><pub-id pub-id-type="pmid">37601652</pub-id><pub-id pub-id-type="pmcid">PMC10432957</pub-id></element-citation></ref><ref id="B101-pharmaceutics-16-01196"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carral</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iglesias</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pena</surname><given-names>C.</given-names></name><name name-style="western"><surname>Molina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Covela</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Arroyo</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Huidobro</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Real-World Data of Paclitaxel and Cetuximab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck</article-title><source>Cancer Diagn. Progn.</source><year>2023</year><volume>3</volume><fpage>264</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.21873/cdp.10211</pub-id><pub-id pub-id-type="pmid">36875311</pub-id><pub-id pub-id-type="pmcid">PMC9949534</pub-id></element-citation></ref><ref id="B102-pharmaceutics-16-01196"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miyake</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tsukahara</surname><given-names>K.</given-names></name></person-group><article-title>Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma</article-title><source>Vivo</source><year>2021</year><volume>35</volume><fpage>1253</fpage><lpage>1259</lpage><pub-id pub-id-type="doi">10.21873/invivo.12376</pub-id><pub-id pub-id-type="pmid">33622928</pub-id><pub-id pub-id-type="pmcid">PMC8045122</pub-id></element-citation></ref><ref id="B103-pharmaceutics-16-01196"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Posch</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kornek</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pammer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aretin</surname><given-names>M.-B.</given-names></name><name name-style="western"><surname>Fuereder</surname><given-names>T.</given-names></name></person-group><article-title>Docetaxel plus Cetuximab Biweekly Is an Active Regimen for the First-Line Treatment of Patients with Recurrent/Metastatic Head and Neck Cancer</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><elocation-id>32946</elocation-id><pub-id pub-id-type="doi">10.1038/srep32946</pub-id><pub-id pub-id-type="pmid">27597175</pub-id><pub-id pub-id-type="pmcid">PMC5011715</pub-id></element-citation></ref><ref id="B104-pharmaceutics-16-01196"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fury</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Wolden</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smith-Marrone</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Gelblum</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Phase I Study of Weekly Nab-Paclitaxel + Weekly Cetuximab + Intensity-Modulated Radiation Therapy (IMRT) in Patients with Stage III&#8211;IVB Head and Neck Squamous Cell Carcinoma (HNSCC)</article-title><source>Ann. Oncol.</source><year>2014</year><volume>25</volume><fpage>689</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdt579</pub-id><pub-id pub-id-type="pmid">24496920</pub-id><pub-id pub-id-type="pmcid">PMC4433511</pub-id></element-citation></ref><ref id="B105-pharmaceutics-16-01196"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeshita</surname><given-names>N.</given-names></name><name name-style="western"><surname>Enokida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fujisawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Motegi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zenda</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Induction Chemotherapy with Paclitaxel, Carboplatin and Cetuximab for Locoregionally Advanced Nasopharyngeal Carcinoma: A Single-Center, Retrospective Study</article-title><source>Front. Oncol.</source><year>2022</year><volume>12</volume><elocation-id>951387</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2022.951387</pub-id><pub-id pub-id-type="pmid">36033502</pub-id><pub-id pub-id-type="pmcid">PMC9402945</pub-id></element-citation></ref><ref id="B106-pharmaceutics-16-01196"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kies</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Holsinger</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>William</surname><given-names>W.N.</given-names></name><name name-style="western"><surname>Glisson</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Ginsberg</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Gillaspy</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Massarelli</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results from a Phase II Prospective Trial</article-title><source>J. Clin. Oncol.</source><year>2010</year><volume>28</volume><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.23.0425</pub-id><pub-id pub-id-type="pmid">19917840</pub-id><pub-id pub-id-type="pmcid">PMC2799235</pub-id></element-citation></ref><ref id="B107-pharmaceutics-16-01196"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deal</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Weissler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hilliard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chera</surname><given-names>B.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hackman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Grilley Olson</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Induction Chemotherapy with Carboplatin, Nab-Paclitaxel and Cetuximab for at Least N2b Nodal Status or Surgically Unresectable Squamous Cell Carcinoma of the Head and Neck</article-title><source>Oral Oncol.</source><year>2018</year><volume>84</volume><fpage>46</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2018.06.028</pub-id><pub-id pub-id-type="pmid">30115475</pub-id></element-citation></ref><ref id="B108-pharmaceutics-16-01196"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>K.-W.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.-B.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.-W.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.-G.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>M.-W.</given-names></name><name name-style="western"><surname>Keam</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.-W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.M.</given-names></name><etal/></person-group><article-title>A Randomized, Multicenter, Phase II Study of Cetuximab with Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer</article-title><source>Oncologist</source><year>2015</year><volume>20</volume><fpage>1119</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2015-0208</pub-id><pub-id pub-id-type="pmid">26304911</pub-id><pub-id pub-id-type="pmcid">PMC4591951</pub-id></element-citation></ref><ref id="B109-pharmaceutics-16-01196"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keil</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hartl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Altorjai</surname><given-names>G.</given-names></name><name name-style="western"><surname>Berghold</surname><given-names>A.</given-names></name><name name-style="western"><surname>Riedl</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pecherstorfer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mayrb&#228;url</surname><given-names>B.</given-names></name><name name-style="western"><surname>De Vries</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schuster</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hackl</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Docetaxel, Cisplatin and 5-FU Compared with Docetaxel, Cisplatin and Cetuximab as Induction Chemotherapy in Advanced Squamous Cell Carcinoma of the Head and Neck: Results of a Randomised Phase II AGMT Trial</article-title><source>Eur. J. Cancer</source><year>2021</year><volume>151</volume><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2021.03.051</pub-id><pub-id pub-id-type="pmid">34022697</pub-id></element-citation></ref><ref id="B110-pharmaceutics-16-01196"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Enokida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fujisawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tahara</surname><given-names>M.</given-names></name></person-group><article-title>Combination Treatment with Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients with Recurrent and/or Metastatic Nasopharyngeal Carcinoma</article-title><source>Front. Oncol.</source><year>2020</year><volume>10</volume><elocation-id>571304</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.571304</pub-id><pub-id pub-id-type="pmid">33117701</pub-id><pub-id pub-id-type="pmcid">PMC7575747</pub-id></element-citation></ref><ref id="B111-pharmaceutics-16-01196"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leiva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cefarelli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Melo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cayol</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Sola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Montani</surname><given-names>H.R.</given-names></name><etal/></person-group><article-title>First-Line Cisplatin, Docetaxel, and Cetuximab for Patients with Recurrent or Metastatic Head and Neck Cancer: A Multicenter Cohort Study</article-title><source>World J. Clin. Oncol.</source><year>2022</year><volume>13</volume><fpage>147</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.5306/wjco.v13.i2.147</pub-id><pub-id pub-id-type="pmid">35316930</pub-id><pub-id pub-id-type="pmcid">PMC8894270</pub-id></element-citation></ref><ref id="B112-pharmaceutics-16-01196"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bossi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Miceli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Locati</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vecchio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Denaro</surname><given-names>N.</given-names></name><name name-style="western"><surname>Caponigro</surname><given-names>F.</given-names></name><name name-style="western"><surname>Airoldi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moro</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A Randomized, Phase 2 Study of Cetuximab plus Cisplatin with or without Paclitaxel for the First-Line Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck</article-title><source>Ann. Oncol.</source><year>2017</year><volume>28</volume><fpage>2820</fpage><lpage>2826</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdx439</pub-id><pub-id pub-id-type="pmid">28950305</pub-id></element-citation></ref><ref id="B113-pharmaceutics-16-01196"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guigay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fayette</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dillies</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Sire</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kerger</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Tennevet</surname><given-names>I.</given-names></name><name name-style="western"><surname>Machiels</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Zanetta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pointreau</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bozec Le Moal</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Cetuximab, Docetaxel, and Cisplatin as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Multicenter, Phase II GORTEC Study</article-title><source>Ann. Oncol.</source><year>2015</year><volume>26</volume><fpage>1941</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdv268</pub-id><pub-id pub-id-type="pmid">26109631</pub-id></element-citation></ref><ref id="B114-pharmaceutics-16-01196"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trieu</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Riess</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Lira</surname><given-names>R.</given-names></name><name name-style="western"><surname>Luciano</surname><given-names>R.</given-names></name><name name-style="western"><surname>Coty</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boothroyd</surname><given-names>D.</given-names></name><name name-style="western"><surname>Colevas</surname><given-names>A.D.</given-names></name></person-group><article-title>Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck</article-title><source>Oncologist</source><year>2018</year><volume>23</volume><fpage>764-e86</fpage><pub-id pub-id-type="doi">10.1634/theoncologist.2017-0618</pub-id><pub-id pub-id-type="pmid">29540603</pub-id><pub-id pub-id-type="pmcid">PMC6058339</pub-id></element-citation></ref><ref id="B115-pharmaceutics-16-01196"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tahara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kiyota</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yokota</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Muro</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Onoe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Homma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taguchi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Phase II Trial of Combination Treatment with Paclitaxel, Carboplatin and Cetuximab (PCE) as First-Line Treatment in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (CSPOR-HN02)</article-title><source>Ann. Oncol.</source><year>2018</year><volume>29</volume><fpage>1004</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdy040</pub-id><pub-id pub-id-type="pmid">29408977</pub-id></element-citation></ref><ref id="B116-pharmaceutics-16-01196"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adkins</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Atiq</surname><given-names>O.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Spanos</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Gitau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rigden</surname><given-names>C.</given-names></name><name name-style="western"><surname>Palka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oppelt</surname><given-names>P.</given-names></name></person-group><article-title>Nanoparticle Albumin-Bound Paclitaxel with Cetuximab and Carboplatin as First-Line Therapy for Recurrent or Metastatic Head and Neck Cancer: A Single-Arm, Multicenter, Phase 2 Trial</article-title><source>Oral Oncol.</source><year>2021</year><volume>115</volume><fpage>105173</fpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2020.105173</pub-id><pub-id pub-id-type="pmid">33548860</pub-id><pub-id pub-id-type="pmcid">PMC8579485</pub-id></element-citation></ref><ref id="B117-pharmaceutics-16-01196"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carinato</surname><given-names>H.</given-names></name><name name-style="western"><surname>Burgy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ferry</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fischbach</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kalish</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guihard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brahimi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Flesch</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bronner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><elocation-id>714551</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.714551</pub-id><pub-id pub-id-type="pmid">34778031</pub-id><pub-id pub-id-type="pmcid">PMC8580328</pub-id></element-citation></ref><ref id="B118-pharmaceutics-16-01196"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsakonas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Specht</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kristensen</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>M.H.C.</given-names></name><name name-style="western"><surname>Haugen Cange</surname><given-names>H.</given-names></name><name name-style="western"><surname>Soderstrom</surname><given-names>K.</given-names></name><name name-style="western"><surname>Friesland</surname><given-names>S.</given-names></name></person-group><article-title>Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck</article-title><source>Cancers</source><year>2020</year><volume>12</volume><elocation-id>3110</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12113110</pub-id><pub-id pub-id-type="pmid">33114379</pub-id><pub-id pub-id-type="pmcid">PMC7693024</pub-id></element-citation></ref><ref id="B119-pharmaceutics-16-01196"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guigay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aup&#233;rin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fayette</surname><given-names>J.</given-names></name><name name-style="western"><surname>Saada-Bouzid</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lafond</surname><given-names>C.</given-names></name><name name-style="western"><surname>Taberna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Geoffrois</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Capitain</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cupissol</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Cetuximab, Docetaxel, and Cisplatin versus Platinum, Fluorouracil, and Cetuximab as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (GORTEC 2014-01 TPExtreme): A Multicentre, Open-Label, Randomised, Phas</article-title><source>Lancet Oncol.</source><year>2021</year><volume>22</volume><fpage>463</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(20)30755-5</pub-id><pub-id pub-id-type="pmid">33684370</pub-id></element-citation></ref><ref id="B120-pharmaceutics-16-01196"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Krauss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Potthoff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Desta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Habl</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mavtratzas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Windemuth-Kiesselbach</surname><given-names>C.</given-names></name><name name-style="western"><surname>Debus</surname><given-names>J.</given-names></name><name name-style="western"><surname>M&#252;nter</surname><given-names>M.W.</given-names></name></person-group><article-title>Phase II Study of Induction Chemotherapy with TPF Followed by Radioimmunotherapy with Cetuximab and Intensity-Modulated Radiotherapy (IMRT) in Combination with a Carbon Ion Boost for Locally Advanced Tumours of the Oro-, Hypopharynx and Larynx-TPF-C-HIT</article-title><source>BMC Cancer</source><year>2011</year><volume>11</volume><elocation-id>182</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-11-182</pub-id><pub-id pub-id-type="pmid">21595970</pub-id><pub-id pub-id-type="pmcid">PMC3118195</pub-id></element-citation></ref><ref id="B121-pharmaceutics-16-01196"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hauswald</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Krauss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haselmann</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lossner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Windemuth-Kieselbach</surname><given-names>C.</given-names></name><name name-style="western"><surname>M&#252;nter</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Debus</surname><given-names>J.</given-names></name></person-group><article-title>Phase II Study of Induction Chemotherapy with Docetaxel, Cisplatin, 5-Fluorouracil Followed by Radioimmunotherapy with Cetuximab and Intensity-Modulated Radiotherapy in Combination with a Carbon Ion Boost for Locally Advanced Tumors of the Oro-, Hypophary and larynx</article-title><source>Clin. Transl. Radiat. Oncol.</source><year>2018</year><volume>13</volume><fpage>64</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.ctro.2018.09.005</pub-id><pub-id pub-id-type="pmid">30370340</pub-id><pub-id pub-id-type="pmcid">PMC6199783</pub-id></element-citation></ref><ref id="B122-pharmaceutics-16-01196"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geoffrois</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>L.</given-names></name><name name-style="western"><surname>De Raucourt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.S.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Maingon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Buffet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pointreau</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sire</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tuchais</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial</article-title><source>J. Clin. Oncol.</source><year>2018</year><volume>36</volume><fpage>3077</fpage><lpage>3083</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.76.2591</pub-id><pub-id pub-id-type="pmid">30016178</pub-id></element-citation></ref><ref id="B123-pharmaceutics-16-01196"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harari</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kies</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Gillison</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Foote</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Machtay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rotman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khuntia</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234</article-title><source>J. Clin. Oncol.</source><year>2014</year><volume>32</volume><fpage>2486</fpage><lpage>2495</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.53.9163</pub-id><pub-id pub-id-type="pmid">25002723</pub-id><pub-id pub-id-type="pmcid">PMC4121506</pub-id></element-citation></ref><ref id="B124-pharmaceutics-16-01196"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marur</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cmelak</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Gillison</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Westra</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bauman</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>L.I.</given-names></name><etal/></person-group><article-title>E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients with HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx&#8212;ECOG-ACRIN Cancer Research Group</article-title><source>J. Clin. Oncol.</source><year>2017</year><volume>35</volume><fpage>490</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.68.3300</pub-id><pub-id pub-id-type="pmid">28029303</pub-id><pub-id pub-id-type="pmcid">PMC5455313</pub-id></element-citation></ref><ref id="B125-pharmaceutics-16-01196"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wanebo</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Burtness</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Ridge</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Ghebremichael</surname><given-names>M.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Psyrri</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pectasides</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rimm</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>F.R.</given-names></name><etal/></person-group><article-title>Induction Cetuximab, Paclitaxel, and Carboplatin Followed by Chemoradiation with Cetuximab, Paclitaxel, and Carboplatin for Stage III/IV Head and Neck Squamous Cancer: A Phase II ECOG-ACRIN Trial (E2303)</article-title><source>Ann. Oncol.</source><year>2014</year><volume>25</volume><fpage>2036</fpage><lpage>2041</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu248</pub-id><pub-id pub-id-type="pmid">25009013</pub-id><pub-id pub-id-type="pmcid">PMC4176450</pub-id></element-citation></ref><ref id="B126-pharmaceutics-16-01196"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adkins</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Trinkaus</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thorstad</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wildes</surname><given-names>T.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Dehdashti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gay</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mehan</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A Phase 2 Trial of Induction Nab-paclitaxel and Cetuximab given with Cisplatin and 5-fluorouracil Followed by Concurrent Cisplatin and Radiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck</article-title><source>Cancer</source><year>2013</year><volume>119</volume><fpage>766</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1002/cncr.27741</pub-id><pub-id pub-id-type="pmid">22991252</pub-id><pub-id pub-id-type="pmcid">PMC3832987</pub-id></element-citation></ref><ref id="B127-pharmaceutics-16-01196"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lefebvre</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Pointreau</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rolland</surname><given-names>F.</given-names></name><name name-style="western"><surname>Alfonsi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baudoux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sire</surname><given-names>C.</given-names></name><name name-style="western"><surname>de Raucourt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Malard</surname><given-names>O.</given-names></name><name name-style="western"><surname>Degardin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tuchais</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study</article-title><source>J. Clin. Oncol.</source><year>2013</year><volume>31</volume><fpage>853</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.42.3988</pub-id><pub-id pub-id-type="pmid">23341517</pub-id></element-citation></ref><ref id="B128-pharmaceutics-16-01196"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villaflor</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Melotek</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Karrison</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Brisson</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Portugal</surname><given-names>L.</given-names></name><name name-style="western"><surname>De Souza</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Ginat</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Stenson</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Langerman</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Response-Adapted Volume de-Escalation (RAVD) in Locally Advanced Head and Neck Cancer</article-title><source>Ann. Oncol.</source><year>2016</year><volume>27</volume><fpage>908</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdw051</pub-id><pub-id pub-id-type="pmid">26884588</pub-id></element-citation></ref><ref id="B129-pharmaceutics-16-01196"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishimura</surname><given-names>G.</given-names></name><name name-style="western"><surname>Taguchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shiono</surname><given-names>O.</given-names></name><name name-style="western"><surname>Komatsu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sano</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yabuki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Arai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hata</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Phase II Trial of Concurrent Bio-Chemoradiotherapy Using Docetaxel, Cisplatin, and Cetuximab for Locally Advanced Head and Neck Squamous Cell Carcinoma</article-title><source>Cancer Chemother. Pharmacol.</source><year>2016</year><volume>77</volume><fpage>1315</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1007/s00280-016-3052-4</pub-id><pub-id pub-id-type="pmid">27154176</pub-id></element-citation></ref><ref id="B130-pharmaceutics-16-01196"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oppelt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Daly</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rich</surname><given-names>J.</given-names></name><name name-style="western"><surname>Paniello</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Pipkorn</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gay</surname><given-names>H.</given-names></name><name name-style="western"><surname>Palka</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Nab-Paclitaxel and Cisplatin Followed by Cisplatin and Radiation (Arm 1) and Nab-Paclitaxel Followed by Cetuximab and Radiation (Arm 2) for Locally Advanced Head and Neck Squamous-Cell Carcinoma: A Multicenter, Non-Randomized Phase 2 Trial</article-title><source>Med. Oncol.</source><year>2021</year><volume>38</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1007/s12032-021-01479-w</pub-id><pub-id pub-id-type="pmid">33683482</pub-id></element-citation></ref><ref id="B131-pharmaceutics-16-01196"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chibaudel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lacave</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lefevre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soussan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Antoine</surname><given-names>M.</given-names></name><name name-style="western"><surname>P&#233;ri&#233;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Belloc</surname><given-names>J.</given-names></name><name name-style="western"><surname>Banal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chabolle</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Induction Therapy with Cetuximab plus Docetaxel, Cisplatin, and 5-Fluorouracil (ETPF) in Patients with Resectable Nonmetastatic Stage III or IV Squamous Cell Carcinoma of the Oropharynx. A GERCOR Phase II ECHO-07 Study</article-title><source>Cancer Med.</source><year>2015</year><volume>4</volume><fpage>721</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1002/cam4.408</pub-id><pub-id pub-id-type="pmid">25684313</pub-id><pub-id pub-id-type="pmcid">PMC4430265</pub-id></element-citation></ref><ref id="B132-pharmaceutics-16-01196"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keil</surname><given-names>F.</given-names></name><name name-style="western"><surname>Selzer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Berghold</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reinisch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kapp</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>De Vries</surname><given-names>A.</given-names></name><name name-style="western"><surname>Greil</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bachtiary</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tinchon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Anderhuber</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Induction Chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil Followed by Radiotherapy with Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck</article-title><source>Eur. J. Cancer</source><year>2013</year><volume>49</volume><fpage>352</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2012.08.004</pub-id><pub-id pub-id-type="pmid">22981499</pub-id></element-citation></ref><ref id="B133-pharmaceutics-16-01196"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Specenier</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Remenar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Buter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schrijvers</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Bergamini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Licitra</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Awada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Fortpied</surname><given-names>C.</given-names></name><name name-style="western"><surname>Menis</surname><given-names>J.</given-names></name><etal/></person-group><article-title>TPF plus Cetuximab Induction Chemotherapy Followed by Biochemoradiation with Weekly Cetuximab plus Weekly Cisplatin or Carboplatin: A Randomized Phase II EORTC Trial</article-title><source>Ann. Oncol.</source><year>2017</year><volume>28</volume><fpage>2219</fpage><lpage>2224</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdx300</pub-id><pub-id pub-id-type="pmid">28911062</pub-id></element-citation></ref><ref id="B134-pharmaceutics-16-01196"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adkins</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oppelt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wildes</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Gay</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Daly</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rich</surname><given-names>J.</given-names></name><name name-style="western"><surname>Paniello</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pipkorn</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Nab-Paclitaxel-Based Induction Chemotherapy with or without Cetuximab for Locally Advanced Head and Neck Squamous Cell Carcinoma</article-title><source>Oral Oncol.</source><year>2017</year><volume>72</volume><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2017.07.001</pub-id><pub-id pub-id-type="pmid">28797458</pub-id></element-citation></ref><ref id="B135-pharmaceutics-16-01196"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merlano</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Denaro</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vecchio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Licitra</surname><given-names>L.</given-names></name><name name-style="western"><surname>Curcio</surname><given-names>P.</given-names></name><name name-style="western"><surname>Benasso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bagicalupo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Numico</surname><given-names>G.</given-names></name><name name-style="western"><surname>Russi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Corvo&#8217;</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00999700">NCT00999700</ext-link>)</article-title><source>Oncology</source><year>2020</year><volume>98</volume><fpage>763</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1159/000507733</pub-id><pub-id pub-id-type="pmid">32629446</pub-id></element-citation></ref><ref id="B136-pharmaceutics-16-01196"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghi</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Paccagnella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>D.</given-names></name><name name-style="western"><surname>Foa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Alterio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Codec&#224;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nol&#232;</surname><given-names>F.</given-names></name><name name-style="western"><surname>Verri</surname><given-names>E.</given-names></name><name name-style="western"><surname>Orecchia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Morelli</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Induction TPF Followed by Concomitant Treatment versus Concomitant Treatment Alone in Locally Advanced Head and Neck Cancer. A Phase II&#8211;III Trial</article-title><source>Ann. Oncol.</source><year>2017</year><volume>28</volume><fpage>2206</fpage><lpage>2212</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdx299</pub-id><pub-id pub-id-type="pmid">28911070</pub-id></element-citation></ref><ref id="B137-pharmaceutics-16-01196"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mes&#237;a</surname><given-names>R.</given-names></name><name name-style="western"><surname>V&#225;zquez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grau</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Garc&#237;a-S&#225;enz</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lozano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carles</surname><given-names>J.</given-names></name><name name-style="western"><surname>Irigoyen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ma&#241;&#243;s</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a-Paredes</surname><given-names>B.</given-names></name><etal/></person-group><article-title>A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck</article-title><source>Int. J. Radiat. Oncol.</source><year>2016</year><volume>94</volume><fpage>289</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2015.10.019</pub-id><pub-id pub-id-type="pmid">26675064</pub-id></element-citation></ref><ref id="B138-pharmaceutics-16-01196"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birnbaum</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dipetrillo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rathore</surname><given-names>R.</given-names></name><name name-style="western"><surname>Merriam</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wanebo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Puthawala</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>D.</given-names></name><name name-style="western"><surname>Luppe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Khurshid</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Cetuximab, Paclitaxel, Carboplatin, and Radiation for Head and Neck Cancer</article-title><source>Am. J. Clin. Oncol.</source><year>2014</year><volume>37</volume><fpage>162</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1097/COC.0b013e31826e06e0</pub-id><pub-id pub-id-type="pmid">23275269</pub-id></element-citation></ref><ref id="B139-pharmaceutics-16-01196"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enokida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Homma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Okami</surname><given-names>K.</given-names></name><name name-style="western"><surname>Minami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakanome</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Maki</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fujisawa</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A Multicenter Phase II Trial of Paclitaxel, Carboplatin, and Cetuximab Followed by Chemoradiotherapy in Patients with Unresectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck</article-title><source>Cancer Med.</source><year>2020</year><volume>9</volume><fpage>1671</fpage><lpage>1682</lpage><pub-id pub-id-type="doi">10.1002/cam4.2852</pub-id><pub-id pub-id-type="pmid">31943834</pub-id><pub-id pub-id-type="pmcid">PMC7050099</pub-id></element-citation></ref><ref id="B140-pharmaceutics-16-01196"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chun</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sumer</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Truelson</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>T.-W.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yordy</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Cooley</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab with Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck</article-title><source>Cancer Investig.</source><year>2017</year><volume>35</volume><fpage>23</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1080/07357907.2016.1213275</pub-id><pub-id pub-id-type="pmid">27892728</pub-id></element-citation></ref><ref id="B141-pharmaceutics-16-01196"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name></person-group><article-title>Effectiveness of Incorporating Cetuximab into Docetaxel/Cisplatin/Fluorouracil Induction Chemotherapy and Chemoradiotherapy for Inoperable Squamous Cell Carcinoma of the Oral Cavity: A Phase II Study</article-title><source>Head Neck</source><year>2017</year><volume>39</volume><fpage>1333</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1002/hed.24766</pub-id><pub-id pub-id-type="pmid">28370774</pub-id></element-citation></ref><ref id="B142-pharmaceutics-16-01196"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishimura</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shiono</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sano</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yabuki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Arai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chiba</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tanabe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oridate</surname><given-names>N.</given-names></name></person-group><article-title>Efficacy and Safety of Postoperative Bio-Chemoradiotherapy Using Cetuximab and Docetaxel for High-Risk Head and Neck Cancer Patients in Japan</article-title><source>Cancer Chemother. Pharmacol.</source><year>2017</year><volume>80</volume><fpage>203</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1007/s00280-017-3352-3</pub-id><pub-id pub-id-type="pmid">28597041</pub-id></element-citation></ref><ref id="B143-pharmaceutics-16-01196"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Argiris</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heron</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Branstetter</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Posluszny</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Seethala</surname><given-names>R.R.</given-names></name><etal/></person-group><article-title>Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer</article-title><source>J. Clin. Oncol.</source><year>2010</year><volume>28</volume><fpage>5294</fpage><lpage>5300</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.30.6423</pub-id><pub-id pub-id-type="pmid">21079141</pub-id><pub-id pub-id-type="pmcid">PMC3018361</pub-id></element-citation></ref><ref id="B144-pharmaceutics-16-01196"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larizadeh</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Mohammadi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shabani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Damghani</surname><given-names>M.A.</given-names></name></person-group><article-title>Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy in Laryngeal Cancer</article-title><source>Asian Pac. J. Cancer Prev.</source><year>2021</year><volume>22</volume><fpage>1633</fpage><lpage>1637</lpage><pub-id pub-id-type="doi">10.31557/APJCP.2021.22.5.1633</pub-id><pub-id pub-id-type="pmid">34048195</pub-id><pub-id pub-id-type="pmcid">PMC8408382</pub-id></element-citation></ref><ref id="B145-pharmaceutics-16-01196"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Muto</surname><given-names>P.</given-names></name><name name-style="western"><surname>Argenone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ionna</surname><given-names>F.</given-names></name><name name-style="western"><surname>Longo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fulciniti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sandomenico</surname><given-names>F.</given-names></name><name name-style="western"><surname>Daponte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Caponigro</surname><given-names>F.</given-names></name></person-group><article-title>Induction Chemotherapy with Docetaxel, Cisplatin and Capecitabine, Followed by Combined Cetuximab and Radiotherapy in Patients with Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck: A Phase I-II Study</article-title><source>Oncology</source><year>2013</year><volume>84</volume><fpage>251</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1159/000347232</pub-id><pub-id pub-id-type="pmid">23428719</pub-id></element-citation></ref><ref id="B146-pharmaceutics-16-01196"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charalambakis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kouloulias</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vaja</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pectasides</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rampias</surname><given-names>T.</given-names></name><name name-style="western"><surname>Economopoulos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Katsaounis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Siolos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bartzi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Perisanidis</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma</article-title><source>Front. Oncol.</source><year>2013</year><volume>3</volume><elocation-id>5</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2013.00005</pub-id><pub-id pub-id-type="pmid">23373010</pub-id><pub-id pub-id-type="pmcid">PMC3557442</pub-id></element-citation></ref><ref id="B147-pharmaceutics-16-01196"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seiwert</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Melotek</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Stenson</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Salama</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Witt</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Brisson</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Chawla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lingen</surname><given-names>M.W.</given-names></name><etal/></person-group><article-title>Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer</article-title><source>Int. J. Radiat. Oncol.</source><year>2016</year><volume>96</volume><fpage>21</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2016.04.030</pub-id><pub-id pub-id-type="pmid">27511844</pub-id></element-citation></ref><ref id="B148-pharmaceutics-16-01196"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>William</surname><given-names>W.N.</given-names></name><name name-style="western"><surname>Papadimitrakopoulou</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>E.E.W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Gillenwater</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Lingen</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>J.O.</given-names></name><etal/></person-group><article-title>Erlotinib and the Risk of Oral Cancer</article-title><source>JAMA Oncol.</source><year>2016</year><volume>2</volume><fpage>209</fpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2015.4364</pub-id><pub-id pub-id-type="pmid">26540028</pub-id><pub-id pub-id-type="pmcid">PMC4771491</pub-id></element-citation></ref><ref id="B149-pharmaceutics-16-01196"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porosnicu</surname><given-names>M.</given-names></name><name name-style="western"><surname>O&#8217;Brien Cox</surname><given-names>A.</given-names></name><name name-style="western"><surname>Waltonen</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Bunch</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>D&#8217;Agostino</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lycan</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>R.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Early [18]FDG PET/CT Scan Predicts Tumor Response in Head and Neck Squamous Cell Cancer Patients Treated with Erlotinib Adjusted per Smoking Status</article-title><source>Front. Oncol.</source><year>2022</year><volume>12</volume><elocation-id>939118</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2022.939118</pub-id><pub-id pub-id-type="pmid">36110959</pub-id><pub-id pub-id-type="pmcid">PMC9468744</pub-id></element-citation></ref><ref id="B150-pharmaceutics-16-01196"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rochaix</surname><given-names>P.</given-names></name><name name-style="western"><surname>Benlyazid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sarini</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rives</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lefebvre</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Allal</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Courbon</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chatelut</surname><given-names>E.</given-names></name><name name-style="western"><surname>Delord</surname><given-names>J.-P.</given-names></name></person-group><article-title>Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma</article-title><source>Clin. Cancer Res.</source><year>2007</year><volume>13</volume><fpage>7086</fpage><lpage>7092</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-1370</pub-id><pub-id pub-id-type="pmid">18056187</pub-id></element-citation></ref><ref id="B151-pharmaceutics-16-01196"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenthal</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Clemons</surname><given-names>L.</given-names></name><name name-style="western"><surname>Desmond</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nabell</surname><given-names>L.</given-names></name></person-group><article-title>Assessment of Erlotinib as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer Patients</article-title><source>Ann. Surg. Oncol.</source><year>2014</year><volume>21</volume><fpage>4263</fpage><lpage>4269</lpage><pub-id pub-id-type="doi">10.1245/s10434-014-3878-0</pub-id><pub-id pub-id-type="pmid">25001094</pub-id></element-citation></ref><ref id="B152-pharmaceutics-16-01196"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kraut</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Rhoades</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Aimiumu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Young</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dancey</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Phase I and Pharmacokinetic Study of Erlotinib (OSI-774) in Combination with Docetaxel in Squamous Cell Carcinoma of the Head and Neck (SSCHN)</article-title><source>Cancer Chemother. Pharmacol.</source><year>2011</year><volume>67</volume><fpage>579</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1007/s00280-010-1332-y</pub-id><pub-id pub-id-type="pmid">20490801</pub-id><pub-id pub-id-type="pmcid">PMC3828747</pub-id></element-citation></ref><ref id="B153-pharmaceutics-16-01196"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lavertu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rezaee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zender</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wasman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Machtay</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Phase II Study of Erlotinib and Docetaxel with Concurrent Intensity-modulated Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma</article-title><source>Head Neck</source><year>2016</year><volume>38</volume><fpage>E1770</fpage><lpage>E1776</lpage><pub-id pub-id-type="doi">10.1002/hed.24313</pub-id><pub-id pub-id-type="pmid">26918562</pub-id><pub-id pub-id-type="pmcid">PMC4844765</pub-id></element-citation></ref><ref id="B154-pharmaceutics-16-01196"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>William</surname><given-names>W.N.</given-names></name><name name-style="western"><surname>Tsao</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ginsberg</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Kies</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Glisson</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E.S.</given-names></name></person-group><article-title>Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas</article-title><source>Oncologist</source><year>2018</year><volume>23</volume><fpage>e526</fpage><lpage>e549</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2017-0661</pub-id><pub-id pub-id-type="pmcid">PMC5947451</pub-id><pub-id pub-id-type="pmid">29371473</pub-id></element-citation></ref><ref id="B155-pharmaceutics-16-01196"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hainsworth</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Spigel</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Greco</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Shipley</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Peyton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stipanov</surname><given-names>M.</given-names></name><name name-style="western"><surname>Meluch</surname><given-names>A.</given-names></name></person-group><article-title>Combined Modality Treatment with Chemotherapy, Radiation Therapy, Bevacizumab, and Erlotinib in Patients with Locally Advanced Squamous Carcinoma of the Head and Neck</article-title><source>Cancer J.</source><year>2011</year><volume>17</volume><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1097/PPO.0b013e3182329791</pub-id><pub-id pub-id-type="pmid">21952273</pub-id></element-citation></ref><ref id="B156-pharmaceutics-16-01196"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agulnik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>E.W.E.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>E.X.</given-names></name><name name-style="western"><surname>Vokes</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Hotte</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Winquist</surname><given-names>E.</given-names></name><name name-style="western"><surname>Laurie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Dancey</surname><given-names>J.E.</given-names></name><etal/></person-group><article-title>Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or ErbB2 Expressing Adenoid Cystic Carcinoma and Non&#8211;Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands</article-title><source>J. Clin. Oncol.</source><year>2007</year><volume>25</volume><fpage>3978</fpage><lpage>3984</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.11.8612</pub-id><pub-id pub-id-type="pmid">17761983</pub-id></element-citation></ref><ref id="B157-pharmaceutics-16-01196"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Souza</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Khattri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seiwert</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Aktolga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kozloff</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Nattam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lingen</surname><given-names>M.W.</given-names></name><etal/></person-group><article-title>A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck</article-title><source>Clin. Cancer Res.</source><year>2012</year><volume>18</volume><fpage>2336</fpage><lpage>2343</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2825</pub-id><pub-id pub-id-type="pmid">22371453</pub-id><pub-id pub-id-type="pmcid">PMC4467891</pub-id></element-citation></ref><ref id="B158-pharmaceutics-16-01196"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hackman</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Deal</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Neil Hayes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chera</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>J.</given-names></name><name name-style="western"><surname>Knowles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Usenko</surname><given-names>D.</given-names></name><name name-style="western"><surname>Grilley-Olson</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Weissler</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Novel Induction Therapy Transoral Surgery Treatment Paradigm with Risk-Adapted Adjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck&#8211;Mature Clinical and Functional Outcomes</article-title><source>Oral Oncol.</source><year>2020</year><volume>110</volume><fpage>104957</fpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2020.104957</pub-id><pub-id pub-id-type="pmid">32823258</pub-id></element-citation></ref><ref id="B159-pharmaceutics-16-01196"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiu</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>E.X.</given-names></name><name name-style="western"><surname>Siu</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Abdul Razak</surname><given-names>A.R.</given-names></name></person-group><article-title>Pharmacokinetic Assessment of Dacomitinib (Pan-HER Tyrosine Kinase Inhibitor) in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma (LA SCCHN) Following Administration through a Gastrostomy Feeding Tube (GT)</article-title><source>Investig. New Drugs</source><year>2015</year><volume>33</volume><fpage>895</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1007/s10637-015-0245-3</pub-id><pub-id pub-id-type="pmid">25937431</pub-id></element-citation></ref><ref id="B160-pharmaceutics-16-01196"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>I.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>M.-J.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>D.-H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.U.</given-names></name><etal/></person-group><article-title>Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck</article-title><source>Clin. Cancer Res.</source><year>2015</year><volume>21</volume><fpage>544</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-1756</pub-id><pub-id pub-id-type="pmid">25424851</pub-id></element-citation></ref><ref id="B161-pharmaceutics-16-01196"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Heo</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.R.</given-names></name></person-group><article-title>A Phase II Study of Poziotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma</article-title><source>Cancer Med.</source><year>2021</year><volume>10</volume><fpage>7012</fpage><lpage>7020</lpage><pub-id pub-id-type="doi">10.1002/cam4.4231</pub-id><pub-id pub-id-type="pmid">34528763</pub-id><pub-id pub-id-type="pmcid">PMC8525103</pub-id></element-citation></ref><ref id="B162-pharmaceutics-16-01196"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Molinari</surname><given-names>F.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mach</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fr&#252;h</surname><given-names>M.</given-names></name><name name-style="western"><surname>Freguia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Corradino</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ghielmini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frattini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Espeli</surname><given-names>V.</given-names></name></person-group><article-title>Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer</article-title><source>Oncologist</source><year>2017</year><volume>22</volume><fpage>782-e70</fpage><pub-id pub-id-type="doi">10.1634/theoncologist.2017-0069</pub-id><pub-id pub-id-type="pmid">28592616</pub-id><pub-id pub-id-type="pmcid">PMC5507653</pub-id></element-citation></ref><ref id="B163-pharmaceutics-16-01196"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rischin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Spigel</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Adkins</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wein</surname><given-names>R.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singhal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>O.</given-names></name><name name-style="western"><surname>Murugappan</surname><given-names>S.</given-names></name></person-group><article-title>PRISM: Phase 2 Trial with Panitumumab Monotherapy as Second-line Treatment in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</article-title><source>Head Neck</source><year>2016</year><volume>38</volume><fpage>E1756</fpage><lpage>E1761</lpage><pub-id pub-id-type="doi">10.1002/hed.24311</pub-id><pub-id pub-id-type="pmid">26681429</pub-id></element-citation></ref><ref id="B164-pharmaceutics-16-01196"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>del Barco Morillo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mes&#237;a</surname><given-names>R.</given-names></name><name name-style="western"><surname>Adansa Klain</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>V&#225;zquez Fern&#225;ndez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Gal&#225;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pastor Borgo&#241;on</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Rivas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Caballero Daroqui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Berrocal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Trufero</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Phase II Study of Panitumumab and Paclitaxel as First-Line Treatment in Recurrent or Metastatic Head and Neck Cancer. TTCC-2009-03/VECTITAX Study</article-title><source>Oral Oncol.</source><year>2016</year><volume>62</volume><fpage>54</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2016.09.009</pub-id><pub-id pub-id-type="pmid">27865372</pub-id></element-citation></ref><ref id="B165-pharmaceutics-16-01196"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-Trufero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lozano Borbalas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pajares Bernad</surname><given-names>I.</given-names></name><name name-style="western"><surname>Taberna Sanz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ortega Izquierdo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cirauqui Cirauqui</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rubi&#243;-Casadevall</surname><given-names>J.</given-names></name><name name-style="western"><surname>Plana Serrahima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ponce Ortega</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Planas Toledano</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Sequential Chemotherapy Regimen of Induction with Panitumumab and Paclitaxel Followed by Radiotherapy and Panitumumab in Patients with Locally Advanced Head and Neck Cancer Unfit for Platinum Derivatives. The Phase II, PANTERA/TTCC-2010-06 Study</article-title><source>Clin. Transl. Oncol.</source><year>2021</year><volume>23</volume><fpage>1666</fpage><lpage>1677</lpage><pub-id pub-id-type="doi">10.1007/s12094-021-02567-z</pub-id><pub-id pub-id-type="pmid">33876416</pub-id></element-citation></ref><ref id="B166-pharmaceutics-16-01196"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wirth</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Posner</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Haddad</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Busse</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Goguen</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Norris</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>Phase I Dose-Finding Study of Paclitaxel with Panitumumab, Carboplatin and Intensity-Modulated Radiotherapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck</article-title><source>Ann. Oncol.</source><year>2010</year><volume>21</volume><fpage>342</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdp477</pub-id><pub-id pub-id-type="pmid">19892746</pub-id></element-citation></ref><ref id="B167-pharmaceutics-16-01196"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wirth</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Dakhil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kornek</surname><given-names>G.</given-names></name><name name-style="western"><surname>Axelrod</surname><given-names>R.</given-names></name><name name-style="western"><surname>Adkins</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pant</surname><given-names>S.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>P.</given-names></name><name name-style="western"><surname>Debruyne</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Oliner</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J.</given-names></name><etal/></person-group><article-title>PARTNER: An Open-Label, Randomized, Phase 2 Study of Docetaxel/Cisplatin Chemotherapy with or without Panitumumab as First-Line Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</article-title><source>Oral Oncol.</source><year>2016</year><volume>61</volume><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2016.07.005</pub-id><pub-id pub-id-type="pmid">27688102</pub-id></element-citation></ref><ref id="B168-pharmaceutics-16-01196"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.</given-names></name></person-group><article-title>Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Combined with Chemoradiotherapy for Induction Chemotherapy Resistant Locally Advanced Nasopharyngeal Carcinoma: A Prospective Phase II Study</article-title><source>Transl. Oncol.</source><year>2024</year><volume>39</volume><fpage>101797</fpage><pub-id pub-id-type="doi">10.1016/j.tranon.2023.101797</pub-id><pub-id pub-id-type="pmid">37865048</pub-id><pub-id pub-id-type="pmcid">PMC10597793</pub-id></element-citation></ref><ref id="B169-pharmaceutics-16-01196"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fayette</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>L.</given-names></name><name name-style="western"><surname>Oprean</surname><given-names>C.</given-names></name><name name-style="western"><surname>Udrea</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jimeno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rischin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nutting</surname><given-names>C.</given-names></name><name name-style="western"><surname>Harari</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Csoszi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cernea</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)</article-title><source>Front. Oncol.</source><year>2016</year><volume>6</volume><elocation-id>232</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2016.00232</pub-id><pub-id pub-id-type="pmid">27843803</pub-id><pub-id pub-id-type="pmcid">PMC5086582</pub-id></element-citation></ref><ref id="B170-pharmaceutics-16-01196"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jimeno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Machiels</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>L.</given-names></name><name name-style="western"><surname>Specenier</surname><given-names>P.</given-names></name><name name-style="western"><surname>Seiwert</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Mardjuadi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kapp</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Royer-Joo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Penuel</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Phase Ib Study of Duligotuzumab (MEHD7945A) plus Cisplatin/5-fluorouracil or Carboplatin/Paclitaxel for First-line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck</article-title><source>Cancer</source><year>2016</year><volume>122</volume><fpage>3803</fpage><lpage>3811</lpage><pub-id pub-id-type="doi">10.1002/cncr.30256</pub-id><pub-id pub-id-type="pmid">27525588</pub-id></element-citation></ref><ref id="B171-pharmaceutics-16-01196"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Phase I Study of A166, an Antibody&#8211;drug Conjugate in Advanced HER2-Expressing Solid Tumours</article-title><source>NPJ Breast Cancer</source><year>2023</year><volume>9</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1038/s41523-023-00522-5</pub-id><pub-id pub-id-type="pmid">37072437</pub-id><pub-id pub-id-type="pmcid">PMC10113253</pub-id></element-citation></ref><ref id="B172-pharmaceutics-16-01196"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baselga</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rischin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ranson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Calvert</surname><given-names>H.</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kieback</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Gianni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bjork</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Five Selected Solid Tumor Types</article-title><source>J. Clin. Oncol.</source><year>2002</year><volume>20</volume><fpage>4292</fpage><lpage>4302</lpage><pub-id pub-id-type="doi">10.1200/JCO.2002.03.100</pub-id><pub-id pub-id-type="pmid">12409327</pub-id></element-citation></ref><ref id="B173-pharmaceutics-16-01196"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Glisson</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wistuba</surname><given-names>I.I.</given-names></name><name name-style="western"><surname>El-Naggar</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lustig</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck</article-title><source>Clin. Cancer Res.</source><year>2012</year><volume>18</volume><fpage>1435</fpage><lpage>1446</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-1951</pub-id><pub-id pub-id-type="pmid">22261807</pub-id><pub-id pub-id-type="pmcid">PMC6167936</pub-id></element-citation></ref><ref id="B174-pharmaceutics-16-01196"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chua</surname><given-names>D.T.T.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.I.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Sham</surname><given-names>J.S.T.</given-names></name><name name-style="western"><surname>Nicholls</surname><given-names>J.</given-names></name><name name-style="western"><surname>Au</surname><given-names>G.K.H.</given-names></name></person-group><article-title>Phase II Study of Gefitinib for the Treatment of Recurrent and Metastatic Nasopharyngeal Carcinoma</article-title><source>Head Neck</source><year>2008</year><volume>30</volume><fpage>863</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1002/hed.20792</pub-id><pub-id pub-id-type="pmid">18213730</pub-id></element-citation></ref><ref id="B175-pharmaceutics-16-01196"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakob</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Kies</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Glisson</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Kupferman</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>El-Naggar</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Gonzalez-Angulo</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Blumenschein</surname><given-names>G.R.</given-names></name></person-group><article-title>Phase II Study of Gefitinib in Patients with Advanced Salivary Gland Cancers</article-title><source>Head Neck</source><year>2015</year><volume>37</volume><fpage>644</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1002/hed.23647</pub-id><pub-id pub-id-type="pmid">24585506</pub-id><pub-id pub-id-type="pmcid">PMC5669372</pub-id></element-citation></ref><ref id="B176-pharmaceutics-16-01196"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>E.E.W.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Stadler</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Recant</surname><given-names>W.</given-names></name><name name-style="western"><surname>Stenson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vokes</surname><given-names>E.E.</given-names></name></person-group><article-title>Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</article-title><source>J. Clin. Oncol.</source><year>2003</year><volume>21</volume><fpage>1980</fpage><lpage>1987</lpage><pub-id pub-id-type="doi">10.1200/JCO.2003.10.051</pub-id><pub-id pub-id-type="pmid">12743152</pub-id></element-citation></ref><ref id="B177-pharmaceutics-16-01196"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Raez</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Agulnik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grushko</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stenson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Olopade</surname><given-names>O.I.</given-names></name><name name-style="western"><surname>Seiwert</surname><given-names>T.Y.</given-names></name><etal/></person-group><article-title>Phase II Study of Gefitinib Adaptive Dose Escalation to Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</article-title><source>Oral Oncol.</source><year>2012</year><volume>48</volume><fpage>887</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2012.03.020</pub-id><pub-id pub-id-type="pmid">22513208</pub-id></element-citation></ref><ref id="B178-pharmaceutics-16-01196"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>E.E.W.</given-names></name><name name-style="western"><surname>Kane</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>List</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Brockstein</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mauer</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vokes</surname><given-names>E.E.</given-names></name></person-group><article-title>Phase II Trial of Gefitinib 250 Mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck</article-title><source>Clin. Cancer Res.</source><year>2005</year><volume>11</volume><fpage>8418</fpage><lpage>8424</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-1247</pub-id><pub-id pub-id-type="pmid">16322304</pub-id></element-citation></ref><ref id="B179-pharmaceutics-16-01196"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fury</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Solit</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sirotnak</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Azzoli</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Kris</surname><given-names>M.G.</given-names></name><etal/></person-group><article-title>A Phase I Trial of Intermittent High-Dose Gefitinib and Fixed-Dose Docetaxel in Patients with Advanced Solid Tumors</article-title><source>Cancer Chemother. Pharmacol.</source><year>2007</year><volume>59</volume><fpage>467</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1007/s00280-006-0286-6</pub-id><pub-id pub-id-type="pmid">16896930</pub-id></element-citation></ref><ref id="B180-pharmaceutics-16-01196"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Argiris</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ghebremichael</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.-W.W.</given-names></name><name name-style="western"><surname>Sachidanandam</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kolesar</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Burtness</surname><given-names>B.</given-names></name><name name-style="western"><surname>Forastiere</surname><given-names>A.A.</given-names></name></person-group><article-title>Phase III Randomized, Placebo-Controlled Trial of Docetaxel with or without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial</article-title><source>J. Clin. Oncol.</source><year>2013</year><volume>31</volume><fpage>1405</fpage><lpage>1414</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.45.4272</pub-id><pub-id pub-id-type="pmid">23460714</pub-id><pub-id pub-id-type="pmcid">PMC3612594</pub-id></element-citation></ref><ref id="B181-pharmaceutics-16-01196"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Waes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Citrin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gius</surname><given-names>D.</given-names></name><name name-style="western"><surname>Colevas</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Harold</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Rudy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nottingham</surname><given-names>L.</given-names></name><name name-style="western"><surname>Muir</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Molecular and Clinical Responses in a Pilot Study of Gefitinib with Paclitaxel and Radiation in Locally Advanced Head-and-Neck Cancer</article-title><source>Int. J. Radiat. Oncol.</source><year>2010</year><volume>77</volume><fpage>447</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.05.037</pub-id><pub-id pub-id-type="pmcid">PMC2868084</pub-id><pub-id pub-id-type="pmid">19879702</pub-id></element-citation></ref><ref id="B182-pharmaceutics-16-01196"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>E.E.W.</given-names></name><name name-style="western"><surname>Haraf</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Kunnavakkam</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stenson</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Brockstein</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lester</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Salama</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer</article-title><source>J. Clin. Oncol.</source><year>2010</year><volume>28</volume><fpage>3336</fpage><lpage>3343</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.27.0397</pub-id><pub-id pub-id-type="pmid">20498391</pub-id><pub-id pub-id-type="pmcid">PMC2903330</pub-id></element-citation></ref><ref id="B183-pharmaceutics-16-01196"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastholt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Specht</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brun</surname><given-names>E.</given-names></name><name name-style="western"><surname>Loft</surname><given-names>A.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kastberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Eriksen</surname><given-names>J.G.</given-names></name></person-group><article-title>Phase I/II Clinical and Pharmacokinetic Study Evaluating a Fully Human Monoclonal Antibody against EGFr (HuMax-EGFr) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck</article-title><source>Radiother. Oncol.</source><year>2007</year><volume>85</volume><fpage>24</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2007.06.007</pub-id><pub-id pub-id-type="pmid">17602769</pub-id></element-citation></ref><ref id="B184-pharmaceutics-16-01196"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saloura</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>E.E.W.</given-names></name><name name-style="western"><surname>Licitra</surname><given-names>L.</given-names></name><name name-style="western"><surname>Billan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dinis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lisby</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gauler</surname><given-names>T.C.</given-names></name></person-group><article-title>An Open-Label Single-Arm, Phase II Trial of Zalutumumab, a Human Monoclonal Anti-EGFR Antibody, in Patients with Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck</article-title><source>Cancer Chemother. Pharmacol.</source><year>2014</year><volume>73</volume><fpage>1227</fpage><lpage>1239</lpage><pub-id pub-id-type="doi">10.1007/s00280-014-2459-z</pub-id><pub-id pub-id-type="pmid">24714973</pub-id></element-citation></ref><ref id="B185-pharmaceutics-16-01196"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machiels</surname><given-names>J.</given-names></name><name name-style="western"><surname>Subramanian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ruzsa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Repassy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lifi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Flygare</surname><given-names>A.</given-names></name><name name-style="western"><surname>S&#248;rensen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lisby</surname><given-names>S.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>P.M.J.</given-names></name></person-group><article-title>Zalutumumab plus Best Supportive Care versus Best Supportive Care Alone in Patients with Recurrent or Metastatic Squamous-Cell Carcinoma of the Head and Neck after Failure of Platinum-Based Chemotherapy: An Open-Label, Randomised Phase 3 Trial</article-title><source>Lancet Oncol.</source><year>2011</year><volume>12</volume><fpage>333</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(11)70034-1</pub-id><pub-id pub-id-type="pmid">21377930</pub-id></element-citation></ref><ref id="B186-pharmaceutics-16-01196"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duvvuri</surname><given-names>U.</given-names></name><name name-style="western"><surname>George</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alvarado</surname><given-names>D.</given-names></name><name name-style="western"><surname>Neumeister</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Chenna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gedrich</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hawthorne</surname><given-names>T.</given-names></name><name name-style="western"><surname>LaVallee</surname><given-names>T.</given-names></name><name name-style="western"><surname>Grandis</surname><given-names>J.R.</given-names></name><etal/></person-group><article-title>Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients</article-title><source>Clin. Cancer Res.</source><year>2019</year><volume>25</volume><fpage>5752</fpage><lpage>5758</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-3453</pub-id><pub-id pub-id-type="pmid">31308059</pub-id><pub-id pub-id-type="pmcid">PMC6820348</pub-id></element-citation></ref><ref id="B187-pharmaceutics-16-01196"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Keam</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Chae</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name></person-group><article-title>A Phase Ia/Ib Study of Novel Anti-ErbB3 Monoclonal Antibody, Barecetamab (ISU104) in Refractory Solid Cancers and Monotherapy or in Combination with Cetuximab in Recurrent or Metastatic Head and Neck Cancer</article-title><source>Int. J. Cancer</source><year>2023</year><volume>153</volume><fpage>1501</fpage><lpage>1511</lpage><pub-id pub-id-type="doi">10.1002/ijc.34622</pub-id><pub-id pub-id-type="pmid">37357950</pub-id></element-citation></ref><ref id="B188-pharmaceutics-16-01196"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marret</surname><given-names>G.</given-names></name><name name-style="western"><surname>Temam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kamal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Even</surname><given-names>C.</given-names></name><name name-style="western"><surname>Delord</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dolivet</surname><given-names>G.</given-names></name><name name-style="western"><surname>Malard</surname><given-names>O.</given-names></name><name name-style="western"><surname>Fayette</surname><given-names>J.</given-names></name><name name-style="western"><surname>Capitain</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Randomized Phase II Study of Preoperative Afatinib in Untreated Head and Neck Cancers: Predictive and Pharmacodynamic Biomarkers of Activity</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>22524</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-49887-4</pub-id><pub-id pub-id-type="pmid">38110561</pub-id><pub-id pub-id-type="pmcid">PMC10728082</pub-id></element-citation></ref><ref id="B189-pharmaceutics-16-01196"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machiels</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Bossi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Menis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fortpied</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lhommel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lemort</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Canevari</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Activity and Safety of Afatinib in a Window Preoperative EORTC Study in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)</article-title><source>Ann. Oncol.</source><year>2018</year><volume>29</volume><fpage>985</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdy013</pub-id><pub-id pub-id-type="pmid">29346507</pub-id></element-citation></ref><ref id="B190-pharmaceutics-16-01196"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burtness</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bourhis</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Vermorken</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>E.E.</given-names></name></person-group><article-title>Afatinib versus Placebo as Adjuvant Therapy after Chemoradiation in a Double-Blind, Phase III Study (LUX-Head &amp; Neck 2) in Patients with Primary Unresected, Clinically Intermediate-to-High-Risk Head and Neck Cancer: Study Protocol for a Randomized Controlled Trial</article-title><source>Trials</source><year>2014</year><volume>15</volume><fpage>469</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-15-469</pub-id><pub-id pub-id-type="pmid">25432788</pub-id><pub-id pub-id-type="pmcid">PMC4289298</pub-id></element-citation></ref><ref id="B191-pharmaceutics-16-01196"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burtness</surname><given-names>B.</given-names></name><name name-style="western"><surname>Haddad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dinis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Trigo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yokota</surname><given-names>T.</given-names></name><name name-style="western"><surname>de Souza Viana</surname><given-names>L.</given-names></name><name name-style="western"><surname>Romanov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vermorken</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bourhis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tahara</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Afatinib vs Placebo as Adjuvant Therapy after Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck A Randomized Clinical Trial</article-title><source>JAMA Oncol.</source><year>2019</year><volume>5</volume><fpage>1170</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2019.1146</pub-id><pub-id pub-id-type="pmid">31194247</pub-id><pub-id pub-id-type="pmcid">PMC6567846</pub-id></element-citation></ref><ref id="B192-pharmaceutics-16-01196"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haddad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guigay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Keilholz</surname><given-names>U.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Fayette</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Souza Viana</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rolland</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cupissol</surname><given-names>D.</given-names></name><name name-style="western"><surname>Geoffrois</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kornek</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Afatinib as Second-Line Treatment in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: Subgroup Analyses of Treatment Adherence, Safety and Mode of Afatinib Administration in the LUX-Head and Neck 1 Trial</article-title><source>Oral Oncol.</source><year>2019</year><volume>97</volume><fpage>82</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2019.08.004</pub-id><pub-id pub-id-type="pmid">31450171</pub-id></element-citation></ref><ref id="B193-pharmaceutics-16-01196"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bello</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arora</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name></person-group><article-title>Afatinib versus Methotrexate as Second-Line Treatment in Asian Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Progressing on or after Platinum-Based Therapy</article-title><source>Ann. Oncol.</source><year>2019</year><volume>30</volume><fpage>1831</fpage><lpage>1839</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdz388</pub-id><pub-id pub-id-type="pmid">31501887</pub-id><pub-id pub-id-type="pmcid">PMC6927323</pub-id></element-citation></ref><ref id="B194-pharmaceutics-16-01196"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunn</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Fury</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Katabi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Haque</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Pfister</surname><given-names>D.G.</given-names></name></person-group><article-title>Phase I Study of Induction Chemotherapy with Afatinib, Ribavirin, and Weekly Carboplatin and Paclitaxel for Stage IVA/IVB Human Papillomavirus-associated Oropharyngeal Squamous Cell Cancer</article-title><source>Head Neck</source><year>2018</year><volume>40</volume><fpage>233</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1002/hed.24938</pub-id><pub-id pub-id-type="pmid">28963790</pub-id><pub-id pub-id-type="pmcid">PMC6760238</pub-id></element-citation></ref><ref id="B195-pharmaceutics-16-01196"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Rudek</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Marur</surname><given-names>S.</given-names></name><name name-style="western"><surname>John</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tsottles</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bonerigo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Veasey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kiess</surname><given-names>A.</given-names></name><name name-style="western"><surname>Quon</surname><given-names>H.</given-names></name><etal/></person-group><article-title>A Phase I Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed by Standard Chemoradiation in HPV-Negative or High-Risk HPV-Positive Locally Advanced Stage III/IVa/IVb Head and Neck Squamous Cell Carcinoma</article-title><source>Oral Oncol.</source><year>2016</year><volume>53</volume><fpage>54</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2015.11.020</pub-id><pub-id pub-id-type="pmid">26705063</pub-id><pub-id pub-id-type="pmcid">PMC4707116</pub-id></element-citation></ref><ref id="B196-pharmaceutics-16-01196"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>L.</given-names></name></person-group><article-title>Microtubules as a Target for Anticancer Drugs</article-title><source>Nat. Rev. Cancer</source><year>2004</year><volume>4</volume><fpage>253</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1038/nrc1317</pub-id><pub-id pub-id-type="pmid">15057285</pub-id></element-citation></ref><ref id="B197-pharmaceutics-16-01196"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matson</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Stukenberg</surname><given-names>P.T.</given-names></name></person-group><article-title>Spindle Poisons and Cell Fate: A Tale of Two Pathways</article-title><source>Mol. Interv.</source><year>2011</year><volume>11</volume><fpage>141</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1124/mi.11.2.12</pub-id><pub-id pub-id-type="pmid">21540474</pub-id><pub-id pub-id-type="pmcid">PMC3086919</pub-id></element-citation></ref><ref id="B198-pharmaceutics-16-01196"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brito</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>C.L.</given-names></name></person-group><article-title>Mitotic Checkpoint Slippage in Humans Occurs via Cyclin B Destruction in the Presence of an Active Checkpoint</article-title><source>Curr. Biol.</source><year>2006</year><volume>16</volume><fpage>1194</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2006.04.043</pub-id><pub-id pub-id-type="pmid">16782009</pub-id><pub-id pub-id-type="pmcid">PMC2749311</pub-id></element-citation></ref><ref id="B199-pharmaceutics-16-01196"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakayama</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>T.</given-names></name></person-group><article-title>Antiproliferative Fate of the Tetraploid Formed after Mitotic Slippage and Its Promotion; A Novel Target for Cancer Therapy Based on Microtubule Poisons</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>663</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21050663</pub-id><pub-id pub-id-type="pmid">27213315</pub-id><pub-id pub-id-type="pmcid">PMC6274067</pub-id></element-citation></ref><ref id="B200-pharmaceutics-16-01196"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dumontet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>M.A.</given-names></name></person-group><article-title>Microtubule-Binding Agents: A Dynamic Field of Cancer Therapeutics</article-title><source>Nat. Rev. Drug Discov.</source><year>2010</year><volume>9</volume><fpage>790</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1038/nrd3253</pub-id><pub-id pub-id-type="pmid">20885410</pub-id><pub-id pub-id-type="pmcid">PMC3194401</pub-id></element-citation></ref><ref id="B201-pharmaceutics-16-01196"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henriques</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pedrosa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sarmento</surname><given-names>B.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>P.M.A.</given-names></name><name name-style="western"><surname>Bousbaa</surname><given-names>H.</given-names></name></person-group><article-title>Mitosis Inhibitors in Anticancer Therapy: When Blocking the Exit Becomes a Solution</article-title><source>Cancer Lett.</source><year>2019</year><volume>440&#8211;441</volume><fpage>64</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2018.10.005</pub-id><pub-id pub-id-type="pmid">30312726</pub-id></element-citation></ref><ref id="B202-pharmaceutics-16-01196"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atrafi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Boix</surname><given-names>O.</given-names></name><name name-style="western"><surname>Subbiah</surname><given-names>V.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Chawla</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Tolcher</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Lorusso</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Eder</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sankhala</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A Phase i Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation</article-title><source>Clin. Cancer Res.</source><year>2021</year><volume>27</volume><fpage>6366</fpage><lpage>6375</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-4185</pub-id><pub-id pub-id-type="pmid">34518310</pub-id></element-citation></ref><ref id="B203-pharmaceutics-16-01196"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>M.L.H.</given-names></name><name name-style="western"><surname>Chavas</surname><given-names>L.M.G.</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Eyers</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Tabernero</surname><given-names>L.</given-names></name></person-group><article-title>Crystal Structure of the Catalytic Domain of the Mitotic Checkpoint Kinase Mps1 in Complex with SP600125</article-title><source>J. Biol. Chem.</source><year>2008</year><volume>283</volume><fpage>21495</fpage><lpage>21500</lpage><pub-id pub-id-type="doi">10.1074/jbc.M803026200</pub-id><pub-id pub-id-type="pmid">18480048</pub-id></element-citation></ref><ref id="B204-pharmaceutics-16-01196"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hiruma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hazraty</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tsakou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Medema</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Perrakis</surname><given-names>A.</given-names></name></person-group><article-title>Understanding Inhibitor Resistance in Mps1 Kinase through Novel Biophysical Assays and Structures</article-title><source>J. Biol. Chem.</source><year>2017</year><volume>292</volume><fpage>14496</fpage><lpage>14504</lpage><pub-id pub-id-type="doi">10.1074/jbc.M117.783555</pub-id><pub-id pub-id-type="pmid">28726638</pub-id><pub-id pub-id-type="pmcid">PMC5582842</pub-id></element-citation></ref><ref id="B205-pharmaceutics-16-01196"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name></person-group><article-title>Mps1/TTK: A Novel Target and Biomarker for Cancer</article-title><source>J. Drug Target.</source><year>2017</year><volume>25</volume><fpage>112</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1080/1061186X.2016.1258568</pub-id><pub-id pub-id-type="pmid">27819146</pub-id></element-citation></ref><ref id="B206-pharmaceutics-16-01196"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>E.S.</given-names></name></person-group><article-title>Kinetochore-Catalyzed MCC Formation: A Structural Perspective</article-title><source>IUBMB Life</source><year>2023</year><volume>75</volume><fpage>289</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1002/iub.2697</pub-id><pub-id pub-id-type="pmid">36518060</pub-id><pub-id pub-id-type="pmcid">PMC7614552</pub-id></element-citation></ref><ref id="B207-pharmaceutics-16-01196"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yatskevich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bellini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Barford</surname><given-names>D.</given-names></name></person-group><article-title>Structure of the Human Outer Kinetochore KMN Network Complex</article-title><source>Nat. Struct. Mol. Biol.</source><year>2024</year><volume>31</volume><fpage>874</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1038/s41594-024-01249-y</pub-id><pub-id pub-id-type="pmid">38459127</pub-id><pub-id pub-id-type="pmcid">PMC11189301</pub-id></element-citation></ref><ref id="B208-pharmaceutics-16-01196"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>P.</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Faria</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bousbaa</surname><given-names>H.</given-names></name></person-group><article-title>Monitoring the Fidelity of Mitotic Chromosome Segregation by the Spindle Assembly Checkpoint</article-title><source>Cell Prolif.</source><year>2011</year><volume>44</volume><fpage>391</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2184.2011.00767.x</pub-id><pub-id pub-id-type="pmid">21951282</pub-id><pub-id pub-id-type="pmcid">PMC6496767</pub-id></element-citation></ref><ref id="B209-pharmaceutics-16-01196"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teixeira</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Moura</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>J.</given-names></name><name name-style="western"><surname>Monteiro</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Bousbaa</surname><given-names>H.</given-names></name></person-group><article-title>An Overview of the Spindle Assembly Checkpoint Status in Oral Cancer</article-title><source>Biomed Res. Int.</source><year>2014</year><volume>2014</volume><elocation-id>145289</elocation-id><pub-id pub-id-type="doi">10.1155/2014/145289</pub-id><pub-id pub-id-type="pmid">24995269</pub-id><pub-id pub-id-type="pmcid">PMC4065761</pub-id></element-citation></ref><ref id="B210-pharmaceutics-16-01196"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarwar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morozov</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Purayil</surname><given-names>H.</given-names></name><name name-style="western"><surname>Daaka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ishov</surname><given-names>A.M.</given-names></name></person-group><article-title>Inhibition of Mps1 Kinase Enhances Taxanes Efficacy in Castration Resistant Prostate Cancer</article-title><source>Cell Death Dis.</source><year>2022</year><volume>13</volume><fpage>868</fpage><pub-id pub-id-type="doi">10.1038/s41419-022-05312-8</pub-id><pub-id pub-id-type="pmid">36229449</pub-id><pub-id pub-id-type="pmcid">PMC9561175</pub-id></element-citation></ref><ref id="B211-pharmaceutics-16-01196"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Felgueiras</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jer&#243;nimo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fardilha</surname><given-names>M.</given-names></name></person-group><article-title>Protein Phosphatase 1 in Tumorigenesis: Is It Worth a Closer Look?</article-title><source>Biochim. Biophys. Acta Rev. Cancer</source><year>2020</year><volume>1874</volume><elocation-id>188433</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbcan.2020.188433</pub-id><pub-id pub-id-type="pmid">32956763</pub-id></element-citation></ref><ref id="B212-pharmaceutics-16-01196"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musacchio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Osswald</surname><given-names>M.</given-names></name><name name-style="western"><surname>Le&#231;</surname><given-names>N.</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>J.</given-names></name><name name-style="western"><surname>nio Pereira</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Maiato</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sunkel</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Conde</surname><given-names>C.</given-names></name></person-group><article-title>Protein Phosphatase 1 Inactivates Mps1 to Ensure Efficient Spindle Assembly Checkpoint Silencing</article-title><source>Elife</source><year>2017</year><volume>6</volume><fpage>e25366</fpage><pub-id pub-id-type="doi">10.7554/eLife.25366.001</pub-id><pub-id pub-id-type="pmid">28463114</pub-id><pub-id pub-id-type="pmcid">PMC5433843</pub-id></element-citation></ref><ref id="B213-pharmaceutics-16-01196"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Mps1 Kinase Regulates Tumor Cell Viability via Its Novel Role in Mitochondria</article-title><source>Cell Death Dis.</source><year>2016</year><volume>7</volume><fpage>e2292</fpage><pub-id pub-id-type="doi">10.1038/cddis.2016.193</pub-id><pub-id pub-id-type="pmid">27383047</pub-id><pub-id pub-id-type="pmcid">PMC4973343</pub-id></element-citation></ref><ref id="B214-pharmaceutics-16-01196"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderhub</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>G.W.-Y.Y.</given-names></name><name name-style="western"><surname>Gurden</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Faisal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Drosopoulos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Woodward</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Innocenti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Westwood</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Naud</surname><given-names>S.S.</given-names></name><etal/></person-group><article-title>High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers</article-title><source>Mol. Cancer Ther.</source><year>2019</year><volume>18</volume><fpage>1696</fpage><lpage>1707</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-18-1203</pub-id><pub-id pub-id-type="pmid">31575759</pub-id></element-citation></ref><ref id="B215-pharmaceutics-16-01196"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woodward</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Innocenti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>K.M.J.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.</given-names></name><name name-style="western"><surname>Henley</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Faisal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>G.W.Y.</given-names></name><name name-style="western"><surname>Box</surname><given-names>G.</given-names></name><name name-style="western"><surname>Westwood</surname><given-names>I.M.</given-names></name><etal/></person-group><article-title>Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4-d]Pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N2-(2-Ethoxy-4-(4-Methyl-4 H-1,2,4-Triazol-3-Yl)Phenyl)-6-Methyl- N8-Neopentylpyr</article-title><source>J. Med. Chem.</source><year>2018</year><volume>61</volume><fpage>8226</fpage><lpage>8240</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00690</pub-id><pub-id pub-id-type="pmid">30199249</pub-id><pub-id pub-id-type="pmcid">PMC6166229</pub-id></element-citation></ref><ref id="B216-pharmaceutics-16-01196"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#246;ffski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Awada</surname><given-names>A.</given-names></name><name name-style="western"><surname>de la Bigne</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Felloussi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Burbridge</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cantero</surname><given-names>F.</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maruzzelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ammattatelli</surname><given-names>K.</given-names></name><name name-style="western"><surname>de Jonge</surname><given-names>M.</given-names></name><etal/></person-group><article-title>First-in-Man, First-in-Class Phase I Study with the Monopolar Spindle 1 Kinase Inhibitor S81694 Administered Intravenously in Adult Patients with Advanced, Metastatic Solid Tumours</article-title><source>Eur. J. Cancer</source><year>2022</year><volume>169</volume><fpage>135</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2022.04.001</pub-id><pub-id pub-id-type="pmid">35567919</pub-id></element-citation></ref><ref id="B217-pharmaceutics-16-01196"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wengner</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Siemeister</surname><given-names>G.</given-names></name><name name-style="western"><surname>Koppitz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kosemund</surname><given-names>D.</given-names></name><name name-style="western"><surname>Klar</surname><given-names>U.</given-names></name><name name-style="western"><surname>Stoeckigt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Neuhaus</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lienau</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bader</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity</article-title><source>Mol. Cancer Ther.</source><year>2016</year><volume>15</volume><fpage>583</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-15-0500</pub-id><pub-id pub-id-type="pmid">26832791</pub-id></element-citation></ref><ref id="B218-pharmaceutics-16-01196"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulze</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Klar</surname><given-names>U.</given-names></name><name name-style="western"><surname>Kosemund</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wengner</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Siemeister</surname><given-names>G.</given-names></name><name name-style="western"><surname>St&#246;ckigt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Neuhaus</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lienau</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bader</surname><given-names>B.</given-names></name><name name-style="western"><surname>Prechtl</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase</article-title><source>J. Med. Chem.</source><year>2020</year><volume>63</volume><fpage>8025</fpage><lpage>8042</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b02035</pub-id><pub-id pub-id-type="pmid">32338514</pub-id></element-citation></ref><ref id="B219-pharmaceutics-16-01196"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitajima</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tani</surname><given-names>T.</given-names></name><name name-style="western"><surname>Springer</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Campisi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Osaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Haratani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Knelson</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Mahadevan</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Ritter</surname><given-names>J.</given-names></name><etal/></person-group><article-title>MPS1 Inhibition Primes Immunogenicity of KRAS-LKB1 Mutant Lung Cancer</article-title><source>Cancer Cell</source><year>2022</year><volume>40</volume><fpage>1128</fpage><lpage>1144.e8</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2022.08.015</pub-id><pub-id pub-id-type="pmid">36150391</pub-id><pub-id pub-id-type="pmcid">PMC9561026</pub-id></element-citation></ref><ref id="B220-pharmaceutics-16-01196"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soria-Bretones</surname><given-names>I.</given-names></name><name name-style="western"><surname>Thu</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Silvester</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cruickshank</surname><given-names>J.</given-names></name><name name-style="western"><surname>El Ghamrasni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ba-alawi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Kiarash</surname><given-names>R.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Chalmers</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>The Spindle Assembly Checkpoint Is a Therapeutic Vulnerability of CDK4/6 Inhibitor&#8211;Resistant ER + Breast Cancer with Mitotic Aberrations</article-title><source>Sci. Adv.</source><year>2022</year><volume>8</volume><fpage>eabq4293</fpage><pub-id pub-id-type="doi">10.1126/sciadv.abq4293</pub-id><pub-id pub-id-type="pmid">36070391</pub-id><pub-id pub-id-type="pmcid">PMC9451148</pub-id></element-citation></ref><ref id="B221-pharmaceutics-16-01196"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>C.Y.-K.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>D.K.-C.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>V.W.-H.</given-names></name><name name-style="western"><surname>Law</surname><given-names>C.-T.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>B.P.-Y.</given-names></name><name name-style="western"><surname>Thu</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Cescon</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Soria-Bretones</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cheu</surname><given-names>J.W.-S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.</given-names></name><etal/></person-group><article-title>CFI-402257, a TTK Inhibitor, Effectively Suppresses Hepatocellular Carcinoma</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2022</year><volume>119</volume><fpage>e2119514119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2119514119</pub-id><pub-id pub-id-type="pmid">35914158</pub-id><pub-id pub-id-type="pmcid">PMC9371652</pub-id></element-citation></ref><ref id="B222-pharmaceutics-16-01196"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szymiczek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pastorino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Napolitano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tanji</surname><given-names>M.</given-names></name><name name-style="western"><surname>Minaai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pagano</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Pass</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Inhibition of the Spindle Assembly Checkpoint Kinase Mps-1 as a Novel Therapeutic Strategy in Malignant Mesothelioma</article-title><source>Oncogene</source><year>2017</year><volume>36</volume><fpage>6501</fpage><lpage>6507</lpage><pub-id pub-id-type="doi">10.1038/onc.2017.266</pub-id><pub-id pub-id-type="pmid">28759042</pub-id><pub-id pub-id-type="pmcid">PMC5690838</pub-id></element-citation></ref><ref id="B223-pharmaceutics-16-01196"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandrashekar</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Karthikeyan</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Korla</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shovon</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Athar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Netto</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Z.S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Manne</surname><given-names>U.</given-names></name><etal/></person-group><article-title>UALCAN: An Update to the Integrated Cancer Data Analysis Platform</article-title><source>Neoplasia</source><year>2022</year><volume>25</volume><fpage>18</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2022.01.001</pub-id><pub-id pub-id-type="pmid">35078134</pub-id><pub-id pub-id-type="pmcid">PMC8788199</pub-id></element-citation></ref><ref id="B224-pharmaceutics-16-01196"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><etal/></person-group><article-title>A Key Genomic Signature Associated with Lymphovascular Invasion in Head and Neck Squamous Cell Carcinoma</article-title><source>BMC Cancer</source><year>2020</year><volume>20</volume><elocation-id>266</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-020-06728-1</pub-id><pub-id pub-id-type="pmid">32228488</pub-id><pub-id pub-id-type="pmcid">PMC7106876</pub-id></element-citation></ref><ref id="B225-pharmaceutics-16-01196"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name></person-group><article-title>Silencing TTK Expression Inhibits the Proliferation and Progression of Prostate Cancer</article-title><source>Exp. Cell Res.</source><year>2019</year><volume>385</volume><fpage>111669</fpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2019.111669</pub-id><pub-id pub-id-type="pmid">31605696</pub-id></element-citation></ref><ref id="B226-pharmaceutics-16-01196"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ang</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Nguyen-T&#226;n</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Westra</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>363</volume><fpage>24</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0912217</pub-id><pub-id pub-id-type="pmid">20530316</pub-id><pub-id pub-id-type="pmcid">PMC2943767</pub-id></element-citation></ref><ref id="B227-pharmaceutics-16-01196"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z.-M.</given-names></name><name name-style="western"><surname>Albers</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>X.</given-names></name></person-group><article-title>Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care</article-title><source>Virol. Sin.</source><year>2021</year><volume>36</volume><fpage>1284</fpage><lpage>1302</lpage><pub-id pub-id-type="doi">10.1007/s12250-021-00413-8</pub-id><pub-id pub-id-type="pmid">34152564</pub-id><pub-id pub-id-type="pmcid">PMC8692589</pub-id></element-citation></ref><ref id="B228-pharmaceutics-16-01196"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramesh</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Devegowda</surname><given-names>D.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thimmulappa</surname><given-names>R.K.</given-names></name></person-group><article-title>NRF2, P53, and P16: Predictive Biomarkers to Stratify Human Papillomavirus Associated Head and Neck Cancer Patients for de-Escalation of Cancer Therapy</article-title><source>Crit. Rev. Oncol. Hematol.</source><year>2020</year><volume>148</volume><fpage>102885</fpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2020.102885</pub-id><pub-id pub-id-type="pmid">32062315</pub-id></element-citation></ref><ref id="B229-pharmaceutics-16-01196"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Namani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rahaman</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name></person-group><article-title>Gene-Expression Signature Regulated by the KEAP1-NRF2-CUL3 Axis Is Associated with a Poor Prognosis in Head and Neck Squamous Cell Cancer</article-title><source>BMC Cancer</source><year>2018</year><volume>18</volume><elocation-id>46</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-017-3907-z</pub-id><pub-id pub-id-type="pmid">29306329</pub-id><pub-id pub-id-type="pmcid">PMC5756380</pub-id></element-citation></ref><ref id="B230-pharmaceutics-16-01196"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>You</surname><given-names>Q.</given-names></name></person-group><article-title>The Keap1&#8211;Nrf2&#8211;ARE Pathway as a Potential Preventive and Therapeutic Target: An Update</article-title><source>Med. Res. Rev.</source><year>2016</year><volume>36</volume><fpage>924</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1002/med.21396</pub-id><pub-id pub-id-type="pmid">27192495</pub-id></element-citation></ref><ref id="B231-pharmaceutics-16-01196"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ronghe</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>H.K.</given-names></name></person-group><article-title>Antioxidant-Mediated up-Regulation of OGG1 via NRF2 Induction Is Associated with Inhibition of Oxidative DNA Damage in Estrogen-Induced Breast Cancer</article-title><source>BMC Cancer</source><year>2013</year><volume>13</volume><elocation-id>253</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-13-253</pub-id><pub-id pub-id-type="pmid">23697596</pub-id><pub-id pub-id-type="pmcid">PMC3665669</pub-id></element-citation></ref><ref id="B232-pharmaceutics-16-01196"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Z.C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>S.Y.</given-names></name></person-group><article-title>Requirement for Human Mps1/TTK in Oxidative DNA Damage Repair and Cell Survival through MDM2 Phosphorylation</article-title><source>Nucleic Acids Res.</source><year>2016</year><volume>44</volume><fpage>1133</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1173</pub-id><pub-id pub-id-type="pmid">26531827</pub-id><pub-id pub-id-type="pmcid">PMC4756815</pub-id></element-citation></ref><ref id="B233-pharmaceutics-16-01196"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scholer-Dahirel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mechta-Grigoriou</surname><given-names>F.</given-names></name></person-group><article-title>The Role of Reactive Oxygen Species and Metabolism on Cancer Cells and Their Microenvironment</article-title><source>Semin. Cancer Biol.</source><year>2014</year><volume>25</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2013.12.007</pub-id><pub-id pub-id-type="pmid">24406211</pub-id></element-citation></ref><ref id="B234-pharmaceutics-16-01196"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name></person-group><article-title>TTK Regulates Proliferation and Apoptosis of Gastric Cancer Cells through the Akt-MTOR Pathway</article-title><source>FEBS Open Bio</source><year>2020</year><volume>10</volume><fpage>1542</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1002/2211-5463.12909</pub-id><pub-id pub-id-type="pmcid">PMC7396433</pub-id><pub-id pub-id-type="pmid">32530571</pub-id></element-citation></ref><ref id="B235-pharmaceutics-16-01196"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>T.</given-names></name></person-group><article-title>Inhibition of Apoptosis through AKT-MTOR Pathway in Ovarian Cancer and Renal Cancer</article-title><source>Aging</source><year>2023</year><volume>15</volume><fpage>1210</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.18632/aging.204564</pub-id><pub-id pub-id-type="pmid">36849137</pub-id><pub-id pub-id-type="pmcid">PMC10008491</pub-id></element-citation></ref><ref id="B236-pharmaceutics-16-01196"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>B.</given-names></name></person-group><article-title>TTK Inhibition Increases Cisplatin Sensitivity in High-Grade Serous Ovarian Carcinoma through the MTOR/Autophagy Pathway</article-title><source>Cell Death Dis.</source><year>2021</year><volume>12</volume><fpage>1135</fpage><pub-id pub-id-type="doi">10.1038/s41419-021-04429-6</pub-id><pub-id pub-id-type="pmid">34876569</pub-id><pub-id pub-id-type="pmcid">PMC8651821</pub-id></element-citation></ref><ref id="B237-pharmaceutics-16-01196"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>R.</given-names></name><name name-style="western"><surname>He</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Song</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Oncogenic B-RafV600E Abrogates the AKT/B-Raf/Mps1 Interaction in Melanoma Cells</article-title><source>Cancer Lett.</source><year>2013</year><volume>337</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2013.05.029</pub-id><pub-id pub-id-type="pmid">23726842</pub-id></element-citation></ref><ref id="B238-pharmaceutics-16-01196"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Annexin A2 Combined with TTK Accelerates Esophageal Cancer Progression via the Akt/MTOR Signaling Pathway</article-title><source>Cell Death Dis.</source><year>2024</year><volume>15</volume><fpage>291</fpage><pub-id pub-id-type="doi">10.1038/s41419-024-06683-w</pub-id><pub-id pub-id-type="pmid">38658569</pub-id><pub-id pub-id-type="pmcid">PMC11043348</pub-id></element-citation></ref><ref id="B239-pharmaceutics-16-01196"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marquard</surname><given-names>F.E.</given-names></name><name name-style="western"><surname>J&#252;cker</surname><given-names>M.</given-names></name></person-group><article-title>PI3K/AKT/MTOR Signaling as a Molecular Target in Head and Neck Cancer</article-title><source>Biochem. Pharmacol.</source><year>2020</year><volume>172</volume><elocation-id>113729</elocation-id><pub-id pub-id-type="doi">10.1016/j.bcp.2019.113729</pub-id><pub-id pub-id-type="pmid">31785230</pub-id></element-citation></ref><ref id="B240-pharmaceutics-16-01196"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serrano</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Sime</surname><given-names>W.</given-names></name><name name-style="western"><surname>Abassi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Daams</surname><given-names>R.</given-names></name><name name-style="western"><surname>Massoumi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jema&#224;</surname><given-names>M.</given-names></name></person-group><article-title>Inhibition of Mitotic Kinase Mps1 Promotes Cell Death in Neuroblastoma</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>11997</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-68829-y</pub-id><pub-id pub-id-type="pmid">32686724</pub-id><pub-id pub-id-type="pmcid">PMC7371706</pub-id></element-citation></ref><ref id="B241-pharmaceutics-16-01196"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freudlsperger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Burnett</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Kannabiran</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Van Waes</surname><given-names>C.</given-names></name></person-group><article-title>EGFR&#8211;PI3K&#8211;AKT&#8211;MTOR Signaling in Head and Neck Squamous Cell Carcinomas: Attractive Targets for Molecular-Oriented Therapy</article-title><source>Expert Opin. Ther. Targets</source><year>2011</year><volume>15</volume><fpage>63</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1517/14728222.2011.541440</pub-id><pub-id pub-id-type="pmid">21110697</pub-id><pub-id pub-id-type="pmcid">PMC3399735</pub-id></element-citation></ref><ref id="B242-pharmaceutics-16-01196"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.</given-names></name><name name-style="western"><surname>Selcuklu</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ramani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ganesan</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Moyer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Targeting Aurora B Kinase Prevents and Overcomes Resistance to EGFR Inhibitors in Lung Cancer by Enhancing BIM- and PUMA-Mediated Apoptosis</article-title><source>Cancer Cell</source><year>2021</year><volume>39</volume><fpage>1245</fpage><lpage>1261.e6</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2021.07.006</pub-id><pub-id pub-id-type="pmid">34388376</pub-id><pub-id pub-id-type="pmcid">PMC8440494</pub-id></element-citation></ref><ref id="B243-pharmaceutics-16-01196"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saurin</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Van Der Waal</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Medema</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Lens</surname><given-names>S.M.A.</given-names></name><name name-style="western"><surname>Kops</surname><given-names>G.J.P.L.</given-names></name></person-group><article-title>Aurora B Potentiates Mps1 Activation to Ensure Rapid Checkpoint Establishment at the Onset of Mitosis</article-title><source>Nat. Commun.</source><year>2011</year><volume>2</volume><fpage>316</fpage><pub-id pub-id-type="doi">10.1038/ncomms1319</pub-id><pub-id pub-id-type="pmid">21587233</pub-id><pub-id pub-id-type="pmcid">PMC3113227</pub-id></element-citation></ref><ref id="B244-pharmaceutics-16-01196"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ustinov</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Korshunova</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Gudimchuk</surname><given-names>N.B.</given-names></name></person-group><article-title>Protein Complex NDC80: Properties, Functions, and Possible Role in Pathophysiology of Cell Division</article-title><source>Biochemistry</source><year>2020</year><volume>85</volume><fpage>448</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1134/S0006297920040057</pub-id><pub-id pub-id-type="pmid">32569552</pub-id></element-citation></ref><ref id="B245-pharmaceutics-16-01196"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jelluma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Brenkman</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>van den Broek</surname><given-names>N.J.F.</given-names></name><name name-style="western"><surname>Cruijsen</surname><given-names>C.W.A.</given-names></name><name name-style="western"><surname>van Osch</surname><given-names>M.H.J.</given-names></name><name name-style="western"><surname>Lens</surname><given-names>S.M.A.</given-names></name><name name-style="western"><surname>Medema</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Kops</surname><given-names>G.J.P.L.</given-names></name></person-group><article-title>Mps1 Phosphorylates Borealin to Control Aurora B Activity and Chromosome Alignment</article-title><source>Cell</source><year>2008</year><volume>132</volume><fpage>233</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.11.046</pub-id><pub-id pub-id-type="pmid">18243099</pub-id></element-citation></ref><ref id="B246-pharmaceutics-16-01196"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Der Waal</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Saurin</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Vromans</surname><given-names>M.J.M.</given-names></name><name name-style="western"><surname>Vleugel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wurzenberger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gerlich</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Medema</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Kops</surname><given-names>G.J.P.L.</given-names></name><name name-style="western"><surname>Lens</surname><given-names>S.M.A.</given-names></name></person-group><article-title>Mps1 Promotes Rapid Centromere Accumulation of Aurora B</article-title><source>EMBO Rep.</source><year>2012</year><volume>13</volume><fpage>847</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1038/embor.2012.93</pub-id><pub-id pub-id-type="pmid">22732840</pub-id><pub-id pub-id-type="pmcid">PMC3432816</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-16-01196-f001" orientation="portrait"><label>Figure 1</label><caption><p>EGFR/HER (<bold>a</bold>) and MPS1 (<bold>b</bold>) signaling pathways. EGFR signaling activates the RAS/RAF/mitogen-activated protein kinase pathway, PI3K/Akt pathway, PLC pathway, signal transducers and activators of transcription pathway, and Src kinase pathway, while MPS1 is involved in the Akt/mTOR pathway and in the activation of oxidative DNA damage repair. Abbreviations: ARE, adenylate-uridylate-rich elements; Aurk A, aurora kinase A; Aurk B, aurora kinase B; BIM, B-cell lymphoma 2 interacting mediator of cell death; DNA, deoxyribonucleic acid; DNA-PKs, DNA-dependent protein kinases; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; FOXO3a, forkhead box O3a; H, histone; HER, human epidermal growth factor receptor; mAbs, monoclonal antibodies; MAPK, mitogen-activated protein kinase; MDM2, mouse double minute 2 homolog; MEK, mitogen-activated protein kinase kinase; MPS1, monopolar spindle 1; mTOR, mammalian target of rapamycin; Nrf2, nuclear factor erythroid 2&#8211;related factor 2; P, phosphate; PI3K, phosphatidylinositol-3 kinase; PKC, protein kinase C; PLC, phospholipase C&#947;; PUMA, p53 upregulated modulator of apoptosis; RAF, rapidly accelerated fibrosarcoma; RAS, rat sarcoma virus; ROS, reactive oxygen species; sMaf, small musculoaponeurotic fibrosarcoma; SOS, son of sevenless; TKI, tyrosine kinase inhibitor; Ub, ubiquitin.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-16-01196-g001.jpg"/></fig><fig position="float" id="pharmaceutics-16-01196-f002" orientation="portrait"><label>Figure 2</label><caption><p>MPS1 role in SAC function. (<bold>a</bold>) Unattached kinetochores activate the SAC. Aurora B promotes the recruitment of activated/phosphorylated MPS1 to the kinetochore by phosphorylating Hec1 in the NDC80 complex. MPS1 then binds the NDC80 complex and phosphorylates KNL1, which is essential for the recruitment of SAC proteins. MPS1 also plays a role in the conversion of O-Mad2 to C-Mad2, leading to MCC formation. Cdc20 binds to the MCC instead of the APC/C, inhibiting the transition from the M phase to the G1 phase of the cell cycle. MPS1 inhibitors will suppress SAC activation leading to chromosome mis-segregation, increasing cell death signaling. (<bold>b</bold>) Attached kinetochores lead to SAC inactivation. With SAC inactive, Cdc20 binds to the APC/C, which leads to cyclin B and securin ubiquitination and degradation. PP1 is, thus, active and inhibits MPS1 function. Consequently, the cell cycle can progress to the G1 phase. Abbreviations: APC/C, anaphase-promoting complex/cyclosome; AurK B, aurora kinase B; BUB1, budding uninhibited by benzimidazoles 1; BUB3, budding uninhibited by benzimidazoles 3; BUBR1, budding uninhibited by benzimidazole-related 1; C-Mad2, closed mitotic arrest deficiency 2; Cdc20, cell division cycle 20 homolog; CDK1, cyclin-dependent kinase; KNL1, kinetochore null protein 1 or kinetochore scaffold 1; Mad1, mitotic arrest deficiency 1; MCC, mitotic checkpoint complex; MPS1, monopolar spindle 1; O-Mad2, open mitotic arrest deficiency 2; SAC, spindle assembly checkpoint.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-16-01196-g002.jpg"/></fig><fig position="float" id="pharmaceutics-16-01196-f003" orientation="portrait"><label>Figure 3</label><caption><p>Transcriptional (<bold>a</bold>) and proteomic (<bold>b</bold>) expression of MPS1 in head and neck squamous carcinoma based on sample types (normal and primary tumors). (<bold>c</bold>) MPS1 mRNA expression levels by tumor samples&#8217; HPV status. TCGA = The Cancer Genome Atlas; CPTAC = Clinical Proteomic Tumor Analysis Consortium.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-16-01196-g003.jpg"/></fig><fig position="float" id="pharmaceutics-16-01196-f004" orientation="portrait"><label>Figure 4</label><caption><p>Correlation analysis of MPS1 overexpression and altered (<bold>a</bold>) mTOR, (<bold>b</bold>) RTK, and (<bold>c</bold>) NRF2 pathways.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-16-01196-g004.jpg"/></fig><fig position="float" id="pharmaceutics-16-01196-f005" orientation="portrait"><label>Figure 5</label><caption><p>Transcriptional (<bold>a</bold>) and protein (<bold>b</bold>) expression of EGFR in normal and primary tumor samples.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-16-01196-g005.jpg"/></fig><table-wrap position="float" id="pharmaceutics-16-01196-t002" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-16-01196-t002_Table 2</object-id><label>Table 2</label><caption><p>Clinical trials targeting MPS1 alone or in combination for cancer treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Intervention</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NCT Identifier</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
BAY-1217389 (Completed)
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced malignancies (solid tumors)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BAY-1217389 + paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The combination of BAY with paclitaxel was associated with considerable toxicity without a therapeutic window.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02366949">NCT02366949</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B202-pharmaceutics-16-01196" ref-type="bibr">202</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
BAY-1161909 (Terminated)
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced malignancies (solid tumors)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BAY-1161909 + paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">As another MPS-1 inhibitor was being developed in parallel (BAY-1217389), the strategic decision was to move forward with the development of the follow-up compound only.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02138812">NCT02138812</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
BOS-172722 (Completed)
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced Nonhematologic Malignancies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BOS-172722 + paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Without results.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03328494">NCT03328494</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
BAL0891
<break/>
(Recruiting)
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced Solid Tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BAL0891 monotherapy and BAL0891 + carboplatin or paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Without results.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05768932">NCT05768932</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
CFI-402257 (Active, not recruiting)
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced Solid Cancers, Breast Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CFI-402257 + Fulvestrant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Without results, Active, Estimated study completion date: May 2027</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02792465">NCT02792465</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CFI-402257 + paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The phase 2 recommended doses were CFI-402257 168 mg + Paclitaxel 80 mg/m<sup>2</sup>. The overall response rate was 5.9% and the clinical benefit rate was 47.1%. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03568422">NCT03568422</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
CFI-402257 (Recruiting)
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced malignancies (solid tumors)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CFI-402257</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Without results, Recruiting, Estimated study completion date: August 2025.</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05251714">NCT05251714</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CFI-402257 + Fulvestrant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
S-81694 (Completed)
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic Breast Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S-81694 + paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">The study was discontinued, and the maximum tolerated dose was not found. The use of S-81694 combined with paclitaxel does not seem to be effective in metastatic breast tumors. </td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03411161">NCT03411161</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic Triple-Negative Breast Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S-81694 + paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1"><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.clinicaltrials.gov/">https://www.clinicaltrials.gov/</uri> (accessed on 2 September 2024)</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>